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Editorial 
Physicians and Peace: Promoting Peace By Pursuing Health 
Adnan Pirbhai, Meds 2005 
The modem definition of health is widely regarded as not 
simply an absence of disease, but rather a state of physical, men-
tal, social and ecological well-being. If one interprets the effects 
of war and violence as they apply to each of these components, a 
sobering picture develops, one that should be of particular con-
cern for health professionals. The physical effects of war are dev-
astatingly obvious, with the increasing numbers of civilian deaths 
particularly concerning. The mental effects are reflected in a very 
high number of war related mental illnesses in victims and com-
batants.! War and violence also carries a high cost to social cohe-
sion and infrastructure, which consequently adversely affect 
health by destroying the networks and physical infrastructures 
that support healthy societies. Some of these examples include 
water systems, food distribution systems, sanitation and primary 
health care.2 Ecologically, there are many examples from the last 
decade that corroborate the destructive capacities of war on the 
environrnent.3 With such widespread effects of war on health, 
combined with a current world climate that puts war almost on 
par with infectious disease as a global cause of morbidity and 
mortality4, it should hardly come as a surprise that physicians 
stand to play very important roles in the effort to delegitimize war 
and promote peace. 
That war and violence negatively impact health is stating the 
all too obvious. However, what is needed in order to pragmatical-
ly outline the role the physician can play in promoting peace 
amidst conflict is a simultaneous understanding of how health 
promoting initiatives can lead to peace. In recent years, there has 
been a considerable amount of interest and attention paid to 
examining the basis of health to peace mechanisms.s Health-
peace initiatives refer to "any initiative that is intended to improve 
the health of a population and to simultaneously heighten that 
population 's level of peace and security."6 Enlisting Hippocratic 
ideals that guide everyday practice, such as extended altruism, a 
commitment to impartiality and scientific rigor, and the overrid-
ing goal of improving health, physicians are highly capable of ini-
tiating and maintaining peace by remaining committed to health. 
Pursuing the 'superordinate goal of health ' has proven to promote 
peace in part by creating "an opportunity to build a negotiating 
framework, to counter dehumanization of the enemy, and some-
times to demonstrate the possibility of stopping the violence."5 
There are several well established examples of health-peace 
initiatives that underscore this point. During the civil war in El 
Salvador, nearly twenty thousand health workers collaborated 
with each other and guerilla fighters to negotiate three days of 
truces each year for the purposes of immunizing chi ldren against 
polio and other diseases7 This initiative is widely regarded as 
spurring peaceful resolution of the conflict. The lessons learned 
through these "days of tranquility" were also enlisted to vaccinate 
endemic (of both disease and conflict) areas such the Democratic 
Republic of Congo and Afghanistan, among others. Another cre-
ative example of a health-peace initiative is the Canadian 
International Scientific Exchange Program (CISEPO), a volun-
tary organization that is implementing an infant screening pro-
gram for hearing Joss between Jordan, Israel and the Palestinian 
Authority. As Dr. Arnold Noyek, the chairman of CISEPO states, 
"We are launching this program not only for the benefit of the 
children, but to build and grow working relationships and pro-
mote regional cooperation between health care and scientific pro-
fessionals. The problem of hearing loss in this region is not con-
fined by political boundaries." Thus, health initiatives are increas-
ingly and convincingly being equated with peace initiatives. 
What is important to ascertain from these and other health-
peace initiative examples, however, is that the nature of the work 
of physicians, epidemiologists and other health workers was not 
centred around using expertise developed in a medical context 
and extending it into the realms of conflict management and pol-
itics. Rather, it should be duly noted that implementing programs 
wholly focused on the overriding goal of health was able to 
achieve peace as a result. However, there is indeed considerable 
opportunity and cause for physicians to become politically out-
spoken in a context of war and violence. 
Physicians have a public perception of being objective, car-
ing, educated and altruistic. In fact, in recent years, physicians 
have been given higher public ranking than politicians in matters 
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of honesty and ethics .8 This perception lends itself to a consider-
able amount of legitimacy and infl uence in public debates . The 
altruisti c pursuit of health, a commjtment to truth and objectivity 
and the legitimacy and status afforded by society, provide physi-
cians with a great deal of moral and technical expertise that 
enables physicians to effecti vely influence public policy and be 
political motivators. 
Traditionally, in the political arena in times of war, physi-
cians were relied on primari ly as scientific experts, for example 
as they testified against the actions of the United States in 
Vietnam from a medical perspective .6 More recently, Medact, a 
UK chari ty of health professionals, publi shed Collateral Damage, 
a report that suggests death to ll s could potentially be in the hun-
dred of thousands as a resul t of the present confl ict in Iraq.9 By 
interpreting politica l decisions in their potential for death and 
destruction, phys icians are able to redefine war as a health issue. 
The best example of this is the work done by International 
Phys icians for the Prevention of Nuclear War (IPPNW) a they 
redefined nuclear war as primarily a public health issue. Pursuing 
scientific evidence in a public fo rum allows physicians to effec-
tively expand their role of experti se from strictly a sc ienti f ic 
realm and become spoke people of a politica l nature as well. 
In the case of the current situation in Iraq, thou ands of 
physicians have chosen to become politically outspoken as they 
united in outlining the disastrous potential health effects of mili-
tary action in Iraq. They also cited, among others, their commit-
ment to truth and obj ectivity in contending that American and 
British leaders failed to supply convincing evidence supporting 
reasons to go to war.IO One of many specific examples includes 
the work of Physicians fo r G lobal Surviva l, the Canadian arm of 
IPPNW, who lobbied Prime Minister Jean Chreti en to reject war 
and pursue peace.'' While purists may contend that physicians 
may be overstepping their bounds by entering moral and political 
debates , others can argue that it is the nature of the politica l deci-
sions in the context of war and their impact on health that make 
physicians as good candidates as any to be politica l spokespeople. 
One other very important role for physicians amidst world 
conflict is through the concept of public health . In matters of 
health , most physicians wiU agree with the notion that prevention 
is preferable to treatment. The same idea naturally applies to war. 
Development indicators and health are positive ly related, so the 
worse off a country and the members of that society are develop-
mentally, the greater the incidence of ill-health .I2 Therefore, if too 
few financial resources are committed to health care and other 
health producing aspects of the society (including education, 
poverty, and equitable distribution of wealth, to name a very few) , 
mortali ty and morbidi ty are likely to increase.IJ This analys is can 
at least partially justi fy the proven a sociation of hi gh level of 
military expenditure with unemployment, poverty, starvation and 
ill health. I4 Similar associat ions also outl ine a list of identi f iable 
public health parameters that can be considered risk factors for 
the development of war and violence. These parameters include 
infec tious di seases, mental health di sorders, vulnerabili ty of pop-
ulation groups, di sparities in health status within and among 
countries, and weakerung of human rights. I5 Since countries with 
the lowest developmenta l scores (based on many of the public 
health parameters outlined above) are also most often involved in , 
4 UWOMJ 73( 1) 2004 
or may soon be involved in violent conflict of some kind, a fair 
conclusion follows : ill-health and war are connected, or converse-
ly, effective public health can promote peace and prevent war. 
Some imoads have already been laid down this path that have 
curtailed the overall destructiveness of war. In addition to the 
1984 Nobel Prize winning achievements of IPPNW in redefining 
nuclear war, the ' rules of war' no longer allow the use of many 
other types of weapons and ban the production of others. This was 
due to the work by the International Committee of the Red Cross 
in defining and outlining the effects of weapons based on health 
effects.6 These two examples chronicle work done by specific 
groups regarding specific aspects of armed conflict. Consider a 
future where the lay person acknowledges and interprets all 
aspects of a war by their effects on the health of those populations 
involved. With the grim prediction of war as one of the top ten 
causes of disability-adjusted life years lost by the year 20204, gen-
erating and implementing effective public health strategies, 
including raising the awareness of war as a public health issue, 
represents yet another avenue physicians can pursue in promoting 
peace. 
Physicians, in various ways, can contribute to a more peace-
fu l world community. Increasingly, research is uncovering sce-
narios where health initiatives can bring health, and consequently 
peace to a region of conflict. An argument also exists for the 
appropriate and effective involvement of physicians as agents for 
peace in the poli tica l arena, while pursuing the superordinate goal 
of health. Finally, public health issues, evidenced as both a cause 
and consequence of war, offer physicians what may be the most 
effective avenue to pursue in order to prevent war and achieve 
peace. The fo undation for a new academic discipline entitled 
Peace Through Health is being developed at McMa ter University 
in Hamilton in light of this growing body of evidence. The case 
for continuing to develop till s di scipline is strong in that many 
believe it is important to apply what is already known in the field, 
outline fu ture area of research and ultimately disseminate the 
f indings and le son to all health profe sionals.s. 16 Others, how-
ever, contend that rather than creating a new discipline and unnec-
essarily committing more resources to such initiatives, what is 
needed is to mainstream the interaction between health, peace and 
conflict reso lution in existing institutions concerned with public 
health, interstate and intersocietal conflict.I 7 Although there is 
some debate regarding how work that needs to be done in the field 
of peace and health should progress, there is no denying that the 
work will and should continue and the connection between health 
and peace will only grow stronger. Phy icians must recogillze that 
while remaining committed to the principles on which health care 
a_nd the profession are based, they are uniquely capable of posi-
tive ly affec~mg ~ar prevention and peace promotion . The imper-
ati ve to enlist this capacity, given the current world climate and 
future outlook, has never been stronger. 
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Diagnostic Review 
Magnetic Resonance Imaging: Opportunities for early diagnosis of 
rheumatoid arthritis 
Nina Ghosh, Meds 2005 
RA is a progressive arthropathy, without appropriate treatment, can result in irreversible joint damage.! 
Early diagnosis presents the challenge of often vague symptoms and signs that progress relatively slowly. 
Radiographs, although able to find structural joint involvement in patients where disease is established, have 
not been sufficiently sensitive in finding early RA joint and soft tissue changes. I MR1 bas thus been looked 
upon as an imaging modality for the detection of early RA pathology due to its more sensitive data and bet-
ter predictive value I In RA, due to its superior contrast resolution and tomographic nature, MR1 can demon-
strate soft tissue and joint involvement better than plain radiograpby.s Specifically, active synovitis and pan-
nus are markedly enhanced by intravenous gadolinium chelate injection. Fat-suppressed Tl-weigbted imag-
ing with gadolinium enhancement is the most sensitive technique to demonstrate these tissues.s Moreover, 
semiautomated methods have been developed to measure the volume of bone erosion with MRI.S This article 
will review the current evidence demonstrating the use of MRI in the early detection of RA. 
INTRODUCTION 
RA is a progressive arthropathy, without appropriate treat-
ment, can result in irreversible joint damage.! Early diagnosis 
presents the challenge of often vague symptoms and signs that 
progress relatively slowly. Furthermore, the early months of RA 
are critical in that irreversible joint damage can occur. Thus, an 
early clinical diagnosis may be key in preventing the long-term 
disability that challenges many RA patients. Radiographs, 
although able to find structural joint involvement in patients 
where disease is established, have not been sufficiently ensitive 
in finding early RA joint and soft tissue changes. I MRI has thus 
been looked upon as an imaging modality for the detection of 
early RA pathology due to its more sensitive data and better pre-
dictive value! According to Emery, MRI could detect abnormali-
ties in 70% of patients at presentation, whereas radiographs were 
able to detect characteristic or pathognomonic joint erosion in 
15% of patients with RA2 
In RA, due to its superior contrast resolution and tomo-
graphic nature, MRI can demonstrate soft tissue and joint 
involvement better than plain radiography.s Specifically, active 
synoviti s and pannus are markedly enhanced by intravenous 
gadolinium chelate injection. Fat-suppressed Tl-weighted imag-
ing with gadolinium enhancement is the most sensitive technique 
to demonstrate these tissues. a Although there has been little vali-
dation on how to score bone erosion using MRI, when strict cri -
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teria for defining bone erosions are applied to scoring, there is a 
97% consistency in the recording of such lesions by MRJ.I 
Moreover, semiautomated methods have been developed to mea-
sure the volume of bone erosion with MRJ.S This article will 
review the current evidence demonstrating the use of MRI in the 
early detection of RA. 
EVALUATION OF THE HANDS AND WRISTS IN EARLY RA 
MRI of the hand and wrist joint can demonstrate joint ero-
sion earlier than plain radiographs and can detect more ero-
sions ,6 pecifically, common sites detected through MRl include 
the capitate, lunate and scaphoid. Bone marrow signal changes 
frequent ly occur and are most frequent in the capitate, lunate and 
triquetrum. MRI also shows synovial thickening and enhance-
ment, most commonly in the radiocarpal joint. More than half of 
patients who present with RA also show tenosynovitis most com-
monly involving the extensor carpi ulnaris tendon. On MRI it is 
seen as sheath fluid, thickening and enhancement.6 
Jorgenssen a ~ so showed that MRI demonstrated abnormality 
of the s~ft tissue m 13 of 15 patients with early RA, compared to 
none usmg standard radiography.? On coronal MRI sites of _ 
.. . I ' syn 
ovitis me uded t~e recess of the distal ulnar, the ctistal radioulnar 
JOint and the rad~ocarpal joint.7 Furthermore, on axial MRI, ten-
dOl~ sheath effusiOn of the digital flexor was demonstrated in 3 
patients.? These d~~a _s uggest that MRI is a sensitive mode of 
detectiOn of synovitis mvolving the wrist in early RA. 
EVALUATION OF SYNOVITIS 
A recent study in which patients were randomized to receive 
treatments with disease modifying antirheumatic drugs, bone 
damage and synovitis were measured by MRI. The MRI data sug-
gested that the level of synovial thickne s was vital in determin-
ing the extent of bone damage.' Since no damage occurred in 
joints without synuvitis, the presence of synovitis suggests that it 
is prognostic for bone damage .4 Unlike plain film or CT radiog-
raphy, MRI can be used to image the synovium including synovi-
um volume and level of inflammation.4 The use of gadolinium-
enhancing imaging properties in the synovium correlated well 
with the microscopic appearances on arthroscopic biopsies. MRI 
has also been shown to be more ensitive than clinical examina-
tion for the identification of synuvitis.4 For instance, Sugimoto et 
al correctly diagnosed 25 out of 26 patients at the onset of RA 
using MRI criteria, 23% more patients than diagnosed using ACR 
criteria.s 
EVALUATION OF THE HUMERAL HEAD 
The early development of joint damage in peripheral joints is 
well known and occurs in approximately 75% of patients during 
the first two years of the disease .3 However, data on the shoulder 
joints are scarce. Radiographic damage to the shoulder has been 
found within six years of disease in more than fifty percent ofRA 
patients. By 12 years of RA, MRI can detect erosions in 96% of 
shoulders, compared to 73% by plain films and 77% by CT.3 
Thus, although MRI examination of the shoulder may not diag-
nose the overall disease process, it is useful in early detection of 
shoulder joint involvement. Erosive changes tend to occur most 
often on the superolateral aspect of the head of the humerus. 
According to Takalo, MRI images of subcortical areas of high 
signal intensity in T2-weighted images and low signal intensity 
on T 1 weighted fulfill criteria for erosions. Using this criteria, 
MRI detected more erosive lesions than other imaging modalities 
such as U/S and CT, particularly in the postero-lateral region of 
the humerus .3 
MRI IN THE DIAGNOSIS OF JUVENILE ARTHRITIS 
MRI of the knee in early JRA depicts the synovium and its 
effects on joint structures in children. Using the criteria of maxi-
mal synovial thickness of 3 mm or a synovial volume of 3 ml , 
Graham et al. Synovial hypertrophy and joint effusions are the 
most frequent MRI findings in the knees in early JRA, however 
occult cartilage and bone erosions may also be identified.9 
LIMITATIONS OF MRI 
Although evidence suggests that MRI is a sensitive, accurate, 
non-invasive modality to assess components of the rheumatoid 
arthritic joint, several practical and diagnostic limitations arise. In 
Canada, the limited availability and expense of MRJ preclude its 
use on a routine basis for diagnosis . 
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Profiles 
An Interdisciplinary Approach to Patient Care 
Maryanne Rockx, Meds 2004 
This article will explore the interactions between two internal medicine subspecialties, endocrinology and car-
diology. After completing three years of internal medicine in London, in July 2002 the residents profiled here 
began subspecialty training, Dr. Wael Haddara in endocrinology/intensive care and Dr. James White in car-
diology. One of the main concerns of an endocrinologist is the management of patients with diabetes mellitus 
(DM). An ever increasing number of Canadians have Type 2 DM, in which atherosclerosis is the primary fac-
tor for morbidity and mortality. An interdisciplinary approach is required to treat them effectively. 
Dr. Haddara graduated in 199 1 with a B.Sc. Pharm. from 
Memorial University of Newfoundland and completed the MD 
degree at Queen 's University in 1999. How did you di scover your 
interest in endocrinology? 
WH: I first became interested in endocrinology during 
my undergrad years. It struck me that profs kept talking 
about " master glands" that control the body's metabolism but 
in reality we knew very little about the details of how that 
worked. 
What part of endocrinology appeals to you and why combine 
it with intensive care? 
WH: Endocrinology is very heavily phys iology-based and 
pharmacology-based. Given my background, I f ind that appeal-
ing. In addition, although it is a very old specialty, in some 
respects it is very young in that there are so many unanswered 
questions. That's a stimulating thing. 
I first became interested in ICU after first year of med-
ical school. I had taken a year off from Medicine because of 
personal reasons and landed a job as a critical care pharma-
cist at the Hamilton General Hospital. It was a great experi-
ence and my interest in ICU was reaffirmed during my resi-
dency. I had always been interested in endocrinology and 
strangely enough my research interests lie at the intersection 
of the two fields. 
Most intensivists in the past were either anesthesiologists 
or respirologists. M etabolism a nd hormonal regulation, 
despite their importance, have not figured prominently in the 
clinical practice of ICU and I hope to change that. 
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What is your favourite book and why? 
WH: The theme of The Count of Monte Cristo is that no 
human being, regardless of power, wealth or influence, is per-
fect. The novel is the story of a man who had every reason to 
believe otherwise but discovers that only God is without fault. 
Dr. Haddara was the chief medical resident at LHSC-UC 
from July to December 2001. 
What was the most challenging part of this role? 
WH: Certainly the most challenging part of being Chief 
Resident at Western is balancing all of the different responsi-
bilities. We continue to carry a significant clinical load during 
the months of being Chief and added to the clinical work are 
the various other duties. Another kind of balance that is some-
times hard to strike is the balance between being part of 
administration and being an advocate for residents. 
Dr. White was the chief medical resident at LHSC-UC from 
January to June 2002? 
What do you consider the most challenging part of this role? 
J W Th is should really be divided into two distinct areas that 
of education and of administration. The educational challenge 
was how to convey knowledge in an interesting and exciting fash-
ion. The administrative challenge, fo r me, was the realization that 
my role was to look out for others and the "greater good " while 
everyone else s role was to let me know their demands, regardless 
of what eve1y one else wanted. Believe me, these roles are not syn-
ergistic! 
How did you discover your interest in cardiology? 
JW One day in Grade 13 biology, my teacher was discussing 
the cardiovascular system. I found it so interesting that I called 
the Chief of Cardiology at UH to see if I could come and do some 
research ... he said yes. I worked in the Cardiac Investigation 
Unit from Grade 13 up until, well, now. The generous mentorship 
and encouragement of the staff cardiologists is what led to my 
interest in cardiology. 
What do you find appealing about the practice of cardiology? 
JW Cardiology is a specialty that is both challenging and 
gratifying. The challenge is found in the acuity and severity of the 
illness as well as the constant appreciation and manipulation of 
cardiovascular phy iology. The gratification is both immediate 
and delayed, from the patient finding relief from pain during a 
myocardial infarction to that of a patient coming back for fo llow-
up visits with chronic congestive heart failure. 
Did a particular cardiologist act as your mentor and what did 
you learn from him? 
JW The physicians that I have done research with for over 
eight years have had a substantial effect on my decision to go into 
cardiology. Both D1~ Peter Pjlugfelder and D1~ Bill Kostuk deserve 
much of the credit for this. D1~ Pjlugfelder especially has con-
veyed to me how rewarding a career in cardiology can be if one 
takes time to understand how the patients ' disease effects their 
lives rather than simply their test va lues. 
The CBC movie Glmy Enough For All details the life of Sir 
Frederick Banting, who won a Nobel Prize in 1923 for his di s-
covery of insulin. It is said that Banting's ideas were conceived in 
London where, besides having a general practice, Banting taught 
orthopaedics at U.W.O. The house where he lived and practiced is 
now Banting House, a national historic site with an eternal flame, 
lit in 1989 to be extinguished when a cure for DM is found . 
Have you seen the movie or been to Banting House and has 
either of these encouraged you to be involved in research or to 
attend medical school? 
WH: I have seen both the movie and visited Banting 
House. The story of insulin is one of the most inspiring stories 
of contemporary medicine. As with many other stories of dis-
covery it is the number of nay-sayers and doubters that I find 
most fascinating. 
Would you use Banting House as a community resource for 
a newly diagnosed diabetic? 
JW Absolutely ! The more people l..7!ow about their condition 
and the research that has taken place and is underway, the more 
they will take part in the treatment. 
What is the impact of DM on today 's health care system? 
WH: I think it is unfortunate that Type 2 DM is on the 
rise when we could probably prevent a significant number of 
people from developing this disease through weight loss and 
weight control. 
J W A profound impact! Type 2 DM is an epidemic in North 
America and the impact. both on the patients themselves and on 
the health care system, has been a crescendo of financial burden. 
As most cases are preventable. we should focu on education in 
order to protect patients at risk and our f uture health care system. 
What are the implications for the future? 
WH: I think more money in health care should be spent 
on prevention than we are doing presently. However, research 
into the mechanisms of insulin resistance and beta cell 
destruction is likely going to yield very important information 
on the basic metabolic function of the body. I think this is a 
very exciting time in endocrinology. 
JW What concerns me the most is if we can sustain the pre-
sent level of care for a population that is aging, and with that age 
getting more disease such as diabetes. As many already know, we 
struggle to provide that care now. What will be the situation in ten 
or twenty years when the portion of the population with signifi-
cant illness expands? 
Many important trials have examined the association of heart 
disease with DM. In the Di abetes Mel litus Insulin-Glucose 
Infu ion in Acute Myocardia l Infarcti on (DIGAMI) trial , heart 
failure accounted for 66% of total mortality following acute 
myocardial infarction 1. 
In the Heart Outcomes Prevention Evaluation (HOPE) trial , 
compared with controls, ramipril-treated diabetic patients experi-
enced a 25% relative-risk reduction of the primary composite 
endpoint (myocardial infarction, stroke, or cardiovascular death), 
a 22% relative-risk reduction in developing myocardial infarction, 
a 20% relative-risk reduction in developing any heart fai lure, a 
33% relative-risk reduction in developing stroke, a 24% relative-
risk reduction in total mortali ty, and a 3 7% relative-ri sk reduction 
in cardiovascular deaths2 
Most recently, researchers are studying a newer ora l hypo-
glycemic agent of the thiazolidinedione class, rosiglitazone. 
Since Type 2 diabetics are at a particularly high risk for heart fail-
ure and have a poor prognosis once they develop it, it is important 
to prevent the onset of DM. A large, prospective tria l, the 
D iabetes Reduction Assessment with Ramipril and Rosiglitizone 
Medication (DREAM) trial , with a target enrollment of 4000 peo-
ple with no diabetes at base line, wi ll evaluate the effects of 
ramipril and/or rosiglitizone in people with impaired glucose tol-
erance. 
Any thoughts on these trials? 
WH: I think this is a good example of prevention. It would 
be nice to know that we can do something for people to keep 
them healthy rather than treat them once heart disease has 
already struck. 
JW Our appreciation of how both traditional and novel 
treatments can retard or even prevent illness is only in its infan-
cy. If one looks at how much we have learnt in the last ten years, 
it is exponentially more than in the last one hundred years. What 
is important is to embrace and utilize this knowledge but also to 
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critically appraise the data and apply it to the individual, rather 
than a generic population. That being said, these trials are 
encouraging and are changing clinical practice. 
What interaction do you see between endocrinologists and 
cardiologists? 
WH: As you have alluded to, diabetics are at a significant 
risk of developing heart disease. So far the interaction 
between cardiologists and endocrinologists has not been the 
closest. As we get more results from clinical trials, however, I 
think there will be much more cooperation. One of the 
endocrinology fellows here at Western conducted a survey of 
cardiologists and their adherence to the DIGAMI protocol 
and found that very few did. On the other hand, some of the 
cardiologists here are undertaking a study on glucose control 
post-MI ... so I think closer cooperation is going to evolve soon. 
JW: Although traditionally there has not been a strong asso-
ciation between these two departments, over the last several years 
the emphasis has shifted to primary and secondary prevention. 
This has united the cardiologists with the slcills of the endocrinol-
ogists to assess and alter cardiovascular risk, such as manage-
ment of lipids and diabetes as well as certain conditions such as 
hyperhomocysteinemia and morbid obesity. I fee l this trend will 
continue with further emphasis on preventative medicine. 
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Clinical Procedures 
Arthrocentesis 
Elizabeth Au-Yeung, Meds 2004 
Arthrocentesis or joint aspiration is a procedure that drains fluid from a joint using a sterile needle and 
syringe. Aspirating a joint can be both therapeutic by relieving painful joint swelling as well as helpful in 
determining the cause of a joint effusion such as arthritis, infection, trauma, or gout. This relatively simple 
technique can be performed in an office setting and can provide a quick diagnosis for the cause of a joint effu-
sion. Complications of arthrocentesis include introduction of infection into a joint space (0.072%)1, trauma 
to surrounding structures (i.e. articular cartilage, nerves, blood vessels, and soft tissue), bleeding, hematoma 
formation, joint injury, and pain. I, 2, 3 Contraindications to arthrocentesis include cellulitis or broken skin 
over the entry site, anticoagulant therapy that is not well controlled, severe primary coagulopathy, suspected 
bacteremia (unless joint is the suspected source of the bacteremia).• Additionally, drugs can be injected into 
the joint after joint aspiration for a variety of purposes. Some commonly used drugs include local anesthet-
ics, corticosteroids, and hyaluronic acid derivatives) 
GENERAL APPROACH TO ARTHROCENTESIS 
The equipment required for arthrocentesis is listed in Table 1. 
Table 1. Equipment 1,2 
Antiseptic solution for skin preparation (i .e. povidone-iodine 
or alcohol) 
Sterile gloves 
Sterile drapes 
Local anesthetics (i .e. lidocaine HCI or bupivicaine HCl) 
Syringes (one or more 5- to 60-mL syringes depending on joint 
and am_gunt of fluid) 
Needles (18- to 25-gauge) 
Hemostat 
Culture and laboratory supplies 
Bandages and compression dressing 
The technique for arthrocentesis can vary depending on the 
site that is being targeted, however a general approach which can 
be applied to all sites is as follows: 1,2,3 
Before aspiration, the process of joint aspiration should be 
explained to the patient and the patient should be placed in a com-
fortable position that will provide access to the site. Maintain 
sterility by using drapes, gloves, and careful technique. 
1. Mark the site of entry on the skin. 
2. Clean the area of skin with antiseptic. 
3. Inject the appropriate amount oflocal anesthetic into the area 
around the joint. 
4. Insert needle carefully taking care not to move the needle 
from side to side. 
5. After insertion, pull back on the plunger to ensure that vas-
cular structures have been avoided. If blood is drawn, with-
draw needle and reposition it. Normal synovial fluid will 
appear clear or pale-yellow. It is possible that blood can be 
drawn from the joint space or that the needle has entered a 
hematoma. 
6. As the needle enters a joint, a "pop" may be felt or heard. As 
the needle is positioned within the joint space, very little pain 
should be felt. 
7. Slowly drain some of the fluid into the syringe. 
8. Withdraw the needle slowly and cover the entry site with a 
dressing and bandage. Bandage should be left on for at least 
8 to 12 hours. 
9. After aspiration or injection, the affected area should be rest-
ed. In particular, weight-bearing joints will require a longer 
period of rest. 
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SITE-SPECIFIC APPROACHES 
. Listed b~low are approaches to joints that commonly require 
either asp iratiOn or injection of medication .! . 4 
1. Shoulder: Subacromial Space 
Use: 1.5-in., 25-gauge needle with 5- to 1 0-mL syringe 
Insert needle between the posterior tip of the acromion and 
the head of the humerus. Aim the needle anteriorly towards 
the coracoid process. 
2. Shoulder: Long Head of Biceps Tendon 
Use: 1.5-in., 25 -gauge needle with 5-mL syringe 
Flex patient 's elbow to a 90° angle and rotate the patient's 
arm (mternall.y and externally) to palpate the tendon lying 
Withm the biCipital groove. Insert needle at the point of max-
imal tenderness. 
3. Knee: Pes Anserine Bursa 
Use: 1.5-in ., 25-gauge needle with 5-mL syringe 
Patient should be seated or supine. This bursa is located 2 em 
below the medial joint line at the insertion of the sartorius 
gracilis, and semitendinous muscles . Insert needle at th~ 
point of maximal tenderness . 
4. Knee: Prepatellar Bursa 
Use: 1.5-in. , 25-gauge needle with 3-mL syringe for anesthesia 
I 0- to 60-mL syringe with 18-gauge needle for aspiration 
Patient should be supine. This bursa is located between the 
skin and the patella. While stabilizing the patella with one 
hand, u e the other hand to insert the needle at a 45° angle to 
the bursa. 
5. Knee: Intra-articular 
Use: 1.5-in., 25-gauge needle with 3-mL syringe for anesthesia 
I 0-. to 60-mL syringe with 18-gauge needle for a pi ration 
Patient should be seated or supine with the knee lightly 
flexed. Palpate the superior lateral aspect of the patella and 
msert the needle into the space between the patella and femur 
parallel to the inferior border of the patella. Angle the needle 
to the centre of the patella . 
6. Hand: Thumb Abductor or Extensor Tendon Sheath 
Use: 3- to 5-mL syringe with 1- to !.Sin., 25-gauge needle 
Abduct the patient's thumb and palpate along the abductor or 
extensor tendon for the point of maximal tenderness. Insert 
n~edle into the point of maximal tenderness at a 45° angle, 
a1mmg away from the hand. Bending the needle at the hub 
may facilitate insertion of the needle along the course of the 
tendon . 
7. Elbow: Lateral Epicondyle 
Use: 1- to 1.5-in . , 25-gauge needle on 5-mL syringe 
Flex the elbow at a 90° angle. Palpate the latera l epicondyle 
for the point of maximal tenderness . Insert the needle 1 em 
superior and I em distal to this point aiming perpendicular to 
the skin ' surface. 
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8. Elbow: Intra-articular 
Use: 10- to 60-mL syringe with 18- to 25-gauge needle for 
aspiration 
Flex the elbow at a 45° angle. Palpate the lateral epicondyle. 
Insert the needle into the joint space inferior to the lateral 
epicondyle and superior to the olecranon process of the ulna. 
9. Hip : Greater Trochanteric Bursa 
Use: 1 0-mL syringe with 1.5- or 2-in., 22- to 25-gauge spinal 
needle 
Patient should be lying on unaffected side. Palpate over the 
posteroinferior edge of the greater trochanter for the point of 
maximal tenderness. Insert needle slowly until it gently con-
tacts bone. Then withdraw the needle 0.5 em to approximate 
the location of this bursa. 
I 0. Foot: Plantar Fascia 
Use : 1.5-in, 25-gauge needle on 5-mL syringe 
Patient should place the foot with the medial (tibial) side 
upward . Palpate the area between the calcaneus and the fas-
cia and insert the needle into this space. 
SYNOVIAL FLUID ANALYSIS 
The aspirated fluid can be analysed for ce ll count, glucose 
levels, protein levels, gram stain, bacterial culture, and other tests 
such as microscopy for crystals if indicated. Blood aspirated from 
a joint (hemarthrosis) can be a result of both traumatic and non-
traumatic causes. on-traumatic causes include hemophilia, syn-
oviOma, pigmented villonodular synovitis, and oral anticoagulant 
therapy.3 Table 2 lists some of the key differences between normal 
and abnormal synovial fluid. 
Table 2. Synovial Fluid Analysis 3,5 
Finding ormal inflammatory Septic 
Colour Clear Yellow to Green Yellow 
Clarity Transparent Opaque Opaque 
Vi cosity High Low Variable 
WBC per mm3 <200 2,000 to 15,000 to 
150,000 200,000 
PMNs <25% >50% >75% 
Mucin clot Good Good to poor Poor 
WBC = white blood cells; PMNs = polymorphonuclear cells 
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Medicine and the Law 
The Assisted Human Reproduction Act: 
Regulation of reproductive therapeutics and technology 
Lillian Barra, Meds 2005 and Natasha Gakhal, Meds 2006 
The advent of cloning and stem cell technology created much excitement within the scientific community with 
respect to reproductive research. These new technologies provided promise to infertile couples and reached 
beyond reproductive issues to offer new opportunities for the cure of such debilitating diseases as cancer, 
Alzheimer's and Parkinson's. ' Cloning and stem cell research, however, involves the use of human embryon-
ic tissues and this leads to complex ethical questions. Public fears of the misuse of these technologies and other 
more longstanding reproductive issues, such as, surrogacy demand the presence of legislation to regulate these 
activities. In response to such concerns, the federal government introduced Biii-C13 to parliament on May 9, 
2002. The bill entitled, the Assisted Human Reproduction Act 2 aims at protecting reproductive rights and pro-
moting scientific advances, while remaining within the ethical limits set by current public opinion. 
CIHR GUIDELINES FOR STEM CELL RESEARCH: 
When Bill-C l3 was introduced to parliament many fe lt that 
it was long overdue. According to Dr. Patricia Baird (head of the 
federal Royal Commission on Reproductive Technologies) : 
"Unless we have a proper management system to reassure people 
that what is being done is ethical , balanced and accountable, I 
think we could end up not, in fact, using the potentially promis-
ing avenues of research that are presenting themselves now." It 
was evident that regulations were needed and in response, the 
CIHR (Canadian Institute for Health Research) released a report 
in June 2001 , Human Stem Cell Research: Opportunities for 
Health and Ethical Perspectives ) The report provides guidelines 
that were developed by the Working Group on Stem Cell research 
chaired by Dr.Janet Rossant, co-head of the department of 
Development and Fetal Health at Toronto Mount Sinai Hospital. 
These guidelines must be met in order for researchers working 
with human stem cells to quali fy for CIHR grants. According to 
the guidelines, it is permitted to use or derive stem cells from 
embryos, human fetal tissue, amniotic fluid, umbilical cords and 
placentas, provided that the embryos were created for the purpose 
of reproduction and are no longer required. The guidelines disal-
low the creation of human embryos via somatic cell nuclear trans-
fer (cloning), as it was fe lt that cloning is an inefficient process 
that leads to abnormalities and is complicated by ethical con-
cem s4. The creation of embryos strictly for research purposes and 
research in which non-human stem cells are combined with a 
human embryo is also disallowed. In order to ensure that these 
guidelines are met, a national oversight body was created consist-
ing of experts in stem cell biology and therapeutics, ethics and 
law, as well as members of the pubJic3. Although, these guidelines 
aim to establish an ethical code for stem cell research, they are not 
legally binding and legislation is needed to prevent the misuse of 
this new technology. 
THE ASSISTED HUMAN REPRODUCTION ACT: 
Introduction: 
The preparation of legislation dealing with reproductive 
therapeutics and technology involved a lengthy process beginning 
in 1989 with the creation of the Royal Commission on New 
Reproductive Technologies. In 1996, Bill C-475 (the Human 
Reproductive and Genetic Technologies Act) was introduced to 
parliament. The bill was highly criticized for including only pro-
hibited actions and for being di fficult to amend, an important con-
cern considering the numerous scientific developments expected 
to occur in the coming years6. Bill C-47 was never passed and it 
was not until 2002, that the federal government presented a new 
bill , Bill C-13 (the Assisted Human Reproduction Act) . It is appar-
ent that the guidelines for stem cell research developed by the 
CIHR significantly influenced this act; sections relating to stem 
cell research closely refl ect the aims of the CIHR. However, Bill-
e 13 addresses a wider range of reproductive health issues. The 
Bill [section 2] stresses that the rights of children born through 
the application of reproductive technology is paramount. Also 
emphasized is that the principle of free and informed consent 
must be promoted and applied as a fundamental condition for the 
use of human reproductive technologies. The legislation aims to 
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protect Canadians from the commercial exploitation of women's 
and men 's reproductive capabilities and to preserve human indi-
viduality, diversity and the integrity of the genome. 
Prohibited activities: 
As expected, the Bill bans the creation of human clones for 
any reason. Also prohibited is the in vitro creation of an embryo 
for any purpose other than creating a human being. It also pro-
hibits the introduction into human embryos of germ-line muta-
tions capable of being transmitted to descendants. Research 
involving the production of human hybrids (human ovum com-
bined with non-human sperm or vice versa [section 3(1)]) and 
human chimeras (an embryo into which a cell of any non-human 
life form has been introduced; or an embryo that consists of cells 
of more than one embryo, fetus or human being [section 3(1)]) is 
banned [section 5(1)]. 
Although the above measures are generally widely support-
ed, the stiffiing of the commercialiazation of assisted reproductive 
technology is more controversial. The act makes it illegal to offer 
payment to surrogate mothers or to counsel or induce someone to 
be a surrogate mother[ section 6]. It is also illegal to purchase, sell 
or provide goods and services in return for ova, sperm, in vitro 
embryos and human cells or genes [Section 7]. Section 5( 1 (e)), 
which prohibits both the identification of the sex of an in vitro 
embryo (except for the purpose of identifying a sex- linked di sor-
der) and any procedure that ensures or increases the probability 
that an embryo will be of a given sex, is felt by some to infringe 
on a person 's freedom of choice. 
Controlled Activities and Privacy Issues: 
The act states that a license must be obtained for a person to 
undertake a controlled activity. The controlled activities include 
the alteration, manipulation or treatment of any reproductive 
material [section 10(1)] or in vitro embryo [section 10(2)]; the 
obtaining, storage, transfer and destruction of gametes and 
embryos [section 10(3)] and the participation in research involv-
ing human transgenics [section 11 (1)]. The law would, therefore, 
allow for embryonic and adult stem ce ll research and for surplus 
embryos created for in vitro fertilization to be used for medical 
research .. However, licensees may only make use of reproductive 
material or in vitro embryos after obtaining the full y informed 
written consent of the donor of these materials and embryos [sec-
tion 8( 1)]. Once consent is given, a licensee must co llect a donor 's 
medical information [section 14(1)] and give the children born 
through the donated reproductive materi al access to thi s materia l 
[section 18(3)]. This information may also be disclosed to an indi-
vidual or organization for sc ientific research or statistical purpos-
es [section 15(5)]. The identity of the donor must never be di s-
closed unless this person has given explicit written consent [sec-
tion 15( 4)]. A licensee is allowed to reimburse surrogate mothers 
and donors of sperm, ovum or in vitro embryos of expenditures 
incurred in the course of a controlled activity[ section 12( 1 )]. 
Assisted Human Reproduction Agency of Canada: 
To regulate reproductive technologies and therapeutics, Bill 
C-1 3 states that an Assisted Human Reproduction Agency 
(AHRA) is to be created as an entity separate from Health 
Canada. According to the bill , the AHRA is responsible for 
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reporting to the Ministry of Health and consists of up to 13 mem-
bers of the Board of Directors reflecting a range of backgrounds 
and disciplines [section 26(2)]. It would be given numerous 
responsibilities including the issuance of licenses for controlled 
activities; designating inspectors and analysts to enforce the Act; 
monitoring and evaluating developments in assisted h~an repro-
duction (AHR); collecting, analyzing and managmg health 
reporting information relating to controlled activities and rep~rt­
ing any risk factors associated with infertility or AHR [sectiOn 
24(1)]. The AHRA would also maintain a donor and offspring 
registry, and set the parameters for stem cell and other reproduc-
tive research. 
Conclusion: 
When Bill-C13 was introduced, it was well received by the 
scientific community. A majority of scientists, including Dr. 
Barbara Beckett (of the Stem Cell Network, representing univer-
sity-based scientists across the country), feel that the act allows 
for the progress of science in a responsible and ethical way. 
However, pro-life groups, supported by the Canadian Alliance 
party, are strongly opposed to the use of embryos for research 
purposes. The Campaign Life Coalition is concerned that the 
Assisted Human Reproduction Act reflects the CIHR guidelines 
rather than the views of MPs. It insists that stem cell research 
should only be conducted with stem cells isolated from adult tis-
sues. Scientists argue that adult stem cells are harder to work with 
and that it is unclear whether adult stem cells have the same 
potential as embryonic stem cells to form cells from every tissue 
in the body. Controversy also surrounds the banning of commer-
cialized AHR. Doctors and lawyers who deal with infertile cou-
ples desperate to conceive fear that there will be a resulting 
decrease in the availability of ova, sperm and surrogate mothers, 
subsequently promoting illegal AHR activities6,7. 
Like Canada, the U.S. permits federal funding of stem cell 
research using embryos discarded from fertility centres. 
Currently, the George Bush administration wants the Senate to 
pass laws banning human cloning for any purposes. The United 
Kingdom, however, has taken a different stance. Although the 
House of Lords has pas ed a bill making reproductive cloning 
illegal, therapeutic cloning to cure illness was not disallowed6. 
Has Canada chosen the right approach to deal with the often con-
troversial issues surrounding reproductive health? Numerous 
questions have arisen since the Assisted Human Reproduction Act 
was introduced to parliament: does the Act accurately reflect pub-
lic opinion? Will scientists comply with the regulations? Will it 
ensure that there are no financial incentives or coercion? How 
wi ll donors feel about the Act? Will there be enough donors to 
meet th~ demands? If not, how should the government respond? 
As the bill undergoes revision, these concerns are hopefully being 
addressed. Nevertheless, wtth the potentially dangerous conse-
quences of the mtsuse of reproductive technologies, an imperfect 
law may be better than no law at all. 
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Health Promotion 
Risk Factors in Osteoarthritis 
Anna Labuda, Meds 2005 
Osteoarthritis affects a vast segment of our population and is associated with significant disability. While 
some risk factors have been clearly established, others receive less support. Recognized risk factors are usu-
ally classified as local or systemic. Naturally however, one may predispose to, result from , or interact with the 
other. It is important to keep in my mind that ultimately, the goal of risk factor studies is to assist with the 
development of strategies against potentially preventable risk factors. Prospective preventable local and sys-
temic risk factors reviewed in this article include occupational factors, sports injuries, past acute joint injury, 
obesity and nutritional factors. Additionally, this article provides a brief overview of other risk factors, which 
are less likely to become targets of intervention. Some of these include the role of muscle weakness, proprio-
ception problems, estrogen and ethnicity in the development of osteoarthritis. 
Arthriti s, which refers to more than l 00 different conditions, 
is the leading debilitating disease in the United States. ' .2 
Osteoarthritis (OA) is the most common form of arthritis, affect-
ing 21 million people. ' As it is primarily a disease of aging, OA 
will become increasingly more prevalent in the near future, due to 
maturation of the baby boomers. OA is responsible for more dif-
ficulty walking and climbing stairs than any other di sease, and it 
is the primary reason for total hip and knee replacements.J Over 
the age of 50, females are more affected with knee, foot and hand 
osteoarthriti s than males; conversely most studies show OA of the 
hip to be more frequent in men.J The impact of arthriti s on 
patients ' lives is tremendous. It includes decreased health-re lated 
quality of life, acti vity limitations, work disabili ty, role limita-
tions, economic consequences, as we ll as psychologica l conse-
quences, social consequences and li fe strain.2 The aim of prima-
ry OA prevention is to reduce these negative outcomes, however, 
for this to be feasible and successful , the ri sk factors for OA must 
be well-identified. To date, a large number of ri sk factors have 
been identified, which generally fa ll into one of two classes, local 
or systemic.J-5 
LOCAL RISK FACTORS 
Phys ical activity, including occupational factors and sports 
participation, has been linked to OA development via non-phys i-
ologic joint loading or inj ury.2,4 It has been found that occupa-
tions in which workers do certain physical activities repetitively 
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increase the risk for OA in those j oints.3.4 At least one study 
showed that a job invo lving medium physica l demands and knee 
bending doubled the ri sk of knee OA in comparison to a job with 
minimal (i.e. sedentary) phy ical demand and no knee bending.6 
Other studies have found correlations between incidence of knee 
OA and duration of knee bending activities in various professions, 
such as carpenters and painters; squatting has also been identified 
as a ri sk factor for knee OA in males.4.7 Other occupational activ-
ities, such as stair and ladder climbing, standing, and lifting heavy 
objects, have been inconsistently associated with increased OA 
incidence.7 Similarly, participation in certain sports may increase 
the ri sk for osteoarthritis. These include high intensity activities, 
with direct impact of the joint via contact with other players, play-
ing surfaces , or equipment.3 Football and soccer are but two 
examples of such sports. On the other hand, moderate, regular 
running has a low to non-existent associated ri sk of osteoarthri-
ti s. J 
Many studies have shown an assoc iation between knee 
injuries and the development of knee 0A.4 In a recent longitudi-
nal study, 1t was found that both knee and hip OA were more like-
ly to occur in those individuals who had suffered a joint injury in 
young adulthood .8 Even though the exact nature of the relation-
ship between joint injuries and OA is unclear, it is apparent that 
articular surface fractures , joint dislocations, ligament and menis-
ca l tears do increa e the risk fo r post-traumatic OA.J It has been 
hypothesized that poss ible ri sk factors for post- injury OA devel-
opment may include residual joint instability or misalignment, 
articular surface di screpancy, increased body weight, and high 
level of activity) 
SYSTEMIC FACTORS 
One of the best described risk factors for OA is obesity5 
Overweight individuals have an increased risk for knee OA, and 
in most studies, thi s association is more marked in women than 
men .3.5 It has been shown that weight increase in women, in the 
mid to later years, definite ly affect the risk of onset of 
osteoarthritis. IO The a sociation of hip OA and obesity is less 
marked than that for knee OA; unilatera l hip OA is not clearly 
associated with obesity, while bilatera l hip OA is. 3 It is thought 
that weight could possibly act in everal ways to predi pose an 
individual to OA. Most of the increased risk for OA is likely 
explained by the overloading of the joints, which can lead to car-
tilage breakdown, failure of ligaments and other support 3 ,5 
Furthermore, adipose ti ssue could predispose underlying bone 
and cartilage to OA via production of atypical concentrations of 
certain growth factors an hormones .s It is of no surprise than that 
in obese individuals, weight loss had been associated with 
reduced risk for osteoarthritis . IO 
Though it has been shown that nutritional factors can 
increase the risk of establi hed knee OA, no evidence has been 
found that these factors influence the ri sk of development of new 
onset OA. I2 In fact, there are very few clinical trial s examining 
the association between diet and OA; the existing trials have pri-
marily focused on vitamins C, D and E. 5 Evidence does exist 
however that indicates prolonged exposure to oxidants con-
tributes to deve lopment of several "aging" di seases, such as 
osteoarthritis ) As oxygen radicals are recognized for destruction 
of cartilage and connective ti ssue, research directed at OA pre-
vention has focused on the use of anti-oxidant vitamins A, C and 
E; vitamin D may also play an important role, v ia bone mineral-
ization and cell differentiation .5,I3 
In addition to the above discussed potentially preventable 
risk factors of OA, several other local and systemic factors have 
been linked to osteoarthritis development. Locally, knee laxity, 
which is the displacement of the tibia with respect to the femur, 
may precede OA development and predispose to the disease.3.4 
Problems of proprioception, which is the conscious and uncon-
scious perception of joint position and movement, may also pre-
cede OA development.J,4 Congenital dislocations and acetabular 
dysplasia have been definitely linked to premature osteoarthritis 
of the hip .3 Some have also proposed that quadriceps weakness 
may increase the risk of knee OA.3.4 Finally, a recent study impli-
cated past surgery as a risk factor for OA, by showing an 
increased risk of knee osteoarthritis 2 1 years after open menisec-
tomy as compared to controls .9 In terms of systemic ri sk factors, 
the increase in incidence of OA among post-menopausal women 
has suggested estradiol deficiency as a risk factor for OA.3·11 
However, there is currently no consensus on this, as estradiol has 
been implicated as both increasing and decreasing the risk for 
OA.II It is evident that heritability plays a crucial role in devel-
opment of OA, at least in some subgroups.s In fact, genetics are 
responsible for over 50% of OA cases in the hips and hands.14 
Finally, ethnic differences in the incidence of hip and knee 
osteoarthriti s have al so been tudied, and the resul ts are confli ct-
ing) Above all , age is the most powerful , and the least pre-
ventable, ri sk factor for the development of OA. 1 
Osteoarthriti s affects a large percentage of the popu lation 
and leads to significant disability. In ome cases, joint rep lace-
ment may be the only hope for an improved quality of li fe . 
Fo llowing the models of OA pathogenesis, risk factors are usual-
ly classified as local or systemic. Naturally however, one may pre-
di pose to , result from , or interact with the other. Some risk fac-
tors, such as increasing age, obesity, past joint injury, occupation-
al factors and developmental abnormalities have been extensive-
ly studied and well establi shed. Other ri sk factors , such as muscle 
weakness, role of estrogen and ethnicity have received less sup-
port. Furthermore, knowledge is lacking regarding the specific 
influence of many of the risk factors on the key events in OA: the 
onset of OA, progression of the disease, and disability in those 
with OA. Ultimate ly however, the goa l of ri sk factor studies is to 
assist with the development of strategies against potentially pre-
ventable risk factors . 
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Forensic Medicine in China 
Mar/is Sabo, B.Sc., Meds 2005 
The Chinese tradition of forensic medicine developed separately from both the Western tradition and med-
ical practice within China. Unique philosophical and societal factors contributed to the early rise and metic-
ulous practices. Beginning with early writings over two thousand years ago, the practice of forensic medical 
investigation has been highly scientific and played a key role in the investigation of deaths. The Chinese are 
credited with developing the first systematic treatise on forensic medicine in the world. Only after European 
practices of autopsy did the practice of forensic medicine in China become fully integrated into the medical 
system. 
INTRODUCTION 
Forensic medicine has been gai ning prominence in recent 
times with the rise of molecular techniques. In Western tradition, 
the autopsy has formed a major component of the post-mortem 
investigation and is a central ski ll in a pathologist's armamentari-
um. However, an entirely different practice arose in China long 
before parallel activities in Western medicine. Rather than devel-
oping alongside medicine as a whole, forensic medicine and 
investigation in China evolved outside the domain of medical 
practitioners and was only integrated at the begirming of the twen-
tieth century. 
INFLUENCES ON CHINESE FORENSIC MEDICINE 
Several factors influenced the early ri se and tructure of 
Chinese forensic medicine. From the beginning, forensic investi-
gations were essentially separate from the medical profession.3 
Chinese physicians were of a low class and not usually ca lled 
upon to give a medical opinion - they dealt with the living and not 
the dead .3 Furthermore, the wu tso (a sort of slave-class under-
taker) and the tso pho (a woman, usua lly the midwife, who exam-
ined female corpses) had no medica l training) 
In contrast to the West, Chinese philosophy was not based in 
religious considerations, and therefore the idea of a higher form 
of justice was not prominent. One school in particular is associat-
ed with the development of forensics. The legist school, originat-
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ing over 2000 years ago, held that the population at large was stu-
pid, predisposed to evil,8 and acted from largely selfish motives 
such that all laws had to be clearly stated and not subject to inter-
pretation) Included was a moral imperative to clear the names of 
the innocent) The legist school had become the official policy of 
the Qin state (22 1 BC). It is not hard to see how such a belief sys-
tem would promote detailed inve tigation to ensure that the cor-
rect per on was punished to the full extent of the law. 
Another factor was the highly organized political structure of 
Chinese government. Each county had a sub-magistrate who was 
in charge of the victim, living or dead.5 His function also includ-
ed searc~ing and arresting the accused.5 Slaves (wu tso) were 
brought m to do the drudge work, and doctors were consulted in 
cases of disease.5 As the system evolved, careful documentation 
had to be made for every case and signed off by the presiding 
official as being factually correct.J,5 
An important feature of Chinese forensic medicine is the 
ex~lusion of dissection and the lack of internal examination. The 
Chmese view of the body and its disorders was built on an ele-
mental theo.ry, and like other cultures of the time, rejected the idea 
that d1ssect10n was nec~ssary for a~ ~derstanding of the body.6 
There was also the behef that mutliahon continued after d th 
which impaired the development of surgery and may ha eal ' 
. . ~a w 
contnbuted to the lack of mternal examination.! In any ev t th 
. f h . . en , e 
energ1es o t e mveshgators were focused on detailed t 1 . ex ema 
observatiOns. 
EARLY DEVELOPMENTS AND WRITINGS 
The first writings on forensic investigation date back to the 
time of the Warring States (475-21 BC) with "The Book of Rites" 
and "Lii Shi Chunqiu" which urged officials to view injuries, ana-
lyze findings , and judge cases.s The next key period was the Qin 
State (252-21 BC) with "Dialogue to Law" and "Feng Zhen Shi ." 
These works were concerned with criminalistics and foren ic.s 
Although findings such as the tell-tale neck marks made by hang-
ing were known,s other investigations were clearly hampered by a 
lack of medical knowledge .3 
Forensic investigation in this period followed a highly scien-
tific approach, as demonstrated by story of Zhang Ju and the 
pigs.5 Zhang Ju was a magistrate (sometime between 27-97 AD) 
who used two pigs to demonstrate the difference between pre and 
post-mortem burning. It was found that the living pig had powder 
and debris in the mouth and nose. By this demonstration, he was 
able to show that the accused was Iying.s 
THE SONG DYNASTY 
The most significant period in the development of foren ic 
medicine in China was the period of the Song Dynasty (960-1287 
AD) . By 1000 AD, all suspicious deaths were examined, with vio-
lent deaths reported and re-examined. By 1174 AD, a standard 
form to be filed in triplicate including such information as the 
name of the prosecution, presiding official at the inquest, the 
assistant, the warrant, time of arrival at the scene, number of 
wounds on the deceased, and the cause of death .5 At this point, the 
wu tso removed the body, anointed it with wine or vinegar to dis-
cover the injuries, and marked the wounds under supervision .3.5 
Doctors were brought in for examinations of the living. s Anterior 
and posterior diagrams were introduced in 1204 so that the coro-
ner could mark wounds accurately) 
SUNG TZ'U AND "THE WASHING AWAY OF WRONGS" 
It was during the Song Dynasty that the definitive work of 
forensic medicine was written. Sung Tz ' u was a public official 
who consolidated all previous learning and practice in the area 
into a single systematic treatise on the subject in 1247 AD. The 
work devotes a section to nearly every type of death with case 
studies and approaches to the investigation of each.2 From the 
very beginning of the work, a meticulous attitude is stressed. 
If death has just taken place, first examine the top of the 
head, and the back, the ears, the nostrils, the throat, &c., and 
all places where anything might be inserted ... Moreovet; 
deaths from self-strangulation, throat-cutting, taking poison, 
burning, drowning, and the like, produce ve1y different 
results, and only the most minute investigation of eve1y little 
detail will ensure a complete and reliable verdict.l 
Among the included theory and techniques are two notewor-
thy examples. The first concerns the concept of "vital spots," 
places on the body where it is particularly susceptible to internal 
injury and death without obvious external signs. There were 16 
anteriorly and 6 posteriorly. Modem medicine has confirmed 
many of these, which include the fontanelles of the skull, occipi-
tal or cervical regions, just superior to the sternum, the perineal 
region, and the scrotum.3 
Numerous techniques are described, including the technique 
of making wounds, evere contu ions and bruise appear on the 
surface of the body. Bones were prepared by burn ing off the fl e h 
and then viewed on a bright day under a red-coloured umbrella. 
Bone bruises would show red traces, and fracture edges would 
have a red halo. Thi method also distinguished pre and post-
mortem fracture because there would be no red on post-mortem 
fractures. The principle seems to be similar to modem infra-red 
lighting.3 
MORE RECENT TRENDS 
After the publication of Sun Tz' u's work, it was recopied 
many times. Together with a later work "The Cancelling of 
Wrong " written in 1308, translations appeared in Japan and 
Korea, forming the basis of foren sic medicine there .3 China pre-
ferred Sung Tz ' u's work and it was the definitive manual up until 
1927.6 The work was so comprehensive that it basically shut 
down further experimentation in the field, much like Galen 's work 
did for Western medicine in the Middle Ages.6 In fact , new find-
ings could not be accepted if they contradicted the text.5 
The Xin Hai Revolution of 1911 changed the ituation sig-
nificantly. The Criminal Procedure Law of 1912 permitted inter-
nal examination (heretofore banned).5 It was at this point that the 
medical profession became involved in examinations of the dead. 
While either the coroner or doctor could perform the external 
examination, only the doctor could perform the autopsy.s The 
demand for such investigation became so great that the first 
department devoted to instruction of autopsy techniques was 
founded in 1930 by Lin Ji , a physician who studied in Germany.s 
At the peak of the period, every physician with one year of hos-
pital experience was trained to be a senior pathologist for serving 
the judicial system.s Others from senior middle schools were 
tapped to become technicians for the courts. Coroners received 6 
months of intensive training.S 
The founding of the Republic in 1949 ushered in a period 
where the use of forensic medicine waxed and waned repeatedly, 
and is currently not as prominent as it was in the first half of the 
twentieth century.s 
COMPARISON WITH EUROPEAN FORENSIC MEDI-
CINE 
Forensic medicine was largely unknown in the practice of 
Greece and Rome, and had a limited use in Hellenistic Egypt. The 
Justinian Code (529-64 AD) urged the cooperation of medical 
experts in various legal problems such as pregnancy, sterility, 
impotence, legitimacy, rape, poisoning, and mental disease.3 This 
is regarded as the highest point in forensic medicine prior to the 
Middle Ages, but no systematic treatise existed.3 
Similar to the sub-magistrate of early Chinese investigation, 
England had a "crowner" in each county investigating suspicious 
deaths by 1194. Bologna was the first city to use expert medical 
investigation in all criminal offences against person in 1252. 
However, the role of the physician was limited to determining 
whether a wound was mortal or whether they were caused pre or 
post-mortem. 
There is a lack of any reference to medico-legal doctors 
through the Middle Ages, and no developments are recorded until 
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1507. In the Germanic territories, expert medical testimony was 
used to guide verd icts in murder, wounding, poisoning, hanging, 
drowning and other such crimes. As with the rest of medicine, 
Vesaliu '"De fabrica humani corporis (1543)" revolutionized the 
situation and put the too ls of dissection into the phys icians ' hands 
rather than the prosectors. The firs t comprehensive text on foren-
sic medicine was printed in 1602 by Fedele followed by 
" Quaestiones medico-l egales" by Zacchia (1621-35) which 
marked the beginning of forensic medicine in Europe.3 It has 
been theorized that the lack of a comprehensive text on forensic 
medi cine in Europe purred the development of the field as doc-
tors sought to explain the mechanics of crime.6 
CONCLUSION 
The Chinese tradition of forensic medicine is a ri ch one 
beginning much earli er than the tradition in Western medicine. 
From very early on, it was a highly scientific practice driven by 
the desire to ensure that only the guilty were punished for crimes. 
In contrast to We tern practices, which included phys icians early 
on, the Chine e tradition only included doctors in po t-mortem 
examinations once Western practices were introduced into the 
Chinese system. Indeed, the emphasis placed on external exami-
nation of the body and the scene of the crime is very simi lar to the 
approach used in thi country today. 
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Assessment of glenohumeral instability and indications for surgical repair 
Blayne Welk (ESc, Meds 2004), Sebastian Rodrigue::-£/izalde (HBSc, Meds 2004) 
The shoulder is an extremely common joint to injure despite the stabilization it receives from both static and 
dynamic structures. Shoulder instability can be identified with a complete physical exam with careful atten-
tion to specific tests for instability. The most severe form of shoulder instability is dislocation. A dislocation 
commonly occurs in young males, especially athletes, when a traumatic force is applied to the shoulder while 
it is abducted and externally rotated. Once the joint is reduced, several factors such as the person 's age and 
the number of times the shoulder has been dislocated must considered in the determination of whether con-
servative or surgical treatment should be attempted. If surgical stabilization is indicated, serious considera-
tion should be given to arthroscopic stabilization due to its increasing reliability and decreased morbidity 
compared to an open procedure. 
INTRODUCTION 
The shoulder repre ents a ball and socket synovial joint, 
formed by the articu lation of the head of the humerus with the 
glenoid cavity of the scapula. The shoulder is the most common-
ly dislocated joint of the body' due to the lack of restraint placed 
on the shoulder joint, and the high potential for injury with an 
active lifestyle. 
The glenohumeral joint is stabi li zed by static and dynamic 
forces. Static forces include the labrum, joint capsule, rotator 
interval , and glenohumeral ligaments. The fibrocartilagenous 
labrum attaches to the glenoid rim and serves to increase the gle-
noid 's depth and act as a shock absorber2. It is important to note 
that the humeral head has a much larger diameter and surface area 
compared to that of the glenoid2. This is responsible for the 
increased range of motion possible in the shoulder joint. The 
fibrous joint capsule attaches medially to the glenoid cavity and 
laterally to the anatomic neck of the humerus3. The rotator inter-
val is composed of the leading edge of the supraspinatus and the 
superior edge of the subscapularis muscles4. Finally, the gleno-
humeral ligaments act to stabi lize the shoulder joint. These 
include the superior, medial and inferior glenohumeral ligaments, 
and the coracohumeralligament3. 
Dynamic forces include the rotator cuff (the 'SITS" 
muscles, consisting of supraspinatus, infraspinatus, teres minor, 
and subscapularis) and the scapular stabili zers (serratus anterior, 
the pectoralis and latissimus dorsi)2. 
The term shoulder instabi lity encompasses laxity, subluxa-
tion , and dislocation . Shoulder laxity describes an inherent loose-
nes in the static forces stabili zing the shoulder. Shoulder sublux-
ation implies that the relationships between the bones of the 
shoulder have changed however there is still contact between the 
joint surfaces. Shoulder dislocation occurs when the humeral 
head is completely put out of jointS 
Many pathological le ions have been identified in traumatic 
and atraumatic shoulder instabi lity. The classical traumatic one is 
the Bankart lesion, in which the anterior inferior labrum and the 
inferior glenohumeral ligament detach from the glenoid rim6. A 
Hill-Sacks les ion is a defect on the posterolateral aspect of the 
humeral head. This is due to compression of the humeral head 
aga inst the anterior glenoid rim during dislocation6. 
NATURAL HISTORY 
The exact prevalence of shoulder instability ha been diffi-
cu lt to accurate ly determine in the general population. It is esti-
mated that 4-8% of the injuries sustained by an active population 
are shoulder related?. Shoulder instabi li ty commonly presents in 
its most severe form as a shoulder dislocation. 
The majority of shoulder dislocations occur in patients dur-
ing their 20's, and are equally likely to occur in either arm inde-
pendent of handedness8. These dislocations are generally classi-
fied by the direction of the dislocation (anterior, posterior, inferi-
or or multidirectional). Approximately 85-90% of these patients 
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are male and 95% of these dislocations are anterior dislocationss. 
Anterior dislocations generally occur when a force is applied 
to the houlder when it is abducted and externally rotated. Other 
possible mechanisms include a direct blow to the shoulder, falling 
with the arm outstretched, a seizure or electrocutions. The chance 
of a recurrent shoulder dislocation is extremely high in those 
younger than 20 years, and much less likely in those o lder than 40 
year 2. 
A patient with an anterior di slocation generally pre ents with 
their arm slightly abducted and internal rotated with pain present 
if the arm is moved7. The patient may report transient loss of sen-
sation in the arm, with numbness and tingling. 
PHYSICAL EXAM 
A full physica l exam of the shoulder should involve carefu l 
observation of the affected and normal shoulder, palpation of 
bony and muscular landmarks , pass ive and active ranges of 
motion, neurovascular exam (especially of the axi llary nerve , 
which if damaged may cause loss of sensation over the lateral 
shoulder and weakness of the deltoid), and a screening exam of 
the elbow and cervical pine. 
There are also specific te t that relate to shoulder instabili-
ty. Although these tests are not necessary for the diagnosis of a 
shoulder dislocation, they provide important prognostic informa-
tion for future dislocation, and may influence the management of 
a subluxation or dislocation once it has occurred5. Some of the 
most common tests include: 
1. Load and Shift test 
The patient is placed in the supine position so that their 
scapula is centered over the edge of the examining table. The arm 
is grasped with one hand near the humeral head and the other 
hand approximately halfway down the humerus. The arm is posi-
tioned in 20 degrees of abduction and pulled with the di stal hand 
while the proximal hand attempts to hift the humeral head. Thi 
is highly pecific ( 100%) for shoulder in tability, but not very 
sensi tive (ranging from 8% for inferior instability to 50% for 
anterior stabi lity)5.9. 
2. Sulcus sign 
This test primarily analyses the superior glenohumeral liga-
ment. The patient is seated with their arms relaxed by their sides. 
Their elbow is grasped and pulled inferiorly. A po itive te t i 
establi shed by the appearance of a dimple in the subacromial 
region . A dimple greater than I em ha a sensitivity of 72% and a 
specificity of 85% for shoulder instability5. 
3. Apprehension/ Augmentation/Relocation test 
The patient is supine with their scapula centered over the edge 
of the examining table. The ir arm is positioned in 90 degrees 
abduction, 90 degrees of fl exion at the elbow, and then externally 
rotated. If the patient report a sensation of an impending di loca-
tion then the Apprehension test is positive. If a sensation of di slo-
cation is enhanced with the application of an anterior force on the 
humeral head, then the Augmentation test is positive, and if this 
sensation is relieved with a posterior force app lied to the humeral 
head then the relocation test was po itive. The augmentation and 
relocation test have a specificity of 1 00%; sensitivity for the aug-
mentation test is 68% and for the relocation test is 57%5. 
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Physical exam under anesthesia is considered the gold stan-
dard for assessing the degree of shoulder instability. Results of a 
physical exam of the shoulder joint under anesthesia demon~trat­
ed a sensitivity of 100% and a specificity of 93% in one tnal of 
55 shoulders clinically diagnosed with shoulder instability 10. 
RADIOLOGY 
Standard X-Ray views of a suspected dislocation include 
anteroposterior views of the shoulder internally and externally 
rotated, an axillary view (especially if posterior dislocation is sus-
pected), a modified axillary view (especially if there is anterior 
instability) and the Stryker notch view (important for assessing 
for a Hill-Sachs lesion)'' · More accurate Iabral imaging may be 
done with the use of MRJ. 
TREATMENT AND SURGICAL OPTIONS 
There are two techniques for the reduction of an anterior dis-
location. The modified Kocher method is carried out by placing 
the patient supine and applying traction on the humerus while the 
arm is in an adducted, externally rotated and flexed positioni 2. If 
this does not spontaneous reduce, then the arm i internally rotat-
ed and further adducted. In the Stimson technique the patient is 
prone and a weight is placed on the dislocated armi 2. Within 15 
minutes the humerus returns to position with the aid of gravity. 
Conservative treatment consists of rest and immobilization, 
the u e of SAID ' and ice for ymptomatic relief followed by 
rehabilitation. Physiotherapy generally consists of range of 
motion exerci ses, isometric/isotonic strengthening, and finally 
activity/sport specific activities7. 
Indication for a urgical approach after the initial reduction 
include the following : the initial dislocation where a second 
occurrence would be dangerous (for example athletes construc-
tion workers, and mountain climber ), a second di location after 
the initial one wa managed con ervatively continued pain from 
glenohumeral ubluxation after con ervative treatment a Hill-
Sacks le ion, and a tom rotator cuff with a greater tubero~ity frac-
ture.2·6·13 There is al o orne support for initial surgical stabiliza-
t~on of the shoulder if the per on is young (less than 25), if the ini-
tial trauma causing the di slocation was minimal , or if general lig-
amentous lax ity is pre enti 4. 
Once the deci ion ha been made to surgica lly tabilize the 
houlder, c_onsideration ~hould be given as to whether an open or 
art~osco~1c procedure IS appropriate . Arthroscopic repair is the-
oretically 1deal due to less time in the operating room Jess blood 
l?ss, a shorter h~s~i~al stay _and fewer post-operativ~ complica-
tiOn . However, mitial tud1es found much higher di slocation 
recurrence ra:es o~ between 13_ to 70~ with arthroscopic repair 
vers~s 0 to ~O Yo w1th open repa1rs2. Th1s limited the use ofarthro-
scob~,l~ re_pair and patient 's willingne s to undergo arthroscopic 
sta 1 1Zat10n. 
Arthroscopic repair has since become much mo 1· bl 
Th · · d . re re I a e . 1 1 ue to better techniques instruments surg1·ca l · 
. ' , expenence 
and post-operatmg roo~ rehab_il_itation .2,I3 One study found that 
open versus arthroscopic stabilization had equivalent 
d . 1 · ·f recurrent 1 ocat10ns 1 the procedure was elected based on e · · 
. . . xammat10n 
under anesthesia, and 1f diagnostic arthroscopy was u ed to 
ensure that no contraindications to arthroscopy exi tedi 5. Such 
contraindications include glenoid bone loss, attenuated capsulo-
labral tissue, engaging Hill Sachs lesion, rotator interval lesions, 
and the absence of a Bankart lesion Is. 
CONCLUSION 
Shoulder instability is a complex problem that plagues many 
young athletes, and is a common traumatic shoulder injury. A 
careful history and physical exam, with proper imaging will lead 
to an accurate diagnosis and assist in determining the appropriate 
treatment course. It is important to recognize the situations in 
which surgical stabilization may be appropriate. If a suitably 
experienced surgeon is available, arthroscopic glenohumeral sta-
bilization may now be an appropriate intervention. 
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Early and late cardiac involvement in rheumatic disorders 
Atu/ Dave Nagpa/ BScPT. Meds 2004 
This paper provides an overview of selected rheumatic conditions and their extraarticular features with a 
focus on cardiac involvement. 
Both seropositive and seronegative arthropathies may present 
with clinica lly appreciable extraarticular features , but the symp-
toms are often overlooked as the much more dominant joint trou-
bles tend to draw the clinician 's attention. Extraarticular features 
including cardiac, pulmonary, neurologic , occular, and vascu litic 
disease can be a considerable source of morbidity, and should be 
excluded in the assessment of a pathologic joint.I .2.3 
INFLAMMATORY ARTHROPATHIES: 
Affecting approximately 0.3 - 0.5% of males and 1.5 - 1.8% 
of females , an inflammatory arthropathy may occur at any age but 
has a peak incidence in the fifth decade of life.I.4 Patients with a 
polyinflammatory arthritis uch as rheumatoid arthriti s typica lly 
present with compla ints of joint pain, swelling, defom1ity, and 
morning stiffness. Commonly affected joints include MTPs, sub-
talars, ankles, knees, shoulders, elbows, wrists, MCPs, and PIPs. 
Joint destruction occurs early; 70% show radiologic signs of dam-
age wi thin 3 years of onset.4 On laboratory inve tigation, 70 - 80% 
wi ll be IgM rheumatoid factor positive. Other marker of the dis-
ease include elevated ESR, CRP, immune complex assays, and 
platelet counts. ' 
Extraarticular features tend to be more prevalent in males 
and seropositives. Common constitutiona l features incl ude 
fatigue , weight loss, and fever. Subcutaneous and intracutaneous 
nodules occur in 20 - 30% of patients; nodules may also develop 
in other tissues including the eye, pleura, perica rdium, and 
parenchyma of the lungs and heart.2 The latter may lead to dys-
function of the heart valves and conducting tissue. Evidence of 
pericarditis is often found in patients with rheumatoid arthrit is but 
is rarely symptomatic; a pericardia) rub can be heard in up to 30% 
of patients, and a pericardia! effusion can be identified echocar-
diographically in 14- 50%.2,5 ln extremis, pericarditis can lead to 
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cardiac tamponade, requmng urgent surgical intervention.s 
Vasculitis is seen in 20% of patients, which may cause circulato-
ry disturbances leading to renal dy function, neuropathies, and 
coronary ischemia .I.2 Other extraarticular manifestations of 
inflammatory arthritis have been described in bone, renal , liver, 
lung, and lymph tissue.I.2.4 
SERONEGATIVE ARTHROPATHIES: 
The seronegative arthropathies are a group of diseases that 
can pre ent with sacroiliitis , spondylitis, peripheral arthritides, 
uveitis, or other extraarticular manife tations. They are associat-
ed with the HLA-B27 allele, with a prevalence estimated at 7% in 
the North American Cauca ian population. I Diseases in this cate-
gory include anh.rylosing spondylitis, Reiter's syndrome, reactive 
arthritis , psoriatic arthritis, juveni le spondyloarthropathy, entero-
pathic arthritis (not B27 positive) , and undifferentiated spondy-
loarthropathy. 
Ankylosing spondylitis presents predominantly in males 
under the age of 40 with inflammatory joint symptoms of the low 
back progressing to nil ROM as the sp ine fuses. Up to 40% of 
these patients wi ll have peripheral joint involvement and/or 
enthesopathy.2 Cardiovascu lar disease develops in up to 50% of 
adult patients with ankylosing spondylitis. 7,8 Diastolic abnormal-
ities apparent on echocardiogram are the most common early 
manifestation, most likely caused by increa ed connective tissue 
deposition in the myocardium.6 Aortic regurgitation secondary to 
aortiti s has been f~und in approximately I per cent of patients, 
u ually m tho e with advanced severe disease. Attioventricular 
block is also a recognized association .? 
The_ ~em~inder of the seronegative art~opathies (except 
adult Stills di sease) are not commonly associated with cardiac 
involvement and wi ll not be di scussed further in thi s review. 
PRESENTATION OF CARDIAC INVOLVEMENT: 
It may be difficult to differentiate primary cardiac disease 
from that of rheumatic involvement, particularly when this 
extraarticular feature presents before the arthritic disease reveals 
itself. The clinical picture is identical in many cases. There are 
therefore a number of clinical situations that must be recognized 
in order to appropriately investigate and successfully treat the 
underlying disease: 
Cases of valvulopathy secondary to ankylosing spondylitis 
preceding the more characteristic symptoms of the disease 
have been reported .8,9 Therefore, in any young male present-
ing with isolated aortic or mitral regurgitation, seronegative 
arthropathy must be in the differential diagnosis . 
20% of rheumatoid arthritis patients will have vasculitis. A 
percentage of them will have coronary artery involvement, 
which can result in angina. I For these patients, a course of 
steroids and immunosuppressants may improve symptoms, 
providing an alternative to more invasive revascularization 
techniques . 
Similar consideration is necessary for late onset cardiac 
involvement. Up to 20% of rheumatoid arthritis patients with 
peripheral joint involvement for more than 30 years have sig-
nificant aortic regurgitation. I These patients can be identified 
and treated before the onset of significant valvulopathy and 
cardiomyopathy to avoid potential complications and more 
invasive treatments (eg. beating-heart annuloplasty vs . va lve 
replacement) . 
Finally, when dealing with an arthropathy, one must rule out 
cardiac causes. Musculoskeletal involvement of bacterial 
endocarditis (BE) can mimic a rheumatic condition: one 
study reports that 74% of BE patients experienced myalgia 
and arthralgia, with the most common articular symptoms 
being polyarticular and symmetric, affecting both the large 
and small joints. 17% of the patients even had a positive test 
for rheumatoid factor. I o 
In the diagnosis and treatment of rheumatic conditions, a 
thorough investigation including a comprehensive review of sys-
tems and physical examination is essential for an accurate assess-
ment and interpretation of the findings. Extraarticular features 
can assist or mislead the clinician, potentially creating unneces-
sary morbidity and mortality. Care must be taken to ensure that 
the entire picture is being seen. 
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beautiful Wawa Lake. The health facility offers 10 acute care beds, 16 long term 
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Telephone Number: 705-856-2335 ext. 3202 
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Arthropathy of Hemochromatosis 
Craig Ainsworth, Meds 2005, Robert Humphrey, Meds 2005 
Hemochromatosis (HC) is an inherited multisystem disorder produced by the excessive accumulation of iron 
in visceral organs and the musculoskeletal system, leading to ceUular damage. Arthritic changes associated 
with HC often precede well recognized features such as diabetes, skin pigmentation and cirrhosis. Arthritis 
has been shown to affect up to 82% of patients with HC and is the single greatest cause of poor quality of life 
in these patients. The arthropathy of HC results from a non-inflammatory degenerative process that is often 
misdiagnosed as osteoarthritis, rheumatoid arthritis or calcium pyrophosphate deposition. However, the 
arthropathy can be differentiated based on its distinctive pattern of joint involvement, radiographic features 
and systemic manifestations. The mainstay of treatment for HC is therapeutic phlebotomy which is used to 
deplete the body of excess iron stores. AJthough this treatment is effective for visceral and cutaneous pathol-
ogy, arthropathy does not respond to phlebotomy. On average, complaints of joint pain and stiffness precede 
the diagnosis of HC by 10 years. This represents a decade of missed opportunity for diagnosis and possible 
prevention of joint destruction and systemic disease. Therefore, screening of high risk populations for detec-
tion of HC and early initiation of treatment is the best strategy for delaying or preventing the complications 
ofHC. 
INTRODUCTION 
Hemochromatosis (HC) is the most common inherited meta-
bolic disorder in the Western world . ' Although the triad of dia-
betes, cirrhosis and skin pigmentation classica lly was used to 
diagnose HC, these features actua lly may be late manifestations 
of the disease.l,2 In reali ty, patients often present years sooner 
with complaints of fat igue, abdominal pain and joint tenderness) 
Iron homeostasis in the body is essential as cellular dysfunc-
tion can result from either excess or deficient iron stores.4 Since 
there are no appreciable means of eliminating iron, regulating 
absorption to meet bodily requirements is essential to ensure ade-
quate ·iron stores .4 HC is a disorder in which iron absorption is in 
excess of the body's requirements . Overtime this leads to satura-
tion of serum transferrin , deposition in parenchymal ce ll s and cel-
lular toxicity.4 The organs that are primarily affected are the liver, 
pancreas, heart, gonads, skin and the joints; the latter of which 
wi ll be the focus of this paper.J 
Hereditary HC (HHC) is the most.common genetic disorder, 
with a reported prevalence as high as I in 200, primari ly in whites 
of northern European and Australian descent.J.4,5 HHC is an auto-
somal recessive disorder, resulting from homozygosity of a 
mutated form of the HFE gene on chromosome 6.4 HFE muta-
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tions have been shown to increase both intestinal iron absorption 
and uptake into tissues .4 The C282Y mutation is the most com-
mon, with a frequency of 12%.4.5 
CLINICAL PRESENTATION 
With the advent of genetic screening and earlier detection in 
recent years, presentation with diabetes, skin pigmentation and 
cirrhosis has become less common.J,6 Correspondingly, Adams et 
aP reported that abdominal discomfort, joint pain and weakness 
have become more prominent presenting complaints . 
I?terestingly, it was also found that joint stiffness and pain per-
Sisted on average I 0 years before a diagnosis of HC was made.J 
It is important to note that women tend to present later than men 
and are at a lower risk of developing severe iron overload, due to 
menstruation , child-birth and lactation .4,5,6 The iron overload and 
associated pathology in HC occurs over many years and thus the 
majority of patients present with symptoms after th~ age of 40.7 
ARTHROPATHY OF HEMOCHROMATOSIS 
. Arthritis was first described as a feature of hemochromatosis 
m _19648 and has since been shown to affect 25 to 82% of 
patients. 1,7,9,IO,II Although ar~hropathy was initially thought to be 
a late consequence of HC, It IS now recognized as an early mani-
festation that precedes visceral symptoms.? Patients are diag-
nosed as having arthriti if they are found to have stiffness, pain, 
and tenderness in at least one joint, with corresponding radi -
ographic changes. 1.9 These radiographic changes may be evident 
prior to the onset of arthritic symptoms. I o 
Many complications of HC have the potentia l to decrease a 
patient 's quality of life. Symptoms that may contribute to thi s 
decline include extreme fatigue , joint pain, impotence, decreased 
libido and headache.2,9 Arthropathy has been shown to cause the 
greatest decline in overall quality of life and phy ical function-
ing .3,9 
The pathogenesis is not completely understood although it is 
thought to be degenerative as opposed to inflammatory, as the 
erythrocyte sedimentation rate is typically norn1al.l Excess iron is 
reported to be present in synovial lining cells of the joints and cal-
cium pyrophospate dihydrate crystals may be found embedded in 
synovial tissue.IO The arthropathy can lead to extensive joint 
destruction with as many as one third of patients whose hips are 
affected requiring joint replacement surgery.! Calcium pyrophos-
phate deposition (CPPD) with chondrocalcinosis is found in 
many cases and commonly affects the wrists, knees, hips and 
symphysis pubis. I 
The distribution of the arthropathy is distinctive, typically 
affecting the second and third metacarpophalangeal (MCP) joints 
of the hand and the intercarpal joints of the wrist.! ,10. 11 It may 
progress to polyarthritis involving the larger joints (hip, knee, 
ankle, shoulder, and elbow) and the spine.IO The first, fourth , and 
fifth MCP joints, and proximal interphalangeal joints are 
involved less frequently. ? There may also be chondrocalcinosis of 
the wrists, knees, symphysis pubis, hips and the elbow, which 
often present as stiff and tender on examination. I,! o 
Common radiographic abnormalities in affected joints 
include the following : loss of articular cartilage with joint space 
narrowing, osteopenia, sclerosis, pseudocysts, osteophytes and 
chondrocalcinosis similar to CPPDJ ,IO,ll ,l2 Abnormalities specif-
ic to the MCP and intercarpal joints of the hand include: joint 
space loss, "hook-like" osteophytes, subchondral cysts , erosion of 
bone, and synovial calcification.7,10, 11 ,12 Based on the above fea-
tures arthropathy can be confirmed radiographically in 81.3%, as 
reported by Sinigaglia et aJ.l 2 
The arthropathy of HC is often misdiagnosed as rheumatoid 
arthritis (RA), OA or CPPD.7 The polyarticular, synrrnetrical 
involvement of the hands and wrists may lead to a misdiagnosis 
of RA, although it can be differentiated based on the fact that the 
arthropathy of HC is not inflammatory.! ,7 Because the arthropa-
thy is degenerative, it may resemble OA.I However the pattern of 
joint involvement is different, as the arthropathy of HC preferen-
tially affects the MCP joints and wrist, which is less common in 
OA.7 Distinguishing between arthritis of HC and CPPD is very 
difficult as the clinical and radiographic manifestations are very 
similar.? 
TREATMENT 
Early detection and initiation of treatment is the best strategy 
for delaying or preventing the complications of HC. Numerous 
treatments have been developed for HC, such as iron chelation 
and erythrocytapheresis; however, therapeutic phlebotomy has 
proven to be the safest, most efficient, and mo t economical ther-
apy.6 On average I uni t of blood (400-450mL) is removed per 
phlebotomy treatment, which corresponds to 200-250mg of iron.6 
Weekly phlebotomy is continued until mild hypoferritinemia is 
achieved (I 0-201lg/mL) .4,5 However, sustaining such level would 
be detrimental to the pati ent and so the goal i to maintain a leve l 
of less than 50!lg/mL.6 
Phl ebotomy is effective at reducing and reversing complica-
tions of HC such as malai e, weakne s, fa tigue, liver pathology, 
cardiomyopathy, hyperpigmentation and diabetes.6 In fact, nor-
mal life-expectancy has been reported in HC patients with regu-
lar phlebotomy, in the absence of c irrhosis, diabetes, or car-
diomyopathy. 6 
On the other hand, phlebotomy has been proven ineffective at 
treating gonadal failure , thyroid di orders, cirrhosis and arthropa-
thy.6.7, 13 In fact, progression of arthriti has been de cribed 
despite phlebotomy therapy.6.13 Furthermore, features of the 
arthropathy often precede the other manifestations of HC .7 
Therefore, early detection of HC and initiation of phlebotomy is 
imperative in an effort to prevent the development of arthropa-
thy.J.6,13 In those patients with existing arthropathy potential man-
agement strategies include relative joint rest, NSAIDs, physical 
therapy, and surgical arthroplasty (usually the hip or knee) .6 
Recognizing arthriti s as a early manifestation of HC may help to 
reduce the time delay between pre entation with arthritic pain and 
diagnosis of HC. 
Diagnosing the arthropathy of HC is important for two rea-
sons: (I) to avoid misdiagnosing another condition such as RA, 
which has different therapeutic implications; and (2) to recognize 
that the patient has HC, and thus phlebotomy can be used to pre-
vent the progression of its complications.? The high prevalence of 
this disorder in Caucasian populations is justification for routine 
screening.s Numerous sources have reported that Transferrin-sat-
uration (TfS) is the most effective screening method for HC and 
iron overload.5,6,7 TfS of~60% in men and ~50% in women on at 
least 2 occasions indicates HC in the absence of other known. 
causes of elevated TfS.6 Although TfS is more sensitive, some 
still recommend serum ferritin levels also be considered.3 
Alternatively, since the gene i inherited and thus present before 
the development of iron overload, genetic screening holds the 
most promise for early detection, treatment and prevention of 
compl ications.J,5 
CONCLUSION 
Arthritis has been shown to affect many patients with HC and 
is the single greatest cause of poor quality oflife in these patients. 
Depletion of excess iron in the body via phlebotomy improves 
survival and decreases systemic complications, except for that of 
arthritis . This lack of correlation between arthropathy and degree 
of iron overload suggests that other still undefined factors influ-
ence the progression of arthropathy in HC. On average, arthritic 
complaints precede the diagnosis of HC by 10 years. This repre-
sents a decade of missed opportunity for diagnosis and possible 
prevention of joint destruction and systemic disease. Therefore 
early detection of HC and initiation of treatment is imperative to 
prevent the development of serious systemic complications as 
well as irreparable joint damage. 
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The Injured Anterior Cruciate Ligament: A Review in Current Concepts 
Alexander Wong, Meds 2005 
The injured anterior cruciate ligament (ACL) is becoming more commonplace in competitive athletes and 
"weekend warriors", and advances in basic research and arthroscopic technology have made surgical recon-
struction using either the quadruple hamstring tendon graft or the bone-patellar tendon-bone graft the cur-
rent standard of care. Longitudinal studies indicate that the majority of patients electing to undergo ACL 
reconstruction report favourable results, with most successfully returning to preoperative activity levels. 
Controversy exists in choosing appropriate candidates for reconstruction, determining the superior graft 
material, and in pre-operative planning and post-operative rehabilitation protocols. Continual progress in 
molecular biology, tissue engineering, and computer-assisted surgery combine to make treatment of the 
injured ACL one of the most dynamic areas in orthopaedic surgery today. 
INTRODUCTION 
For two main reasons, there is no area in orthopaedic surgery 
which is currently receiving more attention and scrutiny than treat-
ment of the injured anterior cruciate ligament (ACL). First, an 
increased emphasis on maintaining an active lifestyle has led to an 
increased incidence of ACL injuries. From skiing alone, it is esti-
mated that there are anywhere from I 00,000 to 150,000 acute rup-
tures in the United States per year.' Secondly, there is still a 
tremendous amount of controversy surrounding the ideal approach 
to treatment, because no single approach has completely solved 
the problem of ACL insufficiency. A significant amount of basic 
science and clinical research along with improved arthroscopic 
surgical technology has allowed management of these injuries to 
evolve from non-operative supportive therapy to primary repair to 
ACL reconstruction. Maintaining an emphasis on clinical rele-
vance, this article provides a review of fundamental concepts 
required to understand how ACL injuries are currently managed. 
ANATOMY AND FUNCTION OF THE NORMAL ACL 
The ACL is a band of dense connective ti ssue containing 
many fascicular subunits which connects the femur and the tibia, 
and it is surrounded by a synovial lining which originates from 
the posterior intercondylar area of the knee.2 It is attached to a 
fossa located on the posterior aspect of the medial surface of the 
lateral femoral condyle, and another fossa in front of and lateral 
to the anterior tibial spine. The ACL moves anteriorly, medially, 
and distally across the knee joint as it passes from the femur to the 
tibia. It al o appears to "twist" in a mild latera l spiral , likely the 
resu lt of the orientation of its bony attachments .3 
The ACL consists offibroblasts surrounded by an extracellu-
lar matrix which consists of two main components: a highly-orga-
nized arrangement of macromolecules (mostly Type I collagen) 
and water. The maintenance of the ligament tissue and its ability 
to respond to changes in load depend on the interactions between 
the cells within the ligament and the extracellular matrix. The 
femoral and tibial attachments occur through an incorporation of 
collagen fibers from the ligament within mineralized bone, and 
consist of a "transition zone" of fibrocartilage and mineralized 
fibrocartilage , allowing a gradual change in stiffness at the 
attachment site .4 The ACL is supplied with blood mainly from 
soft ti ssue sites (the infrapatellar fat pad and synovial lining), and 
numerous nerve fibres and sensory receptors are located through-
out its the entire length. 
The ACL appears to have important proprioceptive and 
mechanical roles within the knee. Although its exact propriocep-
tive function remains undetermined, histological studies have 
demonstrated the presence of proprioceptive nerve endings with-
in the ligament, and clinical studies have suggested that the ACL 
likely has a role in proprioceptive " feedback" to the knee joint.5 
The mechanical role of the ACL is well -defined, as it has been 
shown to carry loads through the entire range of knee motion, pri-
marily resisting forces which would cause the tibia to translate 
anteriorly relative to the femur. During normal activity, the ACL 
carries only small loads (estimated to be no more than 20 percent 
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of its failure capacity), which indicates that the ACL probably 
only nears its fa ilure capac ity in atypical situations such as those 
encountered in sporting activities which involve start-stop and 
pivoting motions as well as rapid deceleration .6 
THE NATURAL HISTORY OF THE INJURED ACL 
A patient who presents with an acute rupture of the ACL will 
have increased tibial translation and swelling in the knee as a result 
of the formation of a local hematoma. When the thin synovial lin-
ing which surrounds the ACL is tom during a complete rupture, 
blood dissipates throughout the joint and does not form a localized 
fibrinous clot which would otherwise occur as part of the normal 
healing process in other damaged ligaments around the body. In 
partial ruptures of the ACL where the synovial lining remains 
intact, a hematoma can form in place and promote the inflammato-
ry response which allows for some degree of healing to the liga-
ment. However, in injuries where the synovial lining has been tom, 
no local healing response is present.? As a result, the natural histo-
ry of untreated ACL ruptures is extremely poor. Chronic instability 
in the knee leads to recurrent injuries which can damage secondary 
structures such as menisci or articular cartilage, promoting the 
onset of osteoarthrosis in the knee.s Hence, surgical intervention 
now involves reconstruction of the ACL as opposed to repair. 
Because it is currently difficult to predict which patients who 
have an ACL injury will experience significant instability and 
progression to osteoarthrosis, it is not possible to determine 
which patients would benefit most from an operation. As a result, 
it is currently accepted that not all such patients require recon-
structive surgery. For example, some patients may engage in vig-
orous rehabilitation to strengthen compensatory musculature 
which surrounds the knee , and others may alter their physical 
activity in order to significantly lessen the risk of re-injury. 
However, numerous studies have shown that certain characteris-
tics define "high-risk" patients who would benefit most from 
reconstruction. Such patients are young, highly-competitive in 
high-speed pivoting sports such as basketball or squash, and have 
a complete rupture of the ACL which may or may not be accom-
panied by injuries to other structures in the knee.9 Other factors 
which may be considered in determining the suitab ility of a 
patient for reconstruction include the presence of an associated 
injury to the menisci (an associated meniscal injury increases the 
risk of osteoarthrosis significantly due to increased knee instabil-
ity), and the patient's profession (certain occupations may involve 
extensive knee-loading) . Ultimately, a surgeon must recommend 
reconstruction based on a total consideration of the patient 's 
lifestyle expectations, motivation for recovery, and current health. 
ACL RECONSTRUCTION 
The topic of ACL reconstruction has spawned considerable 
debate, and this article will attempt to summarize only the main 
issues of contention rather than offer an extensive procedural 
review of various reconstructive procedures. Excellent resources 
exist for those interested in learning more about the techniques of 
reconstructive surgery for the ACL. I o 
The primary goals of ACL reconstruction are restoration of 
knee stability, preservation of the menisci and articular cartilage, 
maintenance of knee motion, and a timely return to normal activ-
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· · 1 d . · . . h t surgeon must Ity me u mg athletics. The main decisiOn t a a 
make is with respect to graft material. Currently, the mos~ co~-
. d le semitendi-mon autogenous graft chmces are the qua rup 
nasus/gracilis tendon graft and the bone-tendon-bone graft. I ~- 12 
The bone-tendon-bone graft is typically an 8- to 1 0-mm Wide 
graft taken from the central one-third of the patellar tendon, along 
with its adjacent patellar and tibial bony ends. In the mid-1980 's, 
studies indicated that a 14-mm bone-tendon-bone graft had about 
170% of the strength of a normal ACL, while the strength of 
either the semitendinosus or gracilis alone were both less than 
that of the intact ligament. I 3 Despite the same study indicating the 
bone-tendon-bone graft was considerably more stiff than a nor-
mal ACL and that either the gracilis or semitendinosus exhibited 
a stiffness far more comparable to that of an intact ligament, it 
was believed that choosing a graft with superior strength was 
more advantageous than choosing a graft with more reasonable 
stiffness properties. Hence, the bone-tendon-bone graft became 
the standard of care for a number of years. 
Beginning in the early 1990's, surgeons began to realize that 
by using either a doubled gracilis tendon or a doubled semitendi-
nosus tendon, or even combining the two together to form a 
quadruple hamstring graft, they could create higher failure loads 
while gaining the advantage of appropriate stiffness characteris-
tics . Recent studies have estimated the strength of the quadruple 
hamstring graft to be as much as 250% stronger than that of a nor-
mal ACL, and this construct has a considerably higher cross-sec-
tional area of collagen than a 1 0-mm bone-tendon-bone graft.l4 
During the operation, the graft is harvested from the donor site 
and secondary injuries to the menisci and articular cartilage are 
addressed, after which the appropriate location for the tibial and 
femoral tunnels are determined. The tunnels are drilled carefully, 
and the graft is then fixated into place. 
The most common complications of ACL reconstruction 
using hamstring tendons is potential post-operative donor site 
weakness due to the loss of the semitendinosus and gracilis mus-
cle tendon units. A number of longitudinal studies have evaluated 
knee flexion strength in patients several years following surgery, 
concluding that it is possible to regain full knee flexion strength 
fo llowing the harvest of hamstring tendons. 15 When using the 
bone-patellar tendon-bone graft, the most common post-operative 
complaint is that of anterior knee pain, with rates in some studies 
as high as 58% of all patients.16 The severity of the pain ranges 
from mild to severe, and suspected causes include damage during 
the harvesting procedure, excess scarring, and inadequate reha-
bilitation. Even with aggressive rehabilitation, permanent loss of 
some degree of knee extension is seen in at least 4% of all 
patients. I 7 Other intraoperative complications common to both 
procedures will not be covered here, but have been reviewed 
extensively elsewhere. I 7-18 
A number of prospective randomized studies comparing both 
procedures have been conducted, and the consensus appears to be 
that there is no significant difference in overall outcome 19-21 
although the incidence of patellofemoral pain appears to be' less 
in patients with hamstring tendon grafts.22 To conclude, it would 
appear that both the quadruple hamstring tendon graft and the 
bone-tendon-bone graft are adequate for ACL reconstruction 
although the harvest of the hamstring tendons appears to be mor~ 
easily tolerated with a subsequent increased rate of recovery of 
function in these patients. 
REHABILITATION FOLLOWING ACL 
RECONSTRUCTION 
It is generally recognized that rehabilitation is crucial to the 
ultimate success of the reconstructed ACL, and although the effi-
cacy of various rehabilitation protocols remains in debate, evi-
dence points to an intensive rehabilitation program preventing the 
onset of early arthrofibrosis and restoring normal strength and 
function earlier. Specific post-operative goals include adequate 
control of pain and swelling in the knee, restoring full range of 
motion and strength, and moving through a gradual functional 
progression which concludes with a successful return to athletic 
activity while preserving knee stability. It has been demonstrated 
that an early range of knee motion is required to avoid postoper-
ative difficulties.23 
The limits to which an intensive rehabilitation protocol can 
induce damage to the healing knee also remains in question . 
Certain exercises involving extension of the knee against quadri-
ceps resistance (termed "open-chain" exercises) have been shown 
to apply additional strain on the ACL, especially in the last few 
degrees of extension if the lower limb is non weight-bearing. In 
addition to exercises specifically designed to restore strength, 
most protocols now include some element of balance or proprio-
ceptive training such as weight-shifting (early phase) or plyomet-
rics (late phase), which help to restore gait control and increase 
the patient's confidence in the leg's ability to perform at a level 
equal to or greater than its preoperative condition. 
FUTURE DIRECTIONS AND CONCLUSION 
Orthopaedic surgeons now have a number of well-established 
techniques to treat the injured ACL, with clinical follow-up stud-
ies demonstrating favourable results in the majority of patients. 
Much effort is currently being focused on understanding the func-
tion of the ACL in vivo as well the biology of the healing ACL 
using biomechanical analysis, which ultimately will lead to the 
improvement of all stages of ACL treatment: pre-operative prepa-
ration, surgical approaches, and rehabilitation protocols. As well , 
advances in molecular biology and tissue engineering as well as 
the continual development of robotic technology and computer-
assisted surgery may one day allow an even greater level of con-
sistency in returning the ACL-injured knee to its preinjury state. 
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Percutaneous Internal Fixation of Distal Tibia Fracture 
Gerard March. Meds 2004 
Distal tibia and ankle fractures offer a special chaUenge to orthopaedic trauma surgeons due to the potential 
long-term implication on a patient's functional gait. I The ankle joint itself offers specific anatomical features 
that add to its stability and must be considered with any reconstruction) Fracture stabilization may take the 
form of closed reduction or operative treatment. Operative treatment may consist of external fixation, inter-
medullary nailing, or screw and plate fixation ) A new procedure of Limited exposure internal fixation, which 
composes of subfacial insertion of stabilization plates with percutaneous screw fixation, offers the promise of 
shorter hospital stays and quicker recovery times.4 We describe a case in which a patient suffers a proximal 
fibular and distal inter-articular tibial fractures. The patient was treated with a Limited exposure internal 
reduction technique. 
CASE 
A 38-year-old white male was seen in the emergency room 
with severe pain and an inability to weight-bear on the right leg. 
The patient reported falling from a standing position while tobog-
ganing earlier in the day. The patient denied striking his head, had 
no loss of consciousness, and reported no other injuries. Upon 
examination the patient appeared genera lly healthy except for an 
obvious swelling and defonnity in the di tal right leg. The patient 
demonstrated normal movement and tability in hi s right knee, 
yet was exquisitely tender upon palpation from the proximal right 
tibia to the right ankle joint. The pati ent was neuro-vascularly 
intact and his skin remained closed. Emergency room x- rays of 
the right leg revealed a closed, comminuted, minimally di splaced 
intra-articular di stal tibia fracture as we ll as a closed, non-com-
minuted, minimally di splaced proximal fibular fracture . The 
remainder of the patient 's exam was unremarkable. 
DISTAL TIBIA AND ANKLE FRACTURES 
The ankle joint 's shape specifically contributes to its stabili-
ty and function as a principle weight-bearing joint. The fibula and 
tibia form a morti se into which the talus acts as a talon .2 The dis-
tal articular surface of the tibia, which forms the medial and supe-
rior aspects of the morti se, is known as the tibia plafond.5 
Relative to the hip or knee joints, the ankle has a large area of 
contact due to the specific mirroring of the proximal and distal 
joint surfaces. The ankle joint is further stabilized by the presence 
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of the joint capsule and strong ankle ligaments that can be ctivid-
ed into three distinct groups: the medial collateral, lateral collat-
eral , and synde motic ligament .2 Tibial plafond fractures gener-
ally occur due to an impact force that is ctirected vertically 
through the talus into the tibia.S The severity of bone, cartilage, or 
soft tissue damage is ctirectly proportional to the size of the 
offending impact force .2.3 
TREATMENT OPTIONS 
A ll treatment options for distal tibia and ankle fractures aim 
for an acceptable reduction of the fracture including adequate 
alignment, rotation, length, and position, as well as restoration of 
the patient ' pre-existing activity leveJ.1 ,2 Low energy, minimally 
di splaced, and isolated distal tibia fractures are commonly treated 
cons.ervatively with closed reduction and progressive weight 
beanng: 1·3•6 The fracture is first reduced with traction along the 
long ax1s of the ltmb and then completed by reversing the mech-
amsm of fracture . The reduction and alignment of the fragments 
are. then mamtamed v1a constant traction or an immobilizing 
s~lmt or cast.2 Contraindication to closed reduction usually 
hmges on one 's ability to adequate ly reduce the fracture and 
mai ntain the reduction in order to allow healing to occur.3,7 
Operative treat~1ent is necessary when closed reduction fails , 
the fracture pa~ern IS inherently unstable, or the fracture itself is 
open.6•8 Operative treatment may include both internal and t _ 
I f . . . ex er na 1xatwn techmques. External fixation generally all fi 
b · b'l · · f ow or as1c sta 1 tzatwn o a fracture with only minimal di sruption of 
soft tissues _7 ,9 The use of external fixation for distal tibial and 
ankle fracture is generally indicated when acute stabiliza tion of 
open fractures is needed, with fractures involving bone loss, or in 
management of concurrent soft tissue injuries including compart-
ment syndrome and burns.2,3,IO However, a drawback of thi s 
method is that the degree of fracture reduction and stabi I ization is 
inferior relative to other fixation methods. Ultimately, external 
fixation balances the loss of stability with the conservation of soft 
tissue structure.?- 10 Additionally, pin tract infection is a common 
problem with external fixator , which can lead to osteomyelitis. I ,3 
Thus, the decision to incorporate external fixation into fracture 
management must include consideration of the severity of the 
fracture , the degree of soft ti ssue injury, and the patient's ability 
and willingness to manage the necessary upkeep of the fixator. 7 
Internal fixation may be classified into procedures that do 
not bring about compression across the fracture plane such as an 
inter-medullary rod or procedures that do bring about compres-
sion such as lag screws or buttress plating. (8) Inter-medullary 
nails are tightly wedged within the medullary canal leading to a 
high degree of endosteal contact. ( 11) Inter-medullary nailing 
techniques have relatively low ri sks of pseudoarthrosis and infec-
tion. Generally, patients enjoy shorter hospital stays with earlier 
full weight ambulation . ( 11) The inter-medullary technique 
becomes problematic however with severely comminuted frac-
tures or fractures that are either proximal or di stal to the shaft of 
the long bone. (3) 
With lag screws, optimal compression forces will be attained 
if the screw is placed perpendicular to the plane of the fracture . 
However, this arrangement is unsatisfactory if there are physio-
logical shear loads such as weight bearing upon an oblique frac-
ture plane. In these cases, the shear and rotational forces are usu-
ally controlled with a buttressing plate or even an external fixa-
tor.2,8, l2 Dynamic Compression Plates (DCP) provide excellent 
stabilization of fracture planes through self compression, but may 
have a detrimental effect upon bone structure due to the fact that 
100% of their under body lies in direct contact with the bone sur-
face .s Limited Contact-Dynamic Compression Plates (LC-DCP) 
have been developed that only have 50% contact with the bone. 
This allows for the formation of callus bridges due to improved 
cortical circulation under the plate.s Furthermore, Point Contact 
Plates (PCP) have been developed where the internal plate does 
not physically contact the bone surface except though pins and 
screws.s 
Conventional Open Reduction and Internal Fixation (ORIF) 
requires exposure of the fracture site. Disruption of soft ti ssues at 
the fracture site during surgery can adversely affect bone heal-
ing.! Further efforts to decrease soft tissue disruption have lead to 
the development of subfacial insertion of stabilization plates with 
percutaneous screw fixation .4,8 The procedure starts with mini-
mal skin incisions either proximal or distal to the fracture site . A 
pre-contoured plate is then inserted beneath the facial and muscle 
layers and positioned along the periosteum. Reduction is achieved 
indirectly and when deemed adequate under intra-operative fluo-
roscopy, percutaneously drilled screws lock the plate securely. II 
Percutaneous osteosynthesis blends the advantages of con-
ventional ORIF with the advantages of external fixation. Fracture 
reduction can be maintained via a strong and stable internal plate, 
while soft tissue integrity is preserved.4 Maintenance of the soft 
tissue envelope allows for the preservation of the periostea l blood 
supply and any fracture hematomas leading to accelerated bone 
regeneration . Furthermore, a percutaneous approach requires 
shorter operating times, has lower operative blood losses, and 
leads to lower wound infection rates .s Percutaneous stabilization 
introduces many technical challenges and increases the need for 
careful pre-operative planning as well as accurate intra-operative 
radiographic imaging. Absolute contra indications for this method 
include poor bone quali ty or fracture where bone loss is signi fi -
cant.4 This method has limited use with severely comm inuted 
intra-articular fractures as it prevents the surgeon from exploring 
the articular surface for subtle deformities.4 Additionally, both the 
patient and the surgeon have to be prepared for a rapid transition 
to an open technique if adequate reduction has not been achieved 
or maintained via the percutaneous approach. 
THE CASE REVISITED 
The patient was admitted to the orthopeadic ward and taken 
to the operating theatre under general anaesthesia . A percuta-
neous plating technique reduced and fixated the tibial fracture 
with a small-fragment 14-hole precontoured low-profile medial-
malleolar periarticular plate. The plate was inserted submuscular-
ly down the periosteum through a di stal incision on the medial 
aspect of the tibia . The plate was secured with two distal fully 
threaded cortical small fragment screws parallel to the tibial pia-
fond. The comminuted fracture was reduced via axial traction and 
slight external rotation . The reduction was secured with several 
proximal percutaneously drilled fully threaded cortical crews. 
Two percutaneously drilled cortical partially threaded or lag 
screws were then used to compress the fracture midway along the 
tibial plate. An anterior to posterior partially threaded cancellous 
screw was then percutaneously drilled in order to secure the 
reduction of the vertical intra-articular fracture line. The percuta-
neous incisions were copiously irrigated and then sutured. The 
patient was placed on post-operative antibiotics and was dis-
charged on post-operative day one in a lower limb cast with a pre-
scription for analgesics . 
Two weeks post operatively, the patient was seen in fracture 
clinic for removal of sutures and cast change. At that time it was 
noted that the fracture was healing. The patient was subsequently 
moved to a lower limb walking cast and allowed to weight-bear 
with the aid of crutches. The patient was seen again in fracture 
clinic six weeks post operatively where fracture union was con-
firmed. Examination of the patient showed only a slight antalegic 
ga it favoring the right ide. Leg length was identical bilaterally 
and the patient exhibited only slight restriction of dorsi flexion of 
the right ankle with all other right knee, ankle, and foot move-
ments normal. The patient remained neurvascularly intact and the 
surgica l incisions had healed without complication. The patient 
was advised to weight bear without crutches using the lower limb 
walking cast and move to full activity as tolerated. 
SUMMARY 
This case shows the advantage of percutaneous stabilization 
technique over traditional open reduction and internal fixation. 
The patient enjoyed a shorter hospital stay and a quicker recovery 
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time as we ll as minimal soft tissue di sruption at the fracture site. 
Presently, percutaneous stabilization is becoming more popular 
among orthopaedic trauma surgeons and new app lications are 
constantly being found.8. II Further study needs to be conducted 
however to both explore possible u es and define the potentia l 
limitations in an effort to standardize and maximize patient care. 
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Ocular Toxicity of Chloroquine and Hydroxychloroquine (Piaquenil) 
used in the Treatment of Rheumatological Diseases 
Chetna Tailor. Meds 2004 
INTRODUCTION 
Cases of rheumatoid arthritis (RA) and discoid and systemic 
lupus erythmatosus (SLE) in which NSAIDS do not provide ade-
quate relief of symptoms and the systemic side effects of 
immunomodulating drugs are wished to be avoided, the patient is 
often started on chloroquine and hydroxychloroquine. These two 
drugs have been used in these rheumatological diseases since the 
early 1950s.l While they provided much needed relief to patients, 
chloroquine and hydroxychloroquine were not without side 
effects. It was less than a decade later that chloroquine-using 
patients started to emerge.2 It was in 1959 that Hobbs presented 
three cases of retinopathy in patients with SLE and RA who were 
treated with chloroquine for 3 years at an average dose of 300 
mg/day.3 
Since the presentation of these initial cases, a great deal of 
research has been conducted into the ophthalmologic conse-
quences of the use of these drugs. Guidelines have been released, 
screening procedures implemented, and dosages adjusted. Most 
of the literature regarding the ophthalmological toxicity of anti -
malarials relates to the use of chloroquine. Where studies have 
looked at hydroxychloroquine, the incidence of problems has 
been much lower. For this reason hydroxychloroquine is almost 
exclusively used today. 
Recent review of all the published literature by the American 
Academy of Ophthalmology in 2002 states that well over 
I ,000,000 individuals have used chloroquine or hydroxychloro-
quine while there has only been less than 20 cases of toxicity 
reported in individuals using low dose levels of either of the 
drugs-and all of these had more than 5 years of usage.4 Several 
other large studies have failed to document any significant ocular 
toxicity with doses less than 6.5mglkg/day hydroxychloroquine, 
regardless of duration of treatments. 6, 7 While the number of 
actual cases of retinal toxicity has been low, the severity of the 
pathology induced when such a case arises , prompts profession-
als to keep a close eye on all patients using either of the drugs on 
a long-term basis. 
PHARMACOKINETICS AND MOLECULAR 
DIFFERENCES OF ANTIMALARIALS 
Although the exact mechanism of action of the antimalarials 
in the treatment of RA and SLE remains uncertain, the pharmaco-
kinetics of these drugs have been studied in great depth.3 Both 
chloroquine and hydroxychloroquine exhibit extensive uptake in a 
variety of tissues and also have extremely long half-lives. Three-4 
months of treatment is required before a steady state is attained in 
the blood stream. Once this level has been reached, 99 .9% of the 
drug is distributed to various tissues where it is slowly released. 
Levels can be detected in urine, red blood cells, and plasma up to 
5 years after the medication has been discontinued.8 ,9 High accu-
mulations are seen in the spleen, lung, and liver, where concentra-
tions may reach several 100 times of that found in serum. Still 
higher concentrations are found in pigmented structures. lO 
On the molecular level there is only one difference in the 
structure of chloroquine and hydroxychloroquine: a hydroxyl 
group. This hydroxyl group limits hydroxychloroquine's ability to 
cross the blood-retinal barrier. Chloroquine on the other hand has 
been hypothesized to cross this barrier. This may partly explain 
the lower incidence of retinopathy caused by hydroxychloroquine 
in comparision to it's sister drug, chloroquine.s 
PATHOPHYSIOLOGY 
Studies have shown that use of chloroquine has resulted in 
the accumulation of large amounts of the drug in all organs of the 
body which are proportional to both the dose and duration of 
treatment.! I , 12. 13 The drug has also been found to have a high 
affinity for melanin granules which are in uveal tissue, retinal 
pigment epithelium, choroids, and in the ciliary body.l4, 15 Once 
bound to melanin granules, there is minimal turnover and long 
term retention of the drug. 16 Build up of the drug results in the 
disturbance of function of the retinal pigment epithelial cell with 
secondary photoreceptor degeneration. I?, 18 Chloroquine has been 
hypothesized to arrest retinal pigment epithelial cellular function 
by the mechanisms of inhibition of protein synthesis or by block-
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ing DNA metabolism and repair.15, 16 Although hydroxychloro-
quine has not been studied in the same detail as chloroquine, 
many postulate that its mechanism of pathogenesis is similar to 
that of chloroquine. 
There are both reversible and irreversible side effects of 
hydroxychloroquine. Revers ible side effects include: corneal 
deposits, loss of fovea l reflex and impairment of accommodation. 
Corneal deposits are the most common side effect and are dose 
related. Often they are asympto'matic. As they are not related to 
retinal problems, they are not usually considered a contraindica-
tion to continuing treatment.20 
Loss of fovea l reflex is also considered as early reversible 
maculopathy or premaculopathy. It is important to note that it has 
been emphasized by Bernstein, a prominent researcher on till s 
topic, that premaculopathy is not a precursor of retinopathy.2 1 
Impairment of accommodation i very rare and only requires a 
temporary reduction in dose.2o 
Retinopathy is the major and potentially most serious irre-
versible side-effect of chloroquine toxicity. Initia lly, patients may 
present wi th visual loss to a red target and mild stippling or mot-
tling othe macular pigmented epithelium. Progress ive pigment 
migrati on can eventually lead to the c lass ic ' bull 's eye' macu-
lopathy (figure !)31, centra l scotoma and reduced acui ty.20 The 
' bull 's eye ' consists of granular hyperpigmentation of the central 
macula which is surrounded, first by a zone of depigmentation, 
Figure 1. Bull 's Eye Maculopathy. There i ~ a~ area of granu_lar 
hyperpigmentation of the central macula wh1ch IS s ~rrounded , f1~st 
by a zone of depigmentation, and then by a second nng of hyperplg-
mentation. 
and then by a second ring of hyperpigmentati on. The greatest reti-
nal damage occurs in a ring stretching fro m approximately 2 to 10 
degrees about f ixation. The fovea is basically spared, and fo r that 
reason 20/20 acui ty often pers ists in the presence of advanced 
retinopathy. This condi tion is almost always bilateral, however, 
asymm etry is not uncommon.J 
Subjecti ve symptoms of maculopathy may include blured 
vi ion, difficul ty reading, central or peripheral scotomas, as well 
as, photophobia , photopsias, ad othe entopic phenomena. Many 
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. visual acuity is fre-patients will be asymptomatic however, as 
quently unaffected.10 
RISK FACTORS AND DOSE 
Studies have found that risk factors for retinopathy may 
include: rugh daily doses of chloroquine (>250 _mg) and hydrox
1
y-
6 5 /k /day) mcreased cumu a-chloroquine ( > 400 mg or > · mg g ' dr 
tive drug doses (use greater than 10 years), and decreased ug 
clearance (60% of HCQ is excreted by the kidney).22 . 
As a result of these studies, patients typically receive ~50 
mg/d of chloroquine or 200-400 mg/day ~f hydroxychlor_oqume. 
More accurate dose calculations take mto consideratiOn the 
patient 's ' lean or ideal' body weight b~ taking into ~cc_ount age, 
sex, and height if the patient is overweight._3. 23 This IS Important 
a hydroxychloroqu ine is retained in the highly cellul~r m~scle, 
liver and retinal ti ssues to a much greater extent than m adipose 
t issu~.24 The recommended maximum daily doses are 4 .0 mg/kg 
hi . 25 for chloroquine and 6.5 mg/kg for hydroxyc oroqume. 
OPHTHALMOLOGIC FOLLOW UP 
Manufacturers of Plaquenil (hydroxychloroquine) have rec-
ommended that an initial baseline ophthalmologic exam should 
be performed and then repeated every 3 months.26 
Although a recommendation of the manufacturers of the 
drug, such a follow-up is not currently the standard of care, or ?as 
it been in the pa t. Thi is due to a number of factors mcludmg 
pati ent non-compliance and differing opinions of health care pro-
fess ionals. In addition, a consistent plan for follow-up has yet to 
be implemented, although many studies and papers have been 
written to ugge t a chedule for follow-up .27. 28, 20, 23 
In an effort to tandardize the care and follow-up of these 
patients and to provide them with adequate care, the American 
Academy of Ophthalmology published retinopathy screening rec-
ommendations for patients using chloroquine or hydroxychloro-
quine in 2002. The e reconm1endation are outlined below. 
SCREENING RECOMMENDATIONS: AMERICAN 
ACADEMY OF OPHTHALMOLOGY 200229 
I. Baseline 
Base line testing hould consist of a complete ophthalmologic 
examination including best-corrected visual acuity and dilated 
examination of the cornea and retina. Visual fields should also be 
examined with an Amsler grid or with Hwnphrey 10-2 fields . 
Color testing should be optional depending on whether the oph-
thalmologist intends to use it for future testing. Fundus photogra-
phy, fluoroscein angiography or multifocal ERG are also optional. 
2. Low risk Patients 
Low ri sk pati ents are ones that have used the drug for less 
than fi ve years; are taking the recommended dose or lower; and 
have no complicating medical conditions. These patients should 
receive an examination of their corneas and retina after papillary 
dilation. Visual f ields should also be tested with an Amsler grid 
or Humphrey 10-2 f ields. Other tests are optional. They should be 
instructed to return if they notice any change in visual acuity, 
Amsler grid appearance (tested at home) , color ensations or 
' adjustment to the dark . Frequency of their visits should be deter-
mined by their age (table 1). 
Table 1. Comprehensive Eye Evaluation for Patients with 
No Risk Factors29 
Age 
20-29 
30-39 
40-64 
65 or older 
3. High risk patients 
Frequency of Examinati on 
At least once during period 
At least twice during period 
Every 2-4 years 
Every 1-2 years 
These patient are those who have used the drug for more 
than 5 years; or are using doses greater than those reconunended; 
or have a complicating medical problem (age-re lated macular 
degeneration, retinal dystrophy, renaVhepatic di sease). These 
patients should receive an annual exam with testing as outlined 
for the low risk patient. Optional te ts hould be used if needed. 
Patients should also be instructed in the use of a Amsler grid and 
given grids to use at home for monthly self testing. 
Although a screening procedure has been recently outlined, it 
is important to note that no gold standard exists for the detection 
of retinopathy at an early stage. Amsler charts are insensitive and 
non-specific with abnormalities in colour testing and scotomas 
being found in 6% of the normal population.20 It is a lso important 
to note that after age 65, 1% of patients develop symptomatic age-
related macular degeneration and that 25% of this population will 
have some asymptomatic macular changes.2 ' There is also no evi-
dence that screening tests will pick up retinopathy at a reversible 
stage or that stopping the drug will prevent progression_20, 30 
MANAGEMENT OF TOXICITY 
No medical therapy has been proven effecitive in chloroquine 
or hydroxychloroquine toxic ity other than cessation of the drug. 
In practice, the management of suspected or recognized toxicity 
depends not only on the presence of retinal damage, but also on 
the medical status of the patient. These drugs are often the safest 
way to control a serious systemic disease and cessation could lead 
to worsening of the underlying disease or necess itate the use of 
other drugs with serious systemic side-effects. Therefore the deci-
sion to discontinue the use of the drug in a patient with recog-
nized toxicity must be made in conjunction with the patient and 
the specialist managing the patient's underlying condition.29 
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Bacterial Septic Arthritis: A Medical Emergency 
David Palma B.Sc.H and Scott Millington. B.Sc., Meds 2004 
A priority in the management of acute onset monoarticular arthritis is to rule out a septic joint. Septic arthri-
tis is a medical emergency, and can lead to extensive joint damage, long-term disability, systemic sepsis and 
possibly death. Early diagnosis and proper treatment is essential in preventing morbidity and mortality. This 
article reviews the epidemiology, risk factors, and common causative organisms of septic arthritis. Current 
approaches to diagnosis and management are discussed, and possible complications are outlined. The goal is 
to aid the reader in rapid recognition and treatment of this important, yet easily overlooked infection, in order 
to prevent the undesirable sequelae of septic arthritis. 
INTRODUCTION 
Septic arthriti is the invasion of a joint space by bacteria, 
viruses, fungi or protozoa. The majority of joint infections are 
caused by bacteria, which will be the focus of this review. The 
incidence of bacterial arthritis is between 2- 10 ca e per I 00,000 
in the general population l , with a bimoda l age di tribution . Peaks 
in incidence occur in chi ldren les than 5 years of age , and in 
adults over age 65 . ' 
Bacterial joint infections are classica ll y divided into two 
groups, gonococcal and n-gonococcal. Non-gonococca l septic 
arthritis is cau ed by severa l organisms :2,3,4.5,6 
1. Staphy lococcus species (40-60% of infections): Mostly 
S. aureus, although S. epidermidis is occasionally impli-
cated, especial ly in prosthetic joints. 
2 . Streptococcus spec ies (10-20% ): Groups A, B, G, or S. 
pneumonia. 
3. Gram negatives (I 0-15% ): Include Escherichia coli. 
Klebsiella species, Haemophilus influenza, and 
Pseudomonas aeruginosa. The latter requires special 
consideration due to its antibiotic resistance. 
4 . Anaerobe (2%): Tend to be associated wi th wounds, 
bites, or surgery. 
5. Other gram positives (very rare) : caused by Listeria or 
Co1y nebacterium species. 
Non-gonococca l septic arthriti s is usually monoarticular (80-
90% of cases)1. Altho ugh any joint can become infected, the knee 
and hip are most commonly involved; shoulder and ankle infec-
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tions are less common7. Intravenous drug users may present with 
atypical joint infection , affecting the temoclavicular, sacroi liac, 
or costochondral joints. 
Gonococcal septic arthriti usually presents as a polyarthritis, 
and affect more women than men (4: I ratio)B. It is cau ed by two 
organ i ms, Nei seria gonorrhea and Neisseria meningitides. N 
gonorrhea is the mo t common cause of septic arthritis in ado-
lescents and young adults . A patient with mucosal gonorrheal 
infection (i .e. urethral, cervical, recta l or pharyngeal) has a 0 .5% 
to 3% ri k of developing a di eminated gonococcal infection 
(DGl). Approximate ly 40% of patient with DGI go on to devel-
op septic arthriti ' · 
Most septic joint infections arise from hematogenous seeding 
of the synovia l membrane7. In some cases, infection can be intro-
duced via penetrating trauma , joint aspiration, corticosteroid 
injection , . or surgery. Contig uous spread fro m nearby 
osteomyeliti S can also cause joint infection . 
The development of septic arthriti s depends on the interac-
tion of the in~adin.g pathogen with the host immune response . 
Factors that dnnm1s~ host inu~une response or promote joint 
seedmg :esult 111 an. mcreased nsk of septic arthritis. Immunity-
re late~ n sk .factors mclude d1abetes me llitus, cortico teroid ther-
apy, c1rrhos1s, hypogammaglobulinemia leukem1·a and tr ' , ex emes 
of age . Factors promot.in.g joint seeding include intravenous sub-
st~nce abuse and ~nor JOmt pathology (e.g. rheumatoid arthriti ).7 
R1 sk factors umque for gonococcal septic arth ·t · · 1 d 
. . n IS me u e 
delayed d1agnos1s of a genitourinary gonococcal · c · 
. . . mtectwn, 
prom1 scu1ty, homosexuality, and low socioeconomic status.7 
DIAGNOSIS 
Non-gonococcal septic arthritis 
Timely recognition and treatment of non-gonococcal septic 
arthriti s is crucial in preventing morb idi ty and morta li ty. 
Class ically, the patient presents with abrupt onset of joint pain, 
with local warmth, swelling, effus ion, and decreased range of 
motion. The joint is often maintained in slight fl exion, which is 
the pos ition of greatest comfort. Palpation of a septi c joint is 
pa inful , a are attempts at fl exion and extension. Children with 
septic arthriti s will often avoid using the affected limb altogether. 
Fever is present in at least 80% of children and 40% of 
adults9. Other constitutional symptoms may include general 
weakness, malaise, and anorexia. The presence of tachycardia and 
hypotension may indi cate generalized sepsis. 
The most important diagnostic tool is synovial flu id culture 
and analys is. Aspiration of the knee joint is relati ve ly easy, where-
as other joints (such as the hip) are more di fficult to aspirate and 
may require surgical consultation and/or radiographic guidance. 
Synovial fluid culture is negative in approximately 20% to 25% 
of clinically suspected septic arthriti s. IO Gram sta in , leukocyte 
count, glucose concentration, and lactate levels are also used to 
diagnose infection. In septic arthri tis , the synovial flui d usually 
contains more than 50,000 leukocytes/mm3, and the glucose con-
centration is less than half the serum glucose concentration. High 
lactate levels in synovial fluid also indicate bacteri al arthri tis. In 
appropriate age group , (young to elderly adul t males, and post-
menopausal females) synovial fluid should a lso be examined by 
polarized light microscopy to rule out crystalline joint disease, 
although concurrent bacteri al arthritis and crysta ll ine joint dis-
ease have been reported. II 
Blood tests are not often helpful in diagnosing septic arthri-
tis. Peripheral white blood cell counts are often wi thin normal 
limits in adults, but are usually elevated in children?. Blood cul -
tures are positive in 25% to 50% of cases9. C-reacti ve protein lev-
els and erythrocyte sedimentation rates are elevated in most 
patients with septic arthritis, but are of little utility in di fferentiat-
ing among acute inflammatory joint diseases?. 
Gonococcal septic arthritis 
Most patients with DGI manifest symptoms of their local 
genital or oral infec tion. DGI can present as a c linical triad of 
migratory oligo- or polyarthriti s, tenosynovitis and dermatiti s. 
The arthriti s is often asymmetrical, frequently involving the 
elbow, wrist, knee and ankle joints. Tenosynovitis and dermatiti s 
are each found in about two-thirds of pati ents with DGI. The 
tenosynovitis is usually asymmetrical, often occuning in the f in-
gers and hands9; at times, the skin overlying the affected tenosyn-
ovium is warm and erythematous. Dermatitis typica lly manifes ts 
as erythematous papules on the trunk and extremities9 (Figure I), 
but a large variety of skin lesions have been reported. 
Joint fluid composition in gonococcal septic arthritis differs 
from that of non-gonococcal septic arthritis.9 In gonococcal sep-
tic arthriti s, leukocyte counts are usually below 50,000 cells/mm3, 
and the joint fluid glucose concentration is normal. Gram stains 
and joint fluid cultures are often negative. When clinical suspi-
cion for gonococcal arthriti s is high, it is important that mucosal 
Figure 1. Papular skin lesion characteristic of disseminated gono-
coccal infection (DSI). Lesions are often found on the trunk and 
extremities. [Source: Kelley's Textbook of Rheumatology, 6th edi-
tion. ©2001 W.B. Saunders Co. Figure 96-5. Used with permission J. 
surfaces are cultured, as such cultures are pos iti ve in 80% of cases 
of gonococcal arthriti s.9 
Imaging is usually unnecessary in the diagnosis of septic 
artluitis, regardless of pathogen. Radiographs may show swelling, 
fat pad displacement, joint space widening, or carti lage de truc-
tion (Figure 2), but usually reveal little in the first days of infec-
tion . However, preexisting conditions, such as osteoarthritis, may 
be detected . Ultrasound can be used to locate small fluid effusion 
and to subsequently guide a piration. MRI, CT and radionuc lide 
scans are used only in ambiguous cases of poss ible septic arthritis, 
or to asce1iain the extent of soft tis ue or bone infections?. 
Figure 2. An anteroposterior view of a septic hip shows loss of carti-
lage and most of the subchondral bone of the femora l head and 
acetabulum. [Source: Kelley's Textbook of Rheumatology, 6th edi-
tion. ©2001 W.B. Saunders Co. Figure 43-24. Used with permission] . 
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DIFFERENTIAL DIAGNOSIS 
A number of disease processes cause a clinical picture simi-
lar to acute septic arthritis. 
In chi ldren, osteomyelitis may cause an effusion in a neigh-
boring joint and can therefore mimic septic arthritis, although the 
two infections can exist concurrently. Juvenile rheumatoid arthri-
ti s occasionally presents as a monoarticular arthritis that can be 
mistaken for septic arthritis ; however, it is most often polyarticu-
lar. Transient synovitis, a e lf-limiting inflammatory process 
often affecting the hip may be mistaken for an infection, although 
patients do not appear ill or febrile.1 2 
In the adult, osteoarthritis, rheumatoid arthriti seronegative 
spondyloarthropathies , and crysta lline joint diseases should be 
considered when evaluating a painful jointl 2 Pre-existing joint 
disease increases the likelihood of a joint becoming infected, due 
to increased risk of joint seeding and, in the case of inflammato-
ry joint diseases, immunosuppression caused both by the inflam-
matory arthritis it elf and immunosuppressive drugs used to treat 
it. Hence, prior joint di ea e is not an acceptable reason to delay 
a piration of an acutely swollen, painful joint, especia lly if it is 
hot and/or erythematous. 
MANAGEMENT 
ot urprisingly, antibiotics are the foundation of therapy for 
septic arthritis . While awaiting culture results, it is crucial to 
begin administration of empi ri c antibiotics based result of the 
Gram stain and clinical data .l3.14,15 Most commonly, gram-posi-
tive cocci are the cause, and a penicillinase-resistant penicillin is 
the appropriate empirical treatment. In the case of suspected 
methicillin-resistant S. aureus (MRSA), vancomycin should be 
substituted. 
In otherwise healthy younger adults with a stain indicating 
Gram-negative organisms, penicillin or ceftriaxone are often used 
empirica lly. Older or immunocompromised host may be treated 
with an aminoglycoside in combination with an anti-p eudomon-
al penicillin or a third-generation cephalo porin .13,14,15 In chi l-
dren less than two years of age, antibiotics should coverS. au reus, 
Group B streptococcus, and H. injluenzae. 
Once culture results are avai lable, it is important to in titute 
specific therapy based on organism (Table I ).16 Antibiotics are 
usually given for a three week IV treatment cour e, often followed 
by two to three weeks of oral therapy.16 This can be extended for 
immunocompromised hosts . lntra-articular antibiotic admi nistra-
tion is rarely used, as it may introduce further infection or provoke 
an inflammatory response. 16 · 1 In addition to antibiotics, needle aspiration or s~g~~~ 
decompression of purulent synovial effusion is nec~ssary. ee e 
. . b · al dramage may be aspiration is generally suffictent, ut surg1c 
. · f An infected pros-required for joints inaccessible to asp1ra wn . 
thetic joint usually has to be surgically removed. . 
. h b .l .t f are adJuncts to Physiotherapy, exercise and re a 1 1 a wn .. 
. . t . adhesions deforrmtles medical and surgical treatment, preven mg , 
and muscle atrophy. 
COMPLICATIONS 
Septic arthritis can lead to both local and systemic complic~­
tions . Twenty-five to fifty percent of non-gonococcal sept~c 
arthritis result in long-term joint damage, and 10-15% result m 
mortality.! Limb amputation is not infrequent .in pati~nts with 
infected prosthetic joints. The prognosis for patients with ~ono­
coccal septic arthritis is favorable , and only 1-3% expenence 
complications7 . 
Unfavorable local sequelae of septic arthritis include soft tis-
sue destruction , ankylosis, adhesions, flexion contractures, and 
avascular necrosis 1. In chi ldren the infection may extend into the 
bone, resulting in growth plate damage and eventual limb length 
discrepancy. Systemic sepsis can occur in patients who are 
immunocompromised, elderly, or very young, and leads to signif-
icant morbidity and mortality. 
Risk factors for a poor outcome include delay in instituting 
treatment, underlying joint di ea e, advanced age, lack of physio-
therapy, and infection of more than one joint7. 
CONCLUSION 
Joint infections pose a diagno tic challenge for physicians. 
Septic arthritis must be suspected in any patient with joint pain, 
and early diagnosi and treatment can have a profound effect on 
morbidity and mortality. Following joint a piration, immediate 
empiric treatment is instituted, and subsequently tailored based on 
culture results . Purulent effusions must be removed by needle 
aspiration or surgical drainage. Physiotherapy and rehabilitation 
helps to prevent long-term sequelae . Prompt treatment of septic 
arthriti can prevent permanent joint or soft tissue damage, sys-
temic sep is , and mortality. 
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Table 1: Specific treatment for septic arthritis based on organism isolated. 
Micro-organism Cultured 
Staphylococci 
MRSA 
Streptococci 
H. influenza 
Enterobacteriaceae 
Pseudomonas 
Gonococcus 
Antimicrobial Treatment 
Cloxaci llin ± rifampicin 
Vancomycin ± rifampicin 
Penicillin ± clindamycin 
Amoxicillin ± clavulanic acid 
Amoxicillin ± clavulanic acid 
Ceftazidime ± aminoglycosides 
Ceftriaxone 
Alternative Treatment 
1st gen. cephalosporin 
Teicoplanin ± rifampicin 
Macrolides 
Fluoroquinolones 
3rd gen. cephalosporin 
Piperacillin ± aminoglycosides 
Spectinomycin 
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Necrobiosis Lipoidica and Diabetes 
Kebbie Josan. Meds 2005 
Necrobiosis lipoidica is a cutaneous disorder of degenerative collagen that is considered a marker of diabetes. 
It is important that primary care providers recognize the signs of necrobiosis lipoidica to aid in efficient diag-
nosis and treatment. Necrobiosis lipoidica may precede the presentation of diabetic disease by years and the 
careful follow up of nondiabetic NL patients may assist in the early detection of diabetes. 
Diabetes mellitus (DM) is the most common endocrine di -
order in the world! and is characterized by impaired g lucose uti-
li zation resulting in hyperglycemia and long term systemic com-
plications. There are also many cutaneous manifestation ofDM. 
It is estimated that between 30% and 71% of diabetic patient will 
develop a cutaneous di order associated with their diabetes.1.2 
Necrobiosis lipoidica, although uncommon, is the best 
known cutaneous marker of DM.3 This condition , which has a 
distinctive c lini ca l ancl hi topathological appearance but 
unknown pathogenesis, was fir t described by Oppenheim in 
1929.4 It was named necrob ios is lipoidica diabet icorum by 
Urbach in I 9324 but because of the occurrence of the condition in 
nondiabetic patients, many now choose to si mply ca ll it necro-
biosis lipoidica (NL). s 
CLINICAL PRESENTATION 
The characteristi c lesion of N L begins as a we ll ci rcum-
scribed erythematou papule or plaque. The slowly enlarg ing 
lesion becomes indurated and develop an elevated reddish bor-
der and atrophic yell ow center. Telangiecta iae are often visible in 
later stages .3 .5,6 The most common site for NL lesions is the 
pretibial and media l malleolar areas, with 85% of les ions occur-
ring here.3 Although other sites such as the face or scalp are 
sometimes affected, the e are more common in nondiabeti cs, and 
only 2% of NL cases have no leg invo lvementS The lesions are 
usually multiple and bilateral and approximately one third of 
them ulcerate. Areas of NL lesions may have decreased or absent 
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sensation to pinprick and fine touch' .3 and at least half of NL 
patients have associated neuropathy.' .6 Although extremely rare, 
squamous cell carcinoma can also ari se in NL lesions.? 
EPIDEMIOLOGY 
L is rare, occurri ng in 0.3% to 1.6% of the diabetic popu-
lation.l .2. Of the population that has· NL, however, the majority 
also have DM. In their now frequently cited studies , Muller and 
Winkelmann howed that 65% of the ir I 71 NL patients had DM. 
Of the remaining L patients, 42% had abnormal oral glucose 
tolerance test (OGTT), and of those with normal OGTT 55% had 
a family history of diabete .4 Usi ng these stati tics, ~ne could 
infer that approximate ly 90% of patients with NL wi ll either 
develop DM, have abnom1al gluco e tolerance, or report a histo-
ry of DM in at lea t one parent. The strength of thi s association 
has recently been challenged by O'Toole et al. who claim that 
only a minori ty of NL patients have DM .9 NL affects females 
three times more often than males and typically appears in the 
th1rd to foUlih decades of li fe .6 NL is associated with both insulin 
dependent and non-insulin dependent diabetes and it may precede 
the onset ofDM, appear concomitantly with DM or after the diag-
nosis of DM.2 
LINK WITH DIABETES 
The association of DM with NL has lead to theories of the 
effects of glycemic control on NL. Most authors report the 
absence of a correlatiOn between diabetic control and the pres-
ence ofNL5·9 based on research done by Dandona and co lleagues 
examining the gycosylated hemoglobin leve ls of patients with 
NL.IO Dandona et al. measured the HbA 1 levels in 22 NL 
patients, 9 with DM and 13 without DM. They found that all 9 of 
the NL diabetic patients had elevated HbA 1 versus all 13 NL non-
diabetic patients who had HbA 1 levels that were normal. These 
researchers concluded that the mi croangiopathic changes in NL 
occur independently of elevated gluco e concentration. Other 
re earchers have challenged this conclusion however. Cohen et al. 
interpreted the results of this study differently, suggesting that NL 
can occur in diabetic and nondiabetic patients, and patients with 
NL and DM are in poor glycemic control.4 Furthermore, there is 
evidence that the histology ofNL les ions from patients with DM 
differ from that of nondiabetic patients4.9 suggesting that the 
pathogenesis of NL may differ in these two groups. 
HISTOLOGY 
Two major histological patterns of NL have been identified : 
the necrobiotic which is usually present in DM and the granulo-
matous which is more common in nondiabetic patients. The maj or 
histological changes are found in the dermis . In the necrobiotic 
reaction, large areas of necrobiotic collagen (young collagen 
fibers seen adjacent to degenerating collagen) are present in the 
lower two thirds of the dermis. A cellular infiltrate consisting of 
histiocytes, fibroblasts , and lymphoid cells surround the necro-
biotic areas, and fat deposits may be scattered between degener-
ating fibers. Elastin fibers are absent and significant vascular 
changes occur.s.6 The granulomatous reaction differs in that there 
is little or no necrobiotic material , a moderate to severe inflam-
matory infiltrate is present near hyalinized collagen, 51nd vascular 
changes are rare .s · 
ETIOLOGY 
Although it is well established that NL is a disorder of degen-
erative collagen, little is known of its pathogenesis. It has been 
suggested that diabetic microangiopathy may contribute to the 
collagen damage seen in NL.6.7 Microangiopathy and thickened 
basement membrane are commonly seen microvascular changes 
in NL, present in two thirds of biopsy specimens.s Binazzi and 
Simonetti suggest that the presence of diabetic microangiopathy 
in NL favors a connection with diabetic disease and suggest that 
these changes sometimes precede diabetic disease and should be 
added to the diagnostic methods of DM.11 
Other popular theories of NL etiology include abnormal 
platelet aggregation3.5 which may be caused by elevated levels of 
factor VIII - related antigen or poor glycemic control. Since 
abnormal collagen is found in NL, some have looked to this as a 
cause. There is a marked decrease in the collagen concentration in 
NL patients. This deficiency of collagen is limited to lesional 
areas and when compared to normal fibroblasts, the fibroblasts 
from affected areas have a reduced collagen synthes izing ability 
in vitro. Although the reason for this is unknown, one poss ibility 
is that this defect is due to inflammatory cell mediators .12 
Increased collagen crosslinking or overhydrated collagen have 
also been suggested as causative factors .s 
Immune mechanisms are another possible cause ofNL. Dahl 
and Ullman used direct immunofluorescence microscopy to show 
that C3, fibrinogen, and immunoglobulins (IgM and IgA) were 
deposited around dermal blood vessel in lesional areas but not in 
normal skin of NL patient . They ugge ted an antibody mediat-
ed va culiti s as the cause of necrobi osis.s A delayed hypersensi-
tivity reaction has also been suggested because of the pre ence of 
f ibrin in lesions assoc iated with palasading histiocytes.6 Other 
theories include sweat gland dysfunction, decreased number of 
cutaneous nerve , decreased plasma lipoproteins, and abnormal 
leukocyte function .s 
TREATMENT 
When there are few subjective symptoms and ulceration is 
absent, treatment of NL is usually not required. Protection from 
injury is important because the lesions are prone to ulcerate and 
bleed. ' If the lesions are painful , there is ulcerati on present or the 
appearance of the lesions is particularly distre sing to the pati ent, 
treatment may be indi cated ) A consistently efficac ious treatment 
for NL has yet to be identified. Various topical, oral, and surgical 
treatments have been tried with variable success. Among the more 
common treatments are nonspecific anti-inflammatory agents 
such as topical , intralesional , and systemic corticosteroids; fibri-
nolytics based on the assumption that angiopathy is associated 
with poor f ibrinolysis ; antiplatelet agents such as aspirin and 
dipyridamole based on the theory that platelet aggregation and 
prostaglandin secretion cause NL; phys ical techniques such as 
excision I grafti ng and laser surgery; and irnnlUnomodulatory 
drugs such as cyclospotin. Other methods that have been used to 
treat NL include the use of anti-malarial drugs, nicotinamide, top-
ical tretinoin, and PUVA.5.7.I3,I4 The lack of controlled studies in 
this area make it diffi cult to asse the effectivene s of the di ffer-
ent therapies. 
CONCLUSION 
Much has yet to be learned about necrobiosis lipoidica. What 
causes NL, what is the most effective treatment for NL, and what 
is the nature of the relationship between NL and diabetes are all 
areas that need further investigation . Primary care physicians 
need to be able to recognize the signs ofNL and should be aware 
of the association of necro.bios is lipoidica and diabetes . Although 
NL is easy to recognize in patients already diagnosed with DM, 
NL is often not con idered without a previous diagno is of dia-
betes. NL can exist with prolonged asymptomatic hyperglycemia 
and its recognition may result in the early detection of diabetes . IS 
Prolonged follow-up and screening for diabetes i indicated for 
nondi abetic patients with NL as._NL can precede the onset of dia-
betes by years .I.I S 
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Cost-Effectiveness to Evaluate HIV/AIDS Interventions in Developing Countries: 
Limitations and Ethics 
Nina Ghosh, Jv/eds 2005 
Millions of Africans continue to be reeped of their lives and livelihoods by this devastating disease. HIV I AIDS 
is responsible for nearly 20% of all deaths and disability-adjusted life years lost in Africa. What should be 
done, how resources should be allocated and how programs and policies should be implemented remain 
debated. To ensure that new resources have the maximal possible effect on the pandemic, cost effectiveness 
can be considered in the design of strategies for prevention and treatment. unless cost-effectiveness studies are 
done in a manner that accounts for the fallibility of non-trial situations, the sociocultural barriers to seeking 
treatment and care, political influences and the value of " intangible" costs and outcomes, they provide a lim-
ited scope for extrapolation and implementation. 
As AIDS emerged insidiously into the medical and social 
landscape of the early 1980s, North Americans were drawn into 
an atmosphere of empathy, horror and compassion. Hollywood 
and the media bombarded us with images. The ravages of AIDS 
were everywhere - from the fiery lesions of Kaposi 's sarcoma on 
Tom Hanks' wasting arms in the film "Philadelphia" to Ryan 
White's heart wrenching campaign against AIDS discrimination. 
AIDS was to be a battle more daunting than any disease we had 
encountered before. 
Slowly, as AIDS transformed from a relentlessly efficient ter-
minal illness to a chronic disease that could be controlled by the 
right drug "cocktail", interest began to wane. No longer could you 
discern a person with HIV walking down the street from a dia-
betic person or a completely healthy person. Out of site, out of 
mind. 
But as North Americans and Europeans sighed with relief 
about the improved and less devastating nature of AIDS, millions 
of Africans continue to be reeped of their lives and livelihoods by 
this devastating disease. HIV I AIDS is responsible for nearly 20% 
of all deaths and disability-adjusted life years lost in Africa. s 
Indeed, the epidemic has reduced life expectancy by more than I 0 
years in the worst affected countries.s 
Yet what should be done, how resources should be allocated 
and how programs and policies should be implemented remain 
debated. 
One school of thought purports that it is imperative to treat 
those already infected with AIDS. The recent reduction in HIV 
drug prices and development of the Global Fund has resulted in a 
renewed push to provide widespread antiretroviral (ARV) treat-
ment to people living with HIVIAIDS in low-income (and some 
middle-income) countries. Pharmaceutical companies have 
reduced the prices of some ARV drugs for developing countries 
by up to 90%.8 
There is also a school of thought that points to prevention of 
HIV I AIDS as a more urgent and feasible approach in resource-
and infrastructurally- scarce contexts. Programs such as educa-
tion, condom distribution, and STD control for instance, may act 
synergistically, and more cost-effectively to address the AIDS 
epidemic. 
A rational approach to the problem of prevention versus 
treatment requires attention be paid to both the economic and eth-
ical facets of the different strategies available. Indeed, there needs 
to be a cognizance that economics and ethics, in this situation, go 
hand-in-hand. Several research and evidence-based approaches 
are available to the policy-maker to address the question of pre-
vention versus treatment. For example, to ensure that new 
resources have the maximal possible effect on the pandemic, cost 
effectiveness can be considered in the design of strategies for pre-
vention and treatment.! On the other hand, efforts must be made 
to ensure that seemingly cost-effective approaches, once imple-
mented, will succeed at the level of the individual. Health-related 
quality of life tools are perhaps the most available and objective 
tools to assess the impact of disease and treatment at the level of 
the individual. In this paper, I will examine the utility and limita-
tions of cost-effectiveness studies in developing policy combat-
ting HIV I AIDS in Africa. 
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COST EFFECTIVENESS ANALYSIS AND HIV/AIDS IN 
AFRICA: GUIDELINES AND UTILITY 
UNAIDS defines cost effectiveness as "a tool which enables 
programme managers to make informed decisions about resource 
allocation by measuring and comparing the consequences of var-
ious interventions"2 
UNAIDS has proposed a standard framework within which 
to carry out cost effectivness analysis of AIDSIHIV interventions 
in developing countries .2 Standardization of cost effectiveness 
studies improves the utility of studies by making them more com-
parable. 
COST EFFECTIVENESS ANALYSIS AND HIV/AIDS IN 
AFRICA: LIMITATIONS 
There are limitations to cost-effectiveness studies, both gen-
erally and in ways that are specific to studies pertaining to 
HIV/AIDS interventions in developing countries. 
General problems encountered in cost-effectiveness tudies 
include how to quantitatively measure the true "value" of intangi-
ble costs and consequences. How can monetary values be 
assigned to the pain and anxiety related to new and foreign med-
ications or conversely to the feelings of self-worth related to 
returning to work after symptoms have improved? Cost-effective-
ness as a determinant in policy-making is also limited in that 
costs and outcomes often have a different impact on different 
individuals or groups. 7 It is possible that an intervention that is 
cost-beneficial to the public health system is not beneficial for 
certain individuals. For example, although a centre offering 
Voluntary Counselling and Treatment theoretically increases 
access to HIV diagno i and treatment, the tigrna a ociated with 
the diagnosis may be, to the individual , a cost too high to bear, 
despite better care and treatment. 
In the context of HIV I AIDS in developing countries, cost 
effectiveness analysis presents specific challenges depending on 
the intervention being measured .2 The primary outcome measure-
ment u ed in prevention program is number of infection avert-
ed. However, it is rarely feasible to measure infections averted in 
a randomized, controlled manner.2 Final ly, prevention strategies 
are rarely implemented ill iso lation to others. Thus, it may be dif-
ficult to accurately attribute infections averted to the most effec-
tive intervention or to estimate the ynergestic effects of multiple 
preventative strategies being run concurrently) 
Measuring consequences in cost-effectiveness studies of 
treatment poses several challenges. ln stud ies of cure and treat-
ment, life years gained or disability adjusted life years (DALY) is 
the ideal outcome.2 However, it is often impossible to measure 
these outcomes due to constraints of time and budget . UN AIDS 
suggests that an alternate outcome is number of infections h·eat-
ed and cured for those studies that evaluate programes aiming to 
treat a particular AIDS-related infection. 
Studies looking at the cost-effectiveness of highly active anti-
retroviral therapy may overestimate its effectiveness in several 
ways. First, studies may not account for increased rates HIV 
transmission since risky behaviour by HIV-positive people with 
improved life expectancy could increase. Some studies indicate 
that the availability of treatment has been positively correlated 
with an increase in ri sky behavior among homosexual men in 
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some developed countries.B Second, since antiretroviral therapy 
has side effects, the value of one year of life is likely to be less 
than the 1 DALY assumed in most studies. 
On the other hand, cost-effectiveness studies exammmg 
HAART interventions in Africa may underestimate positive con-
sequences which cannot be easily measured. First, treatment 
availability may provide incentive to get HIY testing b~ reduc~g 
the stigma against people Jiving with HIYIAIDS and 1mprovmg 
the prospects of life with HIYIAIDS.8 Second, since HAART 
decreases the vira l load in HIY positive individuals, the probabil-
ity of transmitting HIV to others even if they do engage in ri sky 
behaviours is reduced compared to no treatment.8 Finally, cost-
effectiveness studies may not account for the impact of treatment 
on reducing the economic and social burden of the disease, which 
prevention alone cannot do in the short run. 
Another challenge for HIVIAIDS interventions and their 
evaluation is the influence of the context and prevalence in which 
the intervention is implemented. For instance, questions have 
arisen as to whether the cost-effectiveness of interventions 
change as the prevalence rises. A study by Wawer et al. on the 
fai lure of the Rakai mass STD treatment trial in Uganda shows 
that at later stages of the epidemic, STD management may have 
Jess impact as one tries to expand in higher prevalence settings. II 
This has been one of the explanations for the contrast between the 
success of the Mwanza trial , where overall HIV prevalence was 
four percent, in contrast to the failure of the Rakai where the HIV 
prevalence was 16 percent. Thus, it may be difficult to extrapolate 
cost-effectiveness studies between different prevalence settings. 
It is thus apparent that unless cost-effectiveness studies are 
done in a manner that accounts for the fallibility of non-trial sit-
uations , the sociocultural barriers to seeking treatment and care, 
political influence and the value of " intangible" co ts and out-
comes, they provide a limited scope for extrapolation and imple-
mentation. Many would argue that the most unacceptable facet of 
co t-effectivenes analysis of AIDS/HIV interventions in Africa 
is the implicit commoditization of millions of lives in poor coun-
tries in the face of tate-of-the-art treahnents being used by those 
countries who own the lion s share of global wealth. 
CONCLUSION 
In my opinion, the dichotomy of the cost-effectiveness of 
prevention versus the cost -effectiveness of treatment is false . The 
ideal approach is to address both prevention and treatment. 
Ethically, it is imperative to control the epidemic as effectively as 
po sible while providing all the needed care and support for peo-
ple with the disea e. 11 This combined approach may indeed be 
more cost-effective than focusing on one or the other. Reynolds 
et. al show that efforts to provide access to HAART that do not 
incorporate other cost-effective interventions such as access to 
preventative care and treatment of opportunistic infections could 
have a limited effect on morbidity and mortality amon~ HIV-
infected patients.10 However, a definitive conclusion as to the 
cos~-effectiveness of a diversified portfolio of interventions 
agamst HIV I AIDS requires more research. To date, there has been 
no study that h~s systematically documented the cost-effective-
nes~ of a combmed preventative/h·eatment approach in a single 
settmg. 
In the mean time, the human rights perspective cannot be 
ignored. It should be used to incite a so lid effort from the inter-
national community to fund a comprehensive response against 
HIY I AIDS that incorporates treatment. 8 
REFERENCES 
1. BuveA. Bishikwabo-Nsarha::a K. Mutangadura G. Th e spread and effect 
of H/V-1 infection in sub-Saharan Afri ca. Lancet. 2002 Jun 
8;359(9322):2011 -7. Review. 
2. UNA IDS. Cost-effectiveness analysis and HI VIA1DS: UNA IDS 
Technical Update. August 1998 
3. Marseille E. Hofmann PB. Kahn JG. H!V prevention before HAART in 
sub-Saharan Afi'ica. Lancet. 2002 May 2 5: 359(9320) : 1851-6. Review. 
4. M. Taegtmeyer and K. Chebet . Overcoming challenges to the imple-
mentation of antiretrovira/ therapy in Kenya. Lancet !nf Dis 2 (2 002). 
pp. 51- 53 
5. Creese A, Floyd K. Alban A. Guiness L. Cost-effectiveness of H!VIAIDS 
interventions in Afi'ica: A systematic review of evidence. Th e Lancet. 
2002; (3 59) 1635-1 642. 
6. Gausset Q. AIDS and cultural practices in Africa: the case of the Tonga 
(Zambia).Soc Sci Med. 2001 Feb:52(4):509-18 
7. Newell M. Dabis F. Tolly K, Whynes D. Cost-effectiveness and cost ben-
efit in the prevention of mother-to-child transmission of HIV in devel-
oping countries. 
8. Emiko Masaki. MA. MPH: Russell Green, BA : Fiona Greig. BA; Julia 
Walsh, MD. MSc; Malcolm Potts. MB, BChil; PhD. Cost-Effectiveness 
of HIV Interventions for Resource Scarce Countries: Selling Priorities 
fo r H!VIAIDS Management 
9. Stein brook R. Beyond Barcelona - Th e Global Response to H!V N Eng/ 
J Med 2002; 347:553-554. Aug 22. 2002. 
10. Reynolds S. J , Bartlett J G .. Quinn T C.. Beyrer C., Bollinger R. C. 
Antiretrovira/ Therapy Where Resources Are Limited. N Eng/ J Med 
2003; 348: 1806-1809. May 1, 2003. 
11 . Wa wer MJ Sewankambo NK. Serwadda D. Quinn TC, Paxton LA. 
Kiwanuka N. Wabwire-Mangen F. Li C. Lutalo T. Na/ugoda F. Gaydos 
CA. Moulton LH. Meehan MO. Ahmed S. Gray RH. Control of sexually 
transmitted diseases for AIDS prevention in Uganda: a randomised 
community trial. Rakai Proj ect Study Group. Lancet. 1999 Feb 
13;353(9152) :525-35. 
12. Cassels A, Janovsky K. Sectoral investment in health: prescription or 
principles? Soc Sci Med. 1997 Apr:44(7):1073-6 
13. Wiktor SZ. Ekpini E, Karon JM. Nkengasong J. Maurice C. Severin ST. 
Roels TH, Kouassi MK, Lackritz EM. Coulibaly IM, Greenberg AE. 
Short-course oral ::idovudine for prevention of mother-to-child trans-
mission of HIV-1 in Abidjan, Cote d '/voire: a randomised trial. Lancet. 
1999 Mar 6;353(9155):781-5. 
14. Grosskurth H, Mwijarubi E, Todd J. Rwakatare M. Orroth K, Mayaud P. 
Cleophas B, Buve A. Mkanje R, Ndeki L. Gavyole A. Hayes R, Mabey D. 
Operational performance of an STD control programme in Mwanza 
Region. Tan::ania. Sex Transm Infect. 2000 Dec;76(6):426-36 
15. Grosskurth H. Gray R, Hayes R, Mabey D, Wa wer M. Control of sexu-
ally transmitted diseases for HIV-1 prevention: understanding the impli-
cations of the Mwanza and Rakai trials. Lancet. 2000 Jun 
3; 355(921 9): 1981- 7. 
Taking strides toward tomorrow .. . 
Peterborough Regional Health Centre (PRHC) is 
one step closer to a new hospital. Construction - the 
cu lmination of countless hours of consultation and 
planning - is underway. The new facility will allow 
for improved health care delivery and for PRHC to 
further fu lfill its regional role with space for more than 
500 beds and expanded service . 
Currentl y a 390-bed regional referral centre, PRHC 
serves Haliburton , Northumberland and Peterborough 
counties and the City of Kawartha Lakes. 
We are a centre of excellence in the delivery of 
comprehen ive and accessible care, located less than an 
hour 's drive from the Greater Toronto Area, in the 
heart of the Kawarthas. 
To learn about opportunities at 
PRHC, visit 
www.prhc.on.ca. 
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The Effects of Exercise on the Prevention of Heart Disease 
Frederick Yoon, Meds 2005 
Heart disease is the leading cause of death in Canada. It is for this reason that much emphasis bas been placed 
on incorporating more physical activity into one's lifestyle. The beneficial effects of exercise are substantial, 
from improved blood pressure to lower cholesterol levels. Some of these effects are mediated by alterations in 
hormones, namely changes in epinephrine, insulin, and atrial natriuretic factor (ANF). ANF has effects on 
blood volume while ANF, epinephrine, and insulin have effects on attenuating the sympathetic nervous system. 
The preventative effects of physical activity on heart di sease 
have been known ever since the 1950s when Morris et al. report-
ed in the Lancet in 1953 that sedentary London bus drivers had 
significantly higher rates of coronary disease than their bus con-
ductor co lleagues, who had to repeatedly climb the stair between 
the upper and lower decks of London bu es 1. In a more recent 
study at the Lipid Research Clinic, 4276 middle-aged men were 
divided into four groups based on their physical fitness and fol-
lowed for an average of 8.5 years . Coronary heart disease (CHD) 
mortality was six times greater in the least fit group compared to 
the most fit group 1. The main mechanisms through which exer-
cise prevents CHD are altered autonomic activity, structural and 
functional adaptations to the vasculature, increased cardiac blood 
supply, a reduction in the intrinsic heart rate, altered lipid pro-
files , increased insulin sensitivity, reduced body fat, change to 
blood coagulation, improved myocardial and skeletal muscle 
function and a reduced blood pressure . 
Although there is conflicting information on the effects of 
exercise on sympathetic activity, there is at least some data to 
indicate that endurance training induces a reduction in the activi -
ty of the sympathetic nervous system and an increase in the activ-
ity of the parasympathetic nervous system2. Physical activity 
decreases norepinephrine activity at rest as well as in response to 
emotional stress and exercise3. There is also a down-regulation of 
endorphin receptors in the heart. Endorphins faci litates epineph-
rine release and so decreased levels of endorphin receptors 
reduces the sympathetic system3. Cardiopulmonary baroreflex-
48 UWOMJ 73(1) 2004 
mediated increases in blood pressure, renal and mesenteric sym-
patheitic nerve activity, and total peripheral resistance are all 
attenuated in response to exercise. At the same time splanchnic 
and skin blood flow are increased3. All of these responses help to 
reduce blood pre sure. Fewer beta-adrenoceptors (stimulated by 
catecholamine ) are found in the heart after exercise training due 
to down-regulation. One study if male swimmers who underwent 
a 2-month training program shows a drop in mean beta-adreno-
ceptor density from 1074 ± 52 per cell before training to 458 ± 78 
per cell after training4 . Those with the largest change in V02max 
also had the largest drop in beta-adrenoceptor density. 
The larger stroke vo lume observed after exercise training 
helps stimulate the cardiopulmonary baroreceptors by increasing 
the stimulation of stretch receptors in the heart3 . In response to 
stretch receptor stimulation, the cardiopulmonary baroreflex 
attenuates the ympathetic nervous system and thereby inhibits 
vasoconstriction . Elevated parasympathetic activity i a result of 
and raised circulating dopamine levels and dopamine receptors on 
neurons3. Stimulation of dopamine D2 receptors in the nucleus 
ambiguous induces bradycardia by exciting vagal preganglionic 
cardioinhibitory neurons to the heart. 
En?urance trai?ing promotes arteria l compliance, which 
results m larger restmg and maximally dilated arterial diameters. 
When the four coronary arteries of trained runners was stimulat-
ed with nitroglycerine, it was found that the total cross-sectional 
area of these arteries was double that of controls stimulated with 
nitroglycerine, indicating better vasodil atory reserver3. 
Furthermore, the nitric oxide (NO) synthase gene expression and 
NO relea e are increased in response to exercise3. NO is a potent 
vasodilator. A general increase in blood vessel responsiveness to 
vasoactive substances is seen with exercise training. Arterioles 
show an enhanced response to acetylcholine and terminal feed 
arteries exhibit an increased sensitivity to nitropruss ide. Chronic 
exercise increases the total surface area of myocardial capillaries 
for perfusion and transport and, in the presence of coronary steno-
sis, stimulates coronary collateral growthS. The larger the increase 
in Y02max attained through exercise, the larger the arterial com-
pliance and the larger the drop in total peripheral resistance 
achieved3. The structural and functional changes seen in blood 
vessels helps to increase maximal perfusion, oxygen delivery, and 
oxygen uptake so as to increase the efficiency of the cardiovascu-
lar system and reduce the workload on the heart. 
The bradycardia seen in endurance training is accounted ini-
tially by the altered sympathetic and parasympathetic activity 
seen in response to the training. More long tenn reductions in 
heart rate are attributed to a lower intrinsic heart rate3. This adap-
tation is a result of a prolonged atrial action potential, suggesting 
metabolic changes to the pacemaker cells2. Desensitization of 
cardiac 13 receptors to catecholamines also reduces the intrinsic 
heart rate. Pacemaker firing rates increases with atrial stretch. 
Exercise is known to increase atrial and ventricular volume and 
compliance. This will lead to a reduction in stretch induced stim-
ulation of the pacemaker and will therefore lower the firing rate3. 
Exercise training increases HDL cholesterol and lowers LDL 
cholesterol levels so a to increase the HDLILDL ratio . More 
specifically, the HDL2 subfraction ofHDL is also increased which 
is thought to have a protective effect against CHD6. Exercise 
increases lipoprotein lipase (LPL) activity, and this helps LPL's 
action of inillbiting HDL2 breakdown and metabolizing triglyc-
erides. In terms ofLDL cholesterol, it is the small dense LDL sub-
fraction of LDLs that is reduced with exercise, and it is the small 
dense LDL that is associated with a more rapid development of 
atherosclerosis6. LDL receptors are up-regulated in exercise and 
this helps to lower LDL levels. Physically trained muscles have an 
increased ability for lipid metabolism. This is due to elevated 
blood flow in the muscle and increased activity of fat-mobilizing 
and fat-metabolizing enzymes?. Hence, a trained person uses more 
free fatty acids for energy than an untrained person . 
It has been shown that exercise training reduces the ri se in 
plasma insulin concentrations in response to a glucose load2. This 
would indicate that insulin action is improved through endurance 
training. Hyperinsulinemia stimulates the sympathetic nervous 
system, which elevates blood pressure. The increased insulin sen-
sitivity brought about by exercise, and the subsequent decrease in 
circulating insulin, may therefore have significant effects in 
reducing blood pressure6. Increased insulin sensitivity will also 
help prevent the onset of type II diabetes, the complications of 
which include heart disease. Endurance trained muscles contain 
as much as twice the levels of GLUT-4 transporters as untrained 
muscles2 . This contributes to a larger up-take of glucose in 
response to insulin, and, therefore, helps keep blood glucose lev-
els within the proper range6. A decreased plasma insulin concen-
tration during the fasting state is also beneficial because hyperin-
sulinemia is an independent risk factor for arteriosclerosis2. Total 
body fat, and particularly abdomi nal fat , increase the risk ofCHD 
by leading to increa ed blood triglycerides, lower HDL choles-
terol levels, higher LDL chole terol levels, depressed insulin 
metabolism (leading to increased plasma insulin levels) , insulin 
resistance, and rai sed blood pressures. Exercise helps to lower 
body fat and helps people maintain lo t weight. 
Exercise training ha an important effect on blood coagu la-
tion and fibrinolysis. Training decreases platelet aggregation and 
increases fibrinolysis5. En hanced fibrino lysis is due to an 
increase in the release of plasminogen activator from the vesse l 
walls. Exercise can also augment the spontaneous lysis of small 
thrombi in the ca lf, and thereby prevent the formation of larger, 
more dangerous thrombi5. 
Endurance training improves myocardial cellular capacity. 
This leads to greater cardiac contractility and ejection fraction 
(percentage of end-diastolic vo lume ejected from the heart per 
beat6. Decreased vascular resistance results in reduced afterload 
on the heart and makes it eas ier for the hea11 to contract6. Thi s 
will lighten the workload the heart has to do. The left ventricular 
hypertrophy brings about a reduction in the work each sarcomere 
in the ventricle has to do' . It also facilitates the maintenance of 
the high ejection fraction and stroke vo lume at high work rates 
and the deve lopment of a large max imal cardiac output' . 
Trained muscle have an increase in both the number and 
size of mitochondria , and also a potential twofold increase in the 
leve l of enzymes involved in aerobic metabolism?. This helps 
trained muscle extract higher amounts of oxygen from the circu-
lating blood during exercise so as to increase the arteriovenous 
oxygen difference. This augmented arteriovenous difference is, 
however, also due to more effective distribution of cardiac output 
to working muscle and an enhanced ability of trained muscle to 
use oxygen 7. 
Physical exercise helps stimulate the release of arterial natri-
uretic factor (ANF) by the heart, which increases sodium and 
fluid loss and thereby lowers blood pressure6. ANF also inhibits 
the sympathetic nervous system and helps decrease the amount of 
vasoconstriction of blood vessels. The weight Joss brought about 
by exercise is crucial for blood pressure reduction. Up to a certain 
limit, every kilogram of weight loss results in approximately a 1.6 
mmHg fall in systolic pressure and a 1.3 mmHg fall in diastolic 
pres ure6. Meta analysi of 36 studies on thi s subject has shown 
that blood pressure can be reduced as much as 9.9 mmHg sys-
tolically and 7.6 mmHg diastolica lly', although moderate intensi-
ty exercise (below 70% of maximum heart rate) has been shown 
to reduce systolic pressure as much a 20 mmHg and diastolic 
pressure as much as 16 mmHg6. 
Many long term longitudinal studies have shown the enor-
mous cardiovascular benefits of regular phys ical activity. 
Exercise reduces almost all known alterable risk factors for CHD 
from high blood pressure to high plasma choloesterol to hyperin-
sulinemia . It is recommended that people engage in 20-30 min-
utes of moderate-intensity exercise at least three days a week in 
order to improve cardiovascular health9. Moderate intensity is 
between 65% and 85% of heart rate reserve (HRR = maximum 
heart rate - resting heart rate)9. It would be prudent to follow 
health recommendations in order to reduce the chances of devel-
oping this common, yet in many ways preventable, disease. 
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Fast Facts 
WILLIAM 
OSLER 
HEALTH 
CENTRE 
• 4 acute care hospitals (incl. I 
under construction) 
• I ,200 beds by the completion of 
redevelopment 
• O ntario's largest capital 
redevelopment project 
underway 
• Largest O rthopedic service in 
O ntario 
• Full Diagnostic Imaging 
including CT/MRI 
• 7,000 births/yr 
• 170,000 emergency visits/yr 
• 2 10,000 ambulatory care visits/yr 
• 12,000 inpatient operating room 
procedures/yr 
• 46,000 day surgery 
procedu res/yr 
• Over 700 physicians, 4,000 staff 
and 1,400 volunteers 
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EXPLORE NEW FRONTIERS 
IN MEDICINE 
William Osier Health Centre is Ontario's 6th largest hospital corporation. As a regional referral centre, 
we provide programs and services to nearly I million area residents. Our facilities include full-service , 
acute care and ancillary health care facilities in the growing and diverse communities of 
Etobicoke, Brampton, and Georgetown, Ontario. 
William Osier Health Centre is poised for considerable growth with the construction of a 
new, state-of-the-art hospital in Brampton, major expansions to our facilities in Etobicoke and 
Georgetown, and redevelopment of the existing hospital campus in Brampton. Dedicated to improving 
patient care and service quality, its clinical teams are committed to best practices, integrated services 
and innovation within a caring envi ronment. 
Explore the exciting opportunities that await you in the areas of: 
* Anaesthesia * Family and Emergency Medicine * Cardiology * 
* Endocrinology * Geriatrics * Gastroenterology * 
* Neurology * Pediatrics * Psychiatry * Radiology * 
* Respirology * Rheumatology * Surgery * 
Please forward your CV in confidence to: 
Dr. Tom Dickson, Chief of Staff 
William Osier Health Centre, 20 Lynch Street, Brampton, ON L6W 2Z8 
Tel: 905 .796.4911 Fax: 905.796.4915 E-mail: medical_ staff@oslerhc .org 
Surgical Weight Loss Options for the Obese 
Seng Thippha vong and Gladys Chan, Meds 2004 
In 1997, the estimated cost of obesity in Canada was more than $1.8 billion. Morbid obesity is defined as a 
BMI exceeding 40 and bariatric (gastrointestinal) surgery options may be considered as a last resort. Vertical 
banded gastroplasty (VBG) involves the reduction of the amount of food intake by creating a vertical pouch 
along the lesser curvature of the stomach using surgical staples. VBG is advantageous due to low morbidity 
and a lack of any bypass of the lower intestinal tract. However, a long-term failure to maintain weight loss is 
associated with VBG. Adjustable gastric banding creates a small compartment in the proximal stomach and 
has been shown to decrease BMI from 44 kg/m2 to 33.2 kg/m2 with stable results after a follow-up of up to 
86 months (median 36 months). Biliopancreatic bypass involves a subtotal gastrectomy followed by transec-
tion of the proximal ileum to the ileocecal valve. The distal limb is anastomosed to the gastric pouch. 
Biliopancreatic bypass has been shown to have a short-term weight loss of 74% after 2 years while long-term 
weight maintenance has been reported at 78% after 14 years. The Roux-en-Y Gastric bypass involves tran-
section of the jejunum and bringing the proximal jejunum retrocolic through an opening in the transverse 
mesocolon. The proximal jejunum is then anastomosed to a constructed gastric pouch. Long- term results of 
the Roux-en-Y Gastric bypass procedure are quite successful with a mean weight loss of 49.2% of preopera-
tive body weight. General complications of bariatric surgery include deep venous thrombosis, pulmonary 
emboli, atelectasis, peritonitis, and cholelithiasis. 
INTRODUCTION 
Over the past decade, the proportion of obese adults in 
Canada has increased dramatically. The Canadian Community 
Health Survey (CCHS) showed that from 1994/95 to 2000/01 , the 
number of obese Canadians between the ages of 20 to 64 
increased by 24%. Men and women aged 45 to 54 showed the 
greatest increase and account for one-fourth of obese adu lts in 
Canada. I In the United States, simi lar trends were seen in the 
CDC Behavioural Risk Factor Surveillance System (BRFSS) 
report which showed a 61 % increase in the prevalence of obesity 
among U.S. adults from 1991 to 2000.2 Individuals who are obese 
are at higher risk for coronary artery disease, heart failure , dia-
betes, obstructive sleep apnea, arthritis and psychological prob-
lems. In addition, morbidly obese individuals have a 12 time 
reduction in life expectancy. In regard to health care costs, in 
1997 the estimated cost of obesity in Canada was more than $1 .8 
billion, which accounted for 2.4% of total health care costs for a ll 
diseases.3 
Obesity is measured by calculating an individual's body mass 
index (BMI), which is equal to mass (kg) divided by height 
squared (m2). An individual having a BMI greater than 30 would 
be classified as obese. Morbid obesity is defined as a BMI 
exceeding 40 and this genera lly reflects a body weight exceeding 
I 00 lbs over ideal body weight. For morbidly obese individuals, 
bariatric (gastrointestinal) surgery may be considered as a last 
resort. Conservative therapy such as behaviour therapy and exer-
cise for morbidly obese individuals show that only 5% to 10% 
maintain weight loss for more than a few years. iv On the other 
hand, bariatric procedures have shown a greater than 50% success 
rate in maintaining long-term weight loss.4 
Indications for bariatric surgery recommended by the 
National Institutes of Health Consensus Development 
Conference Statement on Gastrointestinal Surgery for Morbid 
Obesity include a BMI greater than 40, or a BMI greater than 35 
in association with a life-threatening condition such as severe dia-
betes mellitus or cardiopulmonary problems (such as severe 
apnea, pickwickian syndrome, and obesity-related cardiomyopa-
thy) .s 
Bariatric surgery involves a restrictive component and/or a 
malabsorptive component. Restrictive methods involve removing 
or bypassing a portion of the stomach to reduce the volume of the 
stomach. This method restricts the amount of food that can be 
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eaten prior to becoming full. Restrictive operations include verti-
cal banded ga troplasty and adjustable gastric banding (the Lap-
Band). Malabsorptive methods involve redirection of bile and 
pancreatic secretions away from food, thus causing incomplete 
digestion and absorption of food . Malabsorptive operations 
include the Roux-en-Y Gastric bypass and biliopancreatic bypass. 
RESTRICTIVE OPERATIONS 
Vertical Banded Gastroplasty 
Description of the operation 
Vertical banded gastroplasty (YBG) was first described by 
Dr. Edward Mason in 1982 and involves the reduction of the 
amount of food intake by creating a vertical pouch along the less-
er curvature of the stomach using surgical staples . The operation 
is performed through a midline supraumbilical incision. A win-
dow is created through both walls of the stomach above the crow 's 
foot and next to the outlet along the lesser curvature. Stap les are 
applied at a point 3 em from the lesser curvature and 7 em below 
the ang le of His. The outlet is reinforced by two rows of staples 
and a polyproplylene mesh collar. The mesh collar is not sutured 
to the stomach itself. This procedure create a pouch that holds 
less that 50 mL.6 
Outcomes 
VBG is advantageous due to a low morbidity and a lack of 
any bypass of the intestinal tract. Mason reported succe sfu l 
weight loss (defined as a loss of 50% or more of excess body 
weight) in only 30.2% of his YBG patients in a 1 0-year follow-up 
study. Another study of 70 VBG patients from 1985 to 1989 
revealed weight loss was greatest during the first 6 months , con-
tinued until 1 year post-operatively and generally cea ed after that 
period. The same study showed that on ly 38% of patients had lost 
and maintained 50% or more of their excess weight. Median 
weight loss at I year post-operation was 36.7 kg or 48% of excess 
body weight.? Long-term failure to maintain weight loss with 
VBG is genera lly associated with enlargement of the gastric 
pouch, increased rate of emptying of the pouch over time, staple 
line dehiscence, and diet change to high-calorie liquids or soft 
foods8. 
Complications 
Potential complications of VBG include outlet stenosis, sta-
ple line dehiscence, wound infection, and band eros ion . Patients 
who undergo YBG may not be able to tolerate red mea t or 
untoasted bread and the Mayo Clinic study bowed that 30% to 
50% of patients continued to vomit once or more per week 3 years 
post-operation. Although VBG results are not sati sfactory for 
long-term maintenance of weight loss, VBG continues to be per-
formed due to its safety and lack of metabolic s ide effects. 
Adjustable Gastric Banding 
De cription of the operation 
Adjustable gastric banding devices were introduced in the 
1990s and are made of Dacron or silicone. Adjustable bands cre-
ate a small compartment in the proximal stomach. Adjustable 
banding can be performed laparoscopically. Five trocars are 
inserted at the supra-umbilica l, sub-xiphoid, right upper quadrant, 
left upper quadrant, and left subcostal positions. The ubcardial 
area is exposed and di ssection of the lesser and greater curvatures 
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is perfom1ed to create a retrogastric tunnel. The band is then put 
into place and closed. Calibration of the stoma needs. to occur ~nd 
retention sutures are then inserted. The band can be mflated vta a 
subcutaneous reservoir pump containing saline to re.strict food 
intake of the stomach. Advantages of laparoscoptc surgery 
include less pain, faster postoperative recovery, and fewer wound 
infections. 
Outcomes 
In a study of 184 patients who underwent Lap-Band insertion 
laparoscopically, the mean excess weight loss was 16% in 4 
weeks, 23% in 3 months, 31 % in 6 months, 58% in 1 year, and 
87% in 2 years. Over 90% of patients were satisfied with their 
outcome.9 In another study, a 7 year retrospective review of the 
Lap-Band revealed that the mean BMI had decreased from 44 
kg/m2 to 33 .2 kg/m2 and was stable after a follow-up of up to 86 
months (median 36 months) .10 
Complications 
A 9% complication rate post-operatively has been reported. 
Complications included band erosion (1.1 %) and slippage of the 
band (2.2%)9. Another common complication is total and irre-
versible food intolerance due to proximal pouch dilatation which 
occurred in 4 .6% of patients I D. 
MALABSORPTIVE PROCEDURES 
Roux-en-Y Gastric bypass 
Description of the operation 
The first gastric bypass was described by Mason and Ito in 
1967, where they performed a Billroth II retrocolic gastroje-
junostomy which anastomosed the fundus of the stomach to the 
jejunum. The procedure was improved by Griffen through the 
construction of a Roux-en-Y gastrojejuno tomy to prevent bile 
reflux gastritis. 
Operating through a midline incision, the first opening is cre-
ated at the lesser curvature of the stomach with a second opening 
at the angle of His. A ga tric pouch is con tructed through the two 
opening with a stapler, isolating the pouch from the remaining 
stomach . The jejunum i then transected and the proximal portion 
is brought retrocolic through an opening in the transverse meso-
colon and ana tomosed to the gastric pouch, creating the Roux-
en-Y limb. This procedure can be altered by using different 
length of the limbs to adju t the malab orption rate . 
Outcomes 
Patients who had this procedure experienced an average of 
ixty pounds weight loss with minimal liver dysfunction and good 
replacement of electro lyte and vitamin deficiencies . In a follow-
up study of 608 patients who had the surgery, the long-term 
results of the procedures are quite successful with a mean weight 
loss of 49.2% of preoperative body weight'' · The tudy a! o 
found that of 298 patients who were previou ly gluco e intoler-
ant, 9 1% had normal fasting glucose, g lycosylated hemoglobins 
and insulin levels post-operatively 12. Other satisfactory outcomes 
include lowering plasma levels of glucose, triglyceride and high-
density lipoproteins. 
Complications 
Early complications include splenic injuries, anastomotic 
leaks, wound infections and pulmonary embolisms. Later com-
plications include stenosis and obstruction of the gastric outlet 
and small bowel, incisional hernia and gallbladder di sea e. 
Nutritional supplement is required to prevent iron, folate , cal ci-
um, and vitamins A, B 12, D, E deficiencies . 
Biliopancreatic Bypass 
Description of the procedure 
The initial procedure was described by Scopinaro in 1981 
and combines a subtota l gastrectomy, with a Roux-en-Y gas-
troileal anastomosis and jejunoileal anastomo is to the ileocecal 
valve. Although this procedure had excellent weight los results, 
complications of protein malnutrition and malabsorption of vita-
mins occurred. Marceau and coworkers further improved the pro-
cedure by changing the subtotal gastrectomy to a sleeve gastrec-
tomy and the gastroileal anastomo is to a Roux-en-Y duode-
noileal anastomosis, thus reducing the incidence of malabsorp-
tion. Both procedures are routinely done in Canada and Europe. 
A midline incision is made and a subtotal gastrectomy is per-
formed, leaving around 200 to 500 mL of gastric pouch. The 
ileum is transected proximal to the ileocecal va lve and the distal 
limb is brought retrocolically and anastomosed to the gastric 
pouch. The biliopancreatic limb is anastomosed end-to-side to the 
ileocecal va lve. The biliopancreatic bypass with a duodenal 
switch is performed by changing the above procedure to create a 
gastric sleeve and transecting the duodenum distal to the pylorus. 
The ileum is transected proximal to the ileocecal valve and the 
distal limb is anastomosed to the proximal duodenum . The bil-
iopancreatic limb is then anastomosed to the distal ileum. 
Outcomes 
For 1356 patients in Italy who had the biliopancreatic bypass, 
the short-term weight loss was 74% in 2 years while long-term 
weight maintenance was reported at 78% in 14 yea rs 13. 
Advantages also included improvement in hypoventilation, 
obstructive sleep apnea syndromes, hypertension and adult-onset 
diabetes . The modified procedure with the duodenal switch was 
performed on 465 patients, with a mean percentage excess weight 
loss at 51 months of 73%14. This procedure had a lower revision 
rate and improvement in calcium and iron homeostasis with no 
significant weight difference when compared to the biliopancre-
atic bypass. 
Complications 
Early compli cations include infection, pulmonary 
embolisms, and anastomotic leak. Late complications include 
marginal ulceration and protein malnutrition and bone demineral-
ization. 
SOME COMPLICATIONS OF BARIATRIC SURGERY 
Deep Venous Thrombosis and Pulmonary Embolus 
In general, morbidly obese patients have a more sedentary 
lifestyle and tend to suffer from degenerative joint disease. They 
may also suffer from polycythemia as a result of having respira-
tory insufficiency of obesity. These, together with undergoing a 
long abdominal surgical procedure in a supine position, predis-
pose them to venous stasis disease leading to the formation of 
deep venous thrombosis. Some patients suffer from obesity 
hypoventilation syndrome that compromises their pulmonary 
reserve, making them vulnerable to death due to mild pulmonary 
embolism. In general practice, patients have sequential compres-
sion stockings placed on ca ll to surgery and are provided with 
subcutaneous heparin before and after the surgery. For those at 
high ri sk, a vena caval f il ter placement before the procedure 
should be considered. However, the risks and complications of the 
procedure, such a pneumothorax and perforation of the right atri-
um, should be di scussed with the patient. 
Atelectasis 
Retraction in open surgery and pneumoperitoneum in laparo-
scopic cases is a common cause of ate lectasis po toperatively. 
Fever and tachycardia are two common symptoms that resolve 
with pulmonary toilet and nocturnal nasa l continuous positive air-
way pressure . 
Peritonitis 
Leakage from anastomosis sites or staple-lines is a common 
but difficult diagnosis that is usually unrecognized until seps is 
has occurred. Increasing abdominal pa in, back pain or hiccup , 
combined with persistent tachyca rdia and fever with pulmonary 
dysfunction are some clinical signs that should alert clinicians to 
possible leakage. Failure to treat may lead to severe systemic sep-
sis, multiple organ failure and death. A contrast study with 
Gastrograffin can help identify the area of leakage fo r both prox-
imal gastric bypass and divided gastric bypass. A re latively well 
patient with subclinical leaks should be closely observed, while 
patients with suspected leaks should undergo a laparotomy to 
repair the defect and drain the upper abdomen. Necrotizing 
wound infections are common after peritonitis and the wound 
should be left open until patient recovers . 
Cholelithiasis 
Rapid weight loss after bariatric surgery causes bile stasis 
and sl udge formation in the gallbladder, leading to gallstones . 
Prophylatic use ofursodiol or cholecystectomy has been found to 
be effective in lowering the incidence of cholelithiasis. 
PATIENT BENEFITS 
The benefits ofbariatric surgery are not only limited to meta-
bolic and health improvement, it also has a large impact on the 
quality of life to the patient. The weight loss contributes greatly 
to the improvement in self-esteem and self-image, allowing 
patients to feel more confident about their abilities. They are also 
more accepted socially and face less di scrimination within the 
workforce. 
CONCLUSION 
The care for obese patients has evolved into an enom1ous 
health-care concern with large economic costs needed for the 
treatment of obes ity-related problems. Bariatric surgery remains 
the most effective long-term treatment for the morbidly obese, 
providing excellent results in weight loss and maintenance and 
possible reversa l of other problems such as gluco e intolerance. 
The most popular procedures are the Roux-en-Y gastric bypass 
and the vertical-banded gastroplasty w ith a high success rate of 
mean weight loss and maintenance. The most current procedures 
in development include laparoscopic Roux-en-Y gastric bypass 
and vertical-banded gastroplasty. Advantages of the laparoscopic 
procedures perforn1ed by experienced surgeons include less pain, 
faster postoperative recovery, fewer hernias and fewer wound 
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infections. Long-term benefits of laparoscopic procedures are 
currently being studied. 
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Dr. Johann Aufreiter - An Appreciation 
Paul/an Steinberg, M.D., FR.C.P(C) 
Clinical Professor and Psychotherapy Program Direct01;Department of Psychiatty, University of Alberta 
Direct01; Psychodynamic Psychiatty Service, University of Alberta Hospital 
Ex Associate ProfessOI~ Department of Psychiatly and Family Medicine, University of Western Ontario 
and 
David Heilbrunn, M.D., FR.C. P(C) 
Member, Canadian Psychoanalytic Society 
Ex Associate ProfessOI~ Department of Psychiatty and Family Medicine, University of Western Ontario 
Dr. Hans Aufreiter, professor in the Department of 
Psychiatry since 1972, passed away peacefully on February 24th, 
200 I after a long battle with illness. He wi ll be greatly missed by 
countless individuals whose lives have been touched in the sixty 
active years of his professional practice as a therapist, teacher, 
colleague and friend. Hans completed his medical training in 
Vienna in 1939 and subsequently studied internal medicine. After 
World War II he undertook psychoanalytic training in Vienna. In 
the early 1950's Hans and his wife, Dr. Gottfriede (Friedl) 
Aufreiter, were invited by Dr. Ewen Cameron to join the facu lty 
at McGill University. They became training analysts with the 
British Psychoanalytic Society to prepare for the task of initiating 
psychoanalytic teaching and training in Canada, together with Dr. 
Clifford Scott with whom the Aufreiters became founding mem-
bers of the Canadian Psychoanalytic Society. 
Through his teaching and supervision, and particularly 
through the medium of personal psychoanalysis, Hans Aufreiter 
directly or indirectly influenced generations of psychoanalysts, 
psychiatrists and other psychotherapists in Canada . In this man-
ner he had a considerable impact on the development of psychia-
try in Canada in the second half of the twentieth century. In 1972 
the Aufreiters moved to London, Ontario at the invitation of Dr. 
Gil Heseltine, the new chair of the Department of Psychiatry of 
the University of Western Ontario. At Western Hans was full pro-
fessor and was the leading teacher of psychotherapy. With the 
support of Friedl and Dr. Bill Tillmann he was able to attract other 
psychoanalysts to London and to influence psychiatrists there to 
undergo psychoanalytic training in Toronto, where he was a train-
ing analyst, with the result that by the early 1980's Western 's psy-
chiatry program had a very strong psychodynamic foundation , 
and London enjoyed a community of psychoanalysts and psy-
chotherapists far out of proportion to its size for a city in Canada. 
Hans was the consummate clinical teacher and could hold an 
audience of professionals spellbound. He was a leading exponent 
in Canada of attachment theory and object relations theory. He 
downplayed the concept of the Oedipus complex, strongly believ-
ing that aggression was not inborn but a consequence of chronic 
frustration in interpersonal relationships. Hans could be provoca-
tive in his promulgation of his theoretical approach; for example, 
his 1975 Ruth Easser Memorial Lecture at Mount Sinai Hospital 
in Toronto was entitled "St. Oedipus and the Holy Penis". Hans 
was thoroughly grounded in psychoanalytic theory but always 
drew his conclusions close to the clinical data he was working 
with. He insisted that psychoanalytic formulation should be firm-
ly based on what the patient has said about him or herself, rather 
than on speculation. He put much emphasis on the significance of 
the day residue in interpreting dreams, which underlines the emo-
tional significance to the patient of what the patient had experi-
enced that day. Hans was single-minded in his commitment to 
teaching psychoanalys is and psychotherapy, and was never too 
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busy to teach or advise a student, often reinforcing his teachings 
with personal and profess ional anecdotes. His dedication to 
teaching, his clinica l acumen , and his infectious enthusiasm have 
been an inspiration to many mental health professionals. Hans 
was a very generous teacher, giving freely of hi s time and energy, 
but had little pati ence with ambivalent pupils and he could be 
quite sharp tongued when provoked. Although London, Ontario 
was a small and somewhat remote outpost of psychoanalys is, 
Hans con tantly pushed for exposure to the very best teachers in 
the fie ld, including Bowlby, Kernberg, Goldberg, Masterson, 
Yolkan, Mitchell , and Gedo . One way in which Hans 's tremen-
dous teaching contribution has been recogn ized in London has 
been the Aufre iter Lectu re to which eminent psychoanalysts are 
invited to present paper on an annual basis. 
Hans 's teachings were spiced with hi s peppery wit. He had 
the rare ski ll of di stilling the essence of good practice and tech-
nique and of capturing complex issues in unforgettable and 
humorous vignettes. The need to be attentive, energeti c, active 
and engaging with pati ents was summed up by hi s caution that if 
we fa il in these tasks, we end up with " two stuffed shirts in the 
room, one in the chair and one on the couch" . His analy and and 
trainees have largely populated and led psychoanalytic societies 
across Canada. It would not be go ing too far to say that Hans, 
with Friedl , transformed the face of Canadian psychiatry in gen-
era l with respect to the foundati on of the Canadi an 
Psychoanalytic Society and In titute in Montreal, and of p ychia-
try in London in parti cular. They were the nidus around which the 
Southwestern Ontario Psychoanalytic Society formed. A measure 
of Hans ' influence is that by the late 1970 's, more than halfofthe 
psychiatry residents in London were undergo ing personal analy-
sis. Hans' psychoanalytic influence is not limited to Canada; hi s 
students have settled as fa r afield as Australia . 
With Hans 's death, Canadian psychiatry has lo t a pioneering 
educator, an exceptionally astute clinic ian, and a highly va lued 
mentor. His oft repeated f irst principl e in li fe and treatment was 
to "be a mensch"; he provided us with the go ld standard in thi s 
regard . Hans 's menschlichke it was ev ident to the many individu-
als he taught and treated with genuine interest, concern , and com-
passion. 
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Hypothyroidism: Should it be treated with T4 or a combination of T3 and T4? 
The controversy wi II soon be over ... 
Natalie Kotowycz, Meds 2005 
For several decades, hypothyroidism has primarily been treated with thyroxine (T4) alone, despite the fact 
that a normal thyroid gland secretes both T4 and triiodothyronine (T3). Although T4 treatment restores thy-
roid hormone levels into the normal range, patients often complain that T4 supplementation does not allevi-
ate all symptoms of hypothyroidism. Patients frequently continue to feel cold, fatigued and have problems 
with weight control. Recent data indicates that when treating patients with hypothyroidism, partial substitu-
tion of T3 for T4 may improve neuropsychological function and mood. The following is a brief synopsis of a 
study currently being completed at Toronto's Sunnybrook and Women's College Health Sciences Center. This 
study is comparing T4 with two different combinations ofT4 and T3 treatment in euthyroid subjects with T4 
treated hypothyroidism. 
Thyroid gland abnormalities have been found to affect five 
percent of the Canadian population . I Hypothyroidism is one of 
the common manifestations of thyroid disease and it is character-
ized by an underproduction of thyroid hormones. A healthy thy-
roid gland produces two hormones - tetraiodothyronine, also 
known as T4 or thyroxine, and triiodothyronine, T3. The former 
comprises 80% of the gland's hormonal output, while T3 , the 
active form of thyroid hormone, makes up 20%.2 
The causes of hypothyroidism are numerous, with the most 
common being an autoimmune disease called Hashimoto 's. In 
Hashimoto 's thyroiditis, thyroid cells are primarily destroyed by 
cell mediated immunity, although thyroid antiperoxidase antibod-
ies (TPOAbs) have also been implicated in its pathogenesis. 
These antibodies inhibit enzyme activity in thyroid cells and stim-
ulate natural killer cell cytotoxicity) Antithyroid antibodies are 
therefore primary diagnostic markers of this disease. The insuffi-
cient number of cells leaves the patient in a hypothyroid state .4 
Other causes of hypothyroidism include thyroid dysgenesis, 
radioiodine exposure, pituitary abnormalities as we ll as postpar-
tum hypothyroidism.s Since thyroid hormones play a pivotal role 
in many bodily functions including growth, metabolism, and 
mood regulation, a deficit results in a wide array of symptoms. 
Typical presenting features of hypothyroidism include feeling 
cold, extreme fatigue despite adequate sleep, weight gain, and 
depression. Other symptoms include brittle nails, thin and dry 
hair, high cholesterol, heavier menstrual cycles, as well as muscle 
aches and cramps. 4 
Customarily, treatment for hypothyroidism has consisted of 
supplementation with T4 alone. Examples ofT4 containing med-
ications include Eltroxin and Synthroid. Although T4 treatment 
does restore thyroid hormone levels back into the normal range, 
not all symptoms resolve with this particular therapy. Patients 
often continue to complain about extreme fatigue , weight gain 
and depression. 
It has generally been assumed that the T4 is adequately trans-
formed into active T3 by the monodeiodination ofT4 in extrathy-
roidal tissue; as a result, it was deemed unnecessary to supple-
ment hypothyroid patients with both T4 and T3 . Nonetheless , a 
1999 study published in the New England Journal of Medicine 
found that in hypothyroid patients, partial substitution of T3 for 
T4 might improve mood and neuropsychological function. 6 This 
sparked the interest of two physicians in Toronto who decided to 
further pursue this topic. At Toronto's Sunnybrook and Women 's 
College Health Sciences Center, Dr. Silverberg, an endocrinolo-
gist, and Dr. Levitt, a psychiatrist, decided to conduct a study that 
specifically compared T4 treatment with T3 treatment and two 
different combinations ofT4 and T3 in hypothyroid patients. 
This study began in the summer of 1999 and it directly com-
pared T4 treatment with combined T3-T4 in 59 subjects with T4 
treated hypothyroidism. In order to participate in the study, par-
ticipants were required to have at least one persistent symptom of 
hypothyroidism. Patients had to be on a stable dose of T4 and 
their blood work had to reveal that they were in a euthyroid state 
as evidenced by a TSH in the normal range. Once participants 
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entered the study, they were divided into various treatment 
groups. The first rece ived the ir current dose ofT4, while the sec-
ond group was given T3 alone in a concentration that physiologi-
ca lly matched their original dose ofT4. The final two groups were 
put on combination treatments consisting of both T3 and T4. One 
group received T4 and T3 in a ratio of 1 to 15 assuming that the 
biopotency of T3 was equal to four times that of T4; the other 
combined group received T4 and T3 in a ratio of 1 to 15 assum-
ing a biopotency of T3 equal to two and a half times that of T4. 
Both groups were given pills in a double blind twice daily dosing 
over a three to six month period. Blood tests were conducted 
every four weeks and once TSH levels were in the normal range 
for two months, various cognitive, psychosocial , physical and lab-
oratory investigations were conducted. 
The phys ica l exam consisted of monitoring pulse rate and 
blood pressure, while the laboratory investigations looked at cho-
lesterol, free T3, free T4, TSH, ferritin and Sex Hormone Binding 
Globulin concentrations. Electrocardiograms and echocardio-
grams were al so conducted in order to look at cardiac function ; 
more specifica lly, the rate of Left Ventricular contraction was 
measured on the subj ects. 
Participants completed a set of cognitive tests and also eval-
uated various Quality of Life measures. The former included the 
California verbal learning test, the 7/24 spatial recall test, various 
symbol-digit substitution tasks, as well as the logical memory test 
from the Wechsler memory scale (revised). The data from thi s 
study has been analyzed, but unfortunately the results cannot be 
presented at thi s point in time. They will be presented to the 
Canadian Society of Endocrinology and Metabolism this fa ll and 
then submitted for publication. 
It has been estimated that more than 60% of euthyroid 
pati ents with T4 treated hypothyroidi sm continue to complain of 
symptoms of hypothyroidism despite normali zation of all blood 
parameters.? If 5% of the Canadian population suffers from this 
condition I and 60% remain symptomatic, there are therefore over 
900,000 Canadians that could potentially benefit from improved 
treatment. Clearly, thi s study is of great ignificance as it will 
reveal whether there is a more suitable way of treating people that 
are suffering from the long-term effects of hypothyroidism. 
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Is dementia in long-standing schizophrenia an entity distinct 
from Alzheimer's Disease? 
Nina Ghosh, Meds 2005 
Severe cognitive impairment is common in elderly patients with schizophrenia. Since Alzheimer's disease is 
the most common cause of dementia in the elderly, it is a plausible co-morbid disease contributing to the 
dementia observed in elderly patients with schizophrenia. Neuropathological surveys indicate that most cases 
of cognitive decline in schizophrenics cannot be explained by the development of neurofibrillary tangles with-
in neurons nor the presence of amyloid senile plaques. Studies comparing the rate of cognitive decline in 
patients with schizophrenia and Alzheimer's also point to the dementia in Schizophrenia as a separate entity 
from that seen in Alzheimer's disease. Based on the evidence, the report contends that in most cases, demen-
tia associated with schizophrenia involves pathophysiological mechanisms different from those involved in 
Alzheimer's disease. However, overlap in sites of pathological decline may result in some overlapping clinical 
findings. 
CASE EXAMPLE 
Miss X is a 65 year-old female who has been living a mental 
health faci lity since the age of 29 after being diagnosed with 
schizophrenia. Though she had struggled with persecut01y audi-
tory hallucinations most of her life, the most striking feature of 
her illness was a genera/lack of affect, extreme difficulty relating 
to others, and considerable lack of motivation. She was relatively 
stable on olanzapine until one year ago, when the nursing staff 
began to notice that Miss X was become increasingly "absent-
minded" with regards to her belongings. On a f ew recent occa-
sions she has had difficuly remembering her brother s name, 
Steven, who visits her on a weekly basis. She can no longer tell 
time and is usually unable to tell others where she is. Changes in 
her dose of olanzapine and a course on clonazapine did not seem 
to improve her cognitive decline. 
INTRODUCTION 
Severe cognitive impairment is common in elderly patients 
with schizophrenia.' Since Alzheimer's disease is the most com-
mon cause of dementia in the elderly, it is a plausible co-morbid 
disease contributing to the dementia observed in elderly patients 
with schizophrenia. Commonalities between dementia in the two 
illnesses include varying degrees of delusional manifestation, 
apathy, lateral/third-ventricular enlargement, reduced frontal lobe 
activity, and hippocampal atrophy.3 Moreover, patients with either 
disease have shown comparable cognitive impairment on stan-
dardized neuropsychological tests.2 The pattern of cognitive 
decline in the elderly with long standing schizophrenia may also 
vary with the predominance of negative versus positive symp-
toms.2 Whether the clinical similarities and dissimilari ties 
between cognitive decline in Alzheimer's disease and those in 
schizophrenia represent similar pathological processes have 
important implications for clinical practice. For instance, similar 
pathophysiological processes may mean a common pharmacolog-
ical approach, such as acety lcholinesterase inhibitors, can be used 
to treat both dementia in Schizophrenia and dementia in 
Alzheimer's disease. This report reviews the current literature to 
address the question whether dementia associated with long-
standing schizophrenia is really a form of Alzheimer's disease. 
Based on the evidence, the report will attempt to contend that in 
most cases, dementia associated with schizophrenia involves 
pathophys iological mechanisms different from those involved in 
Alzheimer's disease. However, overlap in sites of pathological 
decline may result in some similar clinical findings 
EVIDENCE SUPPORTING/REFUTING THE DEMENTIA 
IN LONG-STANDING SCHIZOPHRENIA TO BE 
ALZHEIMER'S DEMENTIA: 
Neuropathological studies are perhaps the gold standard in 
di stingui shing dementia in chronic schizophrenics from 
Alzheimer's dementia. Deposition of the amyloid !3-peptide into 
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plaques in the brain parenchyma and cerebral blood vessel wa ll s, 
accumulation of neurofibrillary tang les in neurons, neuronal loss, 
and synaptic pathology are all dist inguishing fea tures of 
Alzheimer's disease. 10 Patients with schizophrenia are commonly 
heavy smokers (prevalence between 74% and 92%) and nicotine 
can decrease amyloid 13-pept ide tox icity and fibril formation. I I It 
has been proposed that nicotine or nicotinic receptor agonists 
might improve cognjtive fu nctioning not only by supplementing 
cholinergic neurotransmission but also by protecting against amy-
loid 13-peptide neurotoxicity, probably through increased release 
of amyloid precursor protein after act ivation of nicotinic recep-
tors. As is addressed later, the above fi ndings may have important 
implications for pharmacological therapy of dementia in elderly 
schizophrenics. 
Despite superf icial sim ilarities in the clinical and neuropsy-
chological profiles of patients with schizophrenia and comorbid 
dementia , extensive neuropathological probing has failed to find 
any evidence of neurodegeneration or neural injury beyond what 
is typically observed in brains of individuals without neuropsy-
chiatri c illness. Religa et a!. examined the possible invo lvement 
of amyloid beta peptide in cogni tive impairment in schizophreni a 
using immunosorbent assays in postmortem brain samples from 
Alzheimer's di sease patients, from normal elderly compari son 
subj ects and from schizophrenia pati ents showing cognitive 
decline. Although the levels of beta amyloid beta peptide in 
Alzheimer's patients were increased, the amylo id beta-peptide 
levels in schizophrenic pati ents were not significantly much dif-
ferent from control groups. The e results suggest that causes of 
cognitive impairment in pure schizophrenia are different from 
those in Alzheimer's disease .2 A similar neuropathological study 
which also included cogn itive assessment, compared the degree 
of senile plaques between cognitively impaired schizophrenia 
patients, Alzheimer's patients, and age-matched contro ls. The 
number of senile plaques or neurofibrillary tangles was not di f-
ferent in the group with schizophrenia compared with the age-
matched controls.s This study was paralleled by Dwork et a! who 
showed that of the subjects with schizophrenia, 68% had definite 
cognitive impaim1ent, but onl y 8% sati sfi ed neuropathologica l 
criteria for Alzheimer's di sea e.s Thus, it is apparent from neu-
ropathological surveys that most cases of cognitive decline in 
schizophrenics cannot be explained by the development of neu-
rof ibrillary tangles within neurons nor the presence of amyloid 
senile plaques. Thus, if there are clinica l similariti e and between 
these two types of dementia, they mu t be explained by other 
mechanisms- either those at the molecular level or cytoarchitec-
tural level or due to different pathological processes affecting 
similar areas of the bra in. 
Studies comparing CSF markers in patients with schi zophre-
nia and Alzheimer's also po int to a di ffe rence in the underlying 
pathologica l process. For example, although increased cere-
brospinal fluid (CSF) tau prote in level provide a sensitive marker 
of Alzheimer's disease, there appears to be no signif icant di ffe r-
ences in CSF total tau levels between patients with schizophrenia 
and normal control .4 Although the e f indings do not exclude a 
progressive neurodegenerative pathology in Schizophrenia, they 
provide evidence aga inst an Alzheimer's Disease related patholo-
gy associated with increased CSF tau levels. 
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Studies comparing the rate of cognitive decline in patien.ts 
with schizophrenia and Alzheimer's also point to t~e deme~tta 1~ 
Schizophrenia as a separate enti ty fro m that seen m Alzhetmer s 
di sease. Palmer et al examined 1- and 2- year cognitive changes 
among patients having earlier-onset schizophrenia (EOSD), lat~­
onset schizophrenia (LOSD) and Alzheimer 's disease . Thetr 
results based on MMSE and Matti s Dementia Rating Scale 
scores: showed that LOSD pati ents, EOSD patients and normal 
controls had similar rates of decl ine of cognition whereas 
Alzheimer's patients had greater decline.3 In essence, the ir study 
points to dementia in both late and early onset schizophrenia as 
refl ecting more static encephalopathies with slower rates of cog-
nitive decline as compared to Alzheimer's disease. 
A differential pattern of cognitive decline in Alzheimer 's dis-
ease patients versus schizophrenia with comorbid dementia was 
also demonstrated by Heaton et a!. (1994) Their study compared 
the performance of schizophrenia patients with AD patients on an 
expanded Halstead-Reitan Battery. Schizophrenia patient 's pat-
tern of deficits di ffered from AD pati ents in that AD patients 
showed less efficient learning and more rapid fo rgetting. This 
divergent pattern of cogni tive decline between the two diseases 
suggests that most cases of cognitive decline in later life of chron-
ic schizophrenics is a process separate from that occurri ng in AD. 
A distinct pattern of cognitive deficits was also di covered by 
Davidson et aJ.S Using the Consortium to Establish a Registry for 
Alzheimer's Disease (CERAD) test battery, Davidson et a!. com-
pared di fferences in the specif ic patterns of cognitive perfor-
mance of patients with AD with a group of elderly patients w ith 
schizophrenia. Geriatric subject with schizophrenia scored lower 
than AD pati ents on tests of naming and constructional praxis, but 
perfo rmed better than AD patients a measure of delayed recall. 
Interestingly, there are orne clinical similarit ies between the 
pattern of cognitive deficit of Alzhe imer's dementia and demen-
tia in schizophrenia. Brodaty et a! compared cognitive decline 
over f ive years in patients wi th chizophrenia diagnosed at age 59 
years old or over and a healthy conh·ol group. They found that a 
much greater proportion (26%) of patients with late-onset schiz-
ophrenia was found to have Alzheimer's dementia compared to 
0% of the control group. Although the subj ect number in this 
study was small , the results suggest that late-onset schizophrenia 
may be a prodrome of Alzheimer-type dementia. I Since late onset 
Schizophrenia may be a separate enti ty from early onset chizo-
phrenia, the above study doe not further evidence that cognitive 
decline in long-standing schizophrenia involves the same patho-
phys iological process as Alzheimer's disease. A study by Bosikas 
et a l did compare the cogni tive decline in Alzheimer's patients 
and long standing schizophrenic using the "Clock Drawing" test.5 
The study demonstrated that older patients institutionalized with 
chizophrenia and Alzheimer's Disease patients showed similar 
deficits on the clock drawing test compared to control patients. 
The results of this study show that in both schizophrenia and 
Alzheimer's disease cogn itive decline arises in visua l-analytic 
function attention, receptive language, and executive functions 
such as pla1ming, organization, and simultaneous proce sing. The 
same study found that patients w ith AD and schizophrenia could 
not be differentiated on the bas is of specif ic types of errors. 
Unfortunate ly, such a compari son a Clock-drawing is at be t a 
crude measure of similarity and may yield similar results over a 
range of dementia types . 
Recent cytoarchitectural , neuronal morphometric , and 
immunohistochemical studies have indicated overlap in sites of 
pathology, if not process of pathology, between schizophrenia and 
AD. Thus, similarities and differences in memory function 
between the two patient groups may reflect the simi larities and 
differences in the underlying sites and processes of neuropatho l-
ogy. Most studies show impaired memory performance relative to 
controls. This suggests overlap in the site of pathology inc luding 
the hippocampus. However, the more ignificant impairment of 
AD patients on verbal recall and retention of information may be 
due to the more extensive pathology - amyloid plaques and neu-
rofibri llary tangles - observed in the hippocampus in this group .3 
Taking the above evidence a a whole, it wou ld eem that 
cognitive decline and dementia in long-standing schizophrenia is 
an entity separate from that of Alzhei mer's dementia. It is pos i-
ble, however, that some patients with long tanding schizophrenia 
do develop a superimpo ed Alzheimer's dementia . It is probably 
in the hands of the vigilant clinician to monitor signs and symp-
tom of cognitive decline in the elderly long-standing patient with 
schizophrenia and decipher from tests of cognition and patient 
history whether the pattern of cognitive decline reflects one of 
Alzheimer's di ease or one of the natura l hi tory of chizophre-
nia . Such monitoring may influence the physician's decision as to 
the pharmacological approaches to take in treating dementia co 
morbid with schizophrenia . 
APPLYING THE EVIDENCE TO CASE EXAMPLE: 
The rate and degree of decline in Miss Xs cognitive decline 
suggests that he may be one of the f ew patients with schizophre-
nia and comorbid dementia who is actually suffering from both 
schizophrenia-related dementia and Alzheimer s type dementia. 
Thus, after optimizing Miss Xs antipsychotic medication, her 
physician may consider putting Miss X on an acetylcholinesterase 
inhibitor. Importantly, Miss Xs physician should obtain baseline 
measures of cognition (ex MMSE) to monitor Miss Xs course on 
the acetylcholinesterase inhibitOJ" 
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atorvastatin calcium 
tablets 
EFFICACY TO REACH TARGETS 
"liPITOR' 
(atO<VaSiabn calc1um) 
t 0 mg. 20 mg, 40 mg and 80 mg tablets 
THERAPEUTIC CLASSIFICATION· Lipid Metabolism Regulator 
ACTIONS ANO CLINICAL PHARMACOLOGY 
LIPrTOR (atorvastabn calc1um) IS a synthetic lipid-lowenng agent ~ IS a selective, compebtive inh1brtor of 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMG-CcA) reductase ThiS enzyme calalyzes the convers1on of HMG·CoA to mevalonate, wt11Ch IS an ea~y 
and rate-lim1bng step 1n the biOSYflthesls of cholesterol 
LIPrTOR towers plasma cholesterol and lipoprotein levels by 1nh1b1t1ng HMG-CoA reductase and cholesterol synthesiS 1n the liver 
and by 1ncreas1ng the number ol hepatic Low Dens1ty l.ipeprote1n (LDL) receptors on the cell-surtace lor enhanced uptake and 
catabolism of Low Density upoprote1n (LDL) 
LIPrTOR reduces LDL -Cholesterol (LDL -C) and the number of LDL particles UPrTOR also reduces Very Low Dens~ty 
Lipoprotein-Cholesterol (VLDL-C). serum tnglycendes (TG) and lntenmed1ate DerlSIIIy L1peproteins QDL), as well as the number of 
apehpoprote1n B (ape B) conta1n1ng particles. but 1ncreases H1gh Dens1ty LJpeprote1n-Cholesterol (HDL·C). Elevated serum 
cholesterol due to elevated LDL-C IS a major nsk factor for the development of cardiovascular disease. Low serum concentration 
of HDL -CIS also an Independent nsk factor Elevated plasma TG is also a nsk factor for cardiovascular disease. parllculally d due 
to 1ncreased IDL. or assooated with decreased HDL -C or 1ncreased LDL -C 
AtO<VaSiabn IS rap1dly absorbed atter ornl adm1n1stra1Kln. mruomum plasma concentrahons occur Within 1 to 2 hours Atorvastahn 
tablets are 95% to 99% booava1lable compared to solutions 
Mean d1stnbut1on of atorvastabn IS appro~mately 381 htres Atorvastahn is ~98% bound to plasma prote1ns. Atorvastahn IS 
extensively melabol~ed by cytochrome P-450 3A4 to ortho- and para-hydroxylated derivatives and to various beta-o~dation 
products Appro~mately 70% of Clfculabng 1nh1bltory act1~ty for HMG-CoA reductase IS attributed to acllve metabolites 
AtO<VaSiabn and rts metabolrtes are ehm1nated by b11iary excrebon. Less than 2% of a dose of atorvastabn IS recovered 1n unne 
folloWing ornl admlniStrabon. Mean plasma elim1nabon hall-hie of atorvastahn 1n humans IS appro~mately 14 hours. but the 
hall-Ide of 1nhibrtory actMty for HMG-CoA reductase IS 20 to 30 hours due to the contnbuhon of longer-lived active metabolrtes 
INDICATIONS ANO CLINICAL USE 
LIPrTOR (atorvastaun calc1um) IS 1nd1cated as an adjunct to ldestyle changes, 1nclud1ng diet. [at least equivalent to the Adult 
Treatment Panel Ill (AlP II~ TLC d1etj , for the reduellon of elevated total cholesterol. (total-C). LDL-C. TG and apehpoprote1n B (ape 
B) 1n hype~1p1dem1c and dysilpidemlc condiiKlnS, wtlen respcnse to d1et and other nonpharmacologK:al measures alone has been 
Inadequate, 1nclud1ng 
• Primary hypercholesterolemia (Type Ita): 
• Comb1ned (m1xed) hyperl1p1dem1a (Type lib). 1nclud1ng fam1hal comb~ned hype~1pldem1a. regardless of wtlether cholesterol or 
tnglycendes are the lipid abnormality of concern, 
• Dysbetallpcprote~nem~a (Type II~. 
• Hypertngtycendem1a (Type IV), 
• Farmllai hypercllolesterolem~a (homozygous and heterozygous) For homozygous familial hypercholesterolemia, UPrTOR should be 
used as an adjunct to treatments such as LDL apheresiS, or as monotherapy d such treatments are net ava11abfe 
UPrTDR also rruses HDL-cholesterol and therefore lowers the LDL-C/HDL-C and totai ·C/HDL·C ralloS 1n pauents w1th pnmary 
hypercholesterolemia and combined (miXed) hype~IPidem~a (Frednckson Type Ita and lib dysi1p1dem1a). In pealed data from 
24 contnolled cliniCal trials, LIPrTOR rrused HDL-C levels 5%-7% 1n pnmary hypercholesterolemic (type Ita) pahents and 
10%-15% 1n miXed (type lib) dyshp1demic pahents. These changes in HDL-C with HMG-CoA reductase Inhibitors should be 
cons1dered as modest when compared to those observed 1n LDL-C and do not play a primary role in the towenng of 
LDL -C/HDL -C and tolai-C/HDL -C ratios 
In cliniCal trials, LIPrTOR (10 to 80 mg/day) s1gn1f1Cantly 1mproved lipid profiles 1n pabents With a wide vanety of hype~IPidemiC 
and dysilp1dem1c condmons In 2 dose-respcnse stud1es in mildly to moderately hype~1pidem1c pauents (Fredrickson Types Ita 
and lib). LIPrTOR reduced the levels of total cholesterol (29-45%), LDL·C (39-60%), ape B [32-50%). TG [19-37%). and meased 
h1gh density lipoprotein cholesterol (HDL-C) levels (5-9%) Comparable responses were achieved 1n patients With heterozygous 
familial hypercholesterolemia, nen-fam1liaf forms of hypercholesterolemia, combined hyperlipidemia, including familial comb1ned 
hyperlipidemia and pabents with ncn-1nsuhn dependent diabetes mellitus In paben With hypertnglyceridemia (Type IV), UPrTOR 
(10 to 80 mg druly) reduced TG (25-56%) and LDL-C levels (23-40%) LIPrTOR has net been stud1ed in condmons where the 
major abnormality IS elevahon of chylom1crons (TG levels > 11 mmolll). 1 e types I and V. 
In an open-label study in pahents with dysbetalipoprote~nem1a (Type II~. LIPrTOR (10 to 80 mg daily) reduced totai -C (40-57%), 
TG (40-56%) and IDL·C + VLDL·C levels (34-58%) 
In an open label study 1n pahents with homOzygous famll1al hypercholesterolemia (FH) LIPrTOR (1 0 to 80 mg da1ly) reduced 
mean LDL -C levels (22%) In a pilot study, LIPrTOR 80 mg/day showed a mean LDL -C lowenng of 30% for patients net on 
plasmapheresiS and of 31% for pahents whc conhnued plasmapheresis A mean LDL-C lowenng of 35% was observed 1n 
receptor defechve pabents and of 19% 1n receptor nejjalive pahents (see PHARMACOLOGY, Chn~cal Stud1es). 
For more cfelaJ~ on efficacy results by pre-defined classification and pooled data by Fredicl<son types, see PHARMACOLOGY. Oinicaf Studies 
PrKJr to 1n1habng therapy wrth UPrTOR. secondary causes should be excluded lor elevations 1n plasma lipid levels (e g pearly 
controlled diabetes mellrtus. hypothyroidism. nephrohc syndrome, dyspiote~nemias. obstructiVe INer d1sease. and alcoholism). and 
a lipid profile pertormed to measure total cholesterol. LDL-C. HDL-C, and TG For pahents With TG <4 52 mmolll (<400 mg/dl), 
LDL·C can be estimated us~ng the follovnng equahon 
LDL-C (mmolll) = totai-C • [(0 3 x (TG) + HDL-C)J 
LDL-C (mg/dl) = totai-C- [(0.2 x (TG) + HDL-C)] ' 
For pat1ents vnth TG levels >4 52 mmoVL (>400 mg/dl), th1s equallon ~ less accurate and LDL-C concentrallons should be 
measured d~rectly or by ultracentntugahon 
Pahents with high or very h1gh tnglycende levels. 1 e >2 2 mmoVL (200 mg/dl) or >5.6 mmoVL (500 mg/dl). respectively, may 
reqUire lrlglycende-lowering therapy (fenoflbrate, bezafibrate or nicotiniC acid) alone or In combination with UPITOR. 
In general, combination therapy with fibrates must be undertaken cautiously and only alter rtsk-benefrt analysts 
(see WARNINGS, Muscle Effects, PRECAUTIONS. PhamnacokmehC lnteract1011 Stud1es and Potenhal Drug Interactions) 
Elevated serum tnglycendes are most o"en observed 1n pahents with the metabolic syndrome (abdKJrnlnal obes1ty, atherogeniC 
dyslip1dem1a {elevated lrlglycendes. small dense LDL particles and low HDL-cholesterol), 1nsulin resistance with or w1thout 
glucose Intolerance, ra1sed blood pressure and prothromblc and promllammatory states) 
(For the treatment of spec1f1c dysllpldemias refer to the Repert olthe Canadian Wo~ng Group on Hypercholesterolemia and Other 
DysllpidemlaS or to the US NCEP Expert Panel on Detechon, Evaiuallon, and Treatment of High Blood Cholesterol In Adults [Adult 
Treatment Panelllij, under SELECTED BIBLIOGRAPHY 1n product monograph) 
When drugs are prescnbed anenhon to therapeuhc lifestyle changes (reduced 1ntake of saturated fats and cholesterol . we1ght 
reduct1on. 1ncreased physical acllvlty, Ingestion of soluble fibres) should always be mainta1ned and reinforced. 
The Atorvastahn Versus Revasculanzahon Treatments (AVERT) study examined the effect of intensive lipid-lowering In patients 
w1lh stable coron~ary artery d1sease and LDL-C atleast3.0 mmoVL 1n paMnts referred for percutaneous tran~umlnaf coronary 
angiOJllasly (PTCA). Patients were randomiZed for 18 months to LIPITOR 80 mg dally or to PTCA with usual medical care which 
could Include lipid metaboliSm rejjulators. The results of the AVERT study should be considered as exploratory s~nce several 
11mrtahons may affect its des1gn and conduct In the medical-treated group with LIPrTOR there was a trend for a reduced 
1nc1dence ol 1SChem1c events and a delayed 11me to first 1schem1c event The results also suggest that Intensive treatment to 
target LDL-C levels With LIPrTOR IS additive and complementary to ang1optasty and would benefit pahents referred lor this 
procecure (see SELECTED BIBLIOGRAPHY 1n product monograph) 
CONTRAINOICATIONS 
Hypersens1h~ty to any component of this med1cahon 
~ IMlo' cisease or unexplained persistent ~evallonS of serum transamnases exceeding 3 times the Lllf)er t1mrt of ncrmaf (see WARNINGS). 
Prej)nancy and lactation {see PRECAUTIONS). 
WARNINGS 
anmaco i teractions 
The use of HMG-CoA reductase Inhibitors has been associated With severe myopathy, Including rhabdomyolysls. which may be 
more frequent when they are co-administered w1th drugs that tnh1bit the cytochrome P-450 enzyme system. Atorvastatln is 
metabolized by cytochrome P-450 lsoform 3A4 and as such may Interact with agents that inhibit this enzyme. (See WARNINGS, 
Muscle Effects aJnd PRECAUTONS. Drug Interactions and Cytochrome P-450-medlated lnteracuons) 
1 Fnedewald WT era/ Clm Chem 1972, 18(61 489 502 
Hepatic Effects . ncnma rred in <1% of patients 
In dinicaf trials, persistent 1ncreases 1n serum transarninases greater than three times the upper lim~ of :u discontinued serum 
whc rnceived LIPrTOR When the dosage of LIPrTOR was reduced, or wt1en drug treatmentedwasWithrrt~ ; other dinlcal ~gns or 
transaminase teve~ returned to pretreatment levels. The 1ncreases were generaly not assooot J'l 
symptoms. Most patients continued treatment with a reduced dose cd LIPrTOR Without d1nk:af sequelae. . . 
Liver function tests should be pertormed before the initiation of treatment and periodically thereafter. Spe~al ~tt~~~o;e s~e~~t~~ 
paid to patients who develop elevated serum transaminase levels, and in these patients measuremen s 0 
promptly and then pertormed more frequently. _ 
If increases in alanine aminotransferase (ALn or aspartate aminotransferase (ASn show eviden~ of pr~re~or::; 
particularly~ they rise to greater than 3 times the upper hmn of nonmal and are pers1sten~ the osage s ou 
reduced or the drug discontinued. . 
LIPrTOR should be used with caution in patients who consume substanhal quantities of alcohol and/or have a past history of 
lwer d1sease Active liver diSease or unexplained transaminase etevat1ons are contra1nd1CallonS to the use of LIPrTOR, ff such a 
cond1t1on should develop dunng therapy, the drug should be discoobnued. 
Muscle Effects . 
Myopathy, defined as muscle ach1ng or muscle weakness in conjunction w1th increases in creatinine. phosphokinase (CPK) 
values to greater than ten times the upper hmit of normal, should be cons1dered 1n any patient With diffuse. myalgia, muscle 
tenderness or weakness, and/or mar1<ed elevation of CPK. Patients should be acfvlsed to report promptly unexplained muscle pain, 
tenderness or weakness, particularly d accompanied by ml3iruse or fever LIPrTOR therapy should be d1sconbnued ff rnarl<edly 
elevated CPK levels occur or myopathy 1s d1agnosed or suspected. . 
The nsk of myopathy and rhabdomyolysis dunng treatment w1th HMG-.CoA reductase inhibitors is increased with concurrent 
administration of cyclospcrin, fibriC acid derivatives, erythromycin, ctanthromyc1n, n1ac1n (niCOtiniC ac1d), ~ole antifungals or 
nef~odone As there IS no expenence to date With the use of LIPrTOR given concurrently with. these drugs. with the .exception of 
pharmacokinellc studies conducted 1n healthy subjects w1th erythromycin and clarithromyon, the benefits and nsks of such 
combined therapy should be carefully conSidered (see PRECAUTONS. Pharmacokinebc lnteracllon Studies and Potenhal 
Drug Interactions). 
Rhabdomyolysls has been reperted 1n very rare cases wrth LIPrTOR (see PRECAUTONS, Drug Interactions). 
Rhabdornyolysls with renal dysfuncbon secondary to myoglob1nuna has also been reported with HMG-CoA reductase inhiMors. 
LIPrTOR therapy should be temporanly withheld or diSCOOtinued in any pabent with an acute seneus condrtion suggestive of a 
myopathy or ha~ng a nsk factor predispoSing to the developiment of renal frulure secondary to rhabdomyolysiS (such as severe acute 
1nfecb0n. hypoterlSion, maJOf surgery, trauma. severe metaboliC, endocnne and electnolyte disorders, and uncontrolled seizures). 
PRECAIITIONS 
General 
The effects of atorvastatin-induced changes in lipiOprotein levels, including reduction of serum cholesterol on 
cardiovascular morbidity or mortality or total mortality have not been established. 
Before 1nst1tut1ng therapy With UPrTOR (atorvastabn calcium). an anempt sllould be made to contnol elevated serum lipeprotein 
levels with appropnate d1et, exercise. and we1ght reduction in overweight pat1ents. and to treat other unde~ymg med1cal 
problems (see INDICATIONS AND CLINICAL USE). Pabents should be a~sed to infonn subsequent physicians of the prior use of 
LIPrTOR or any other lip1d-lowenng agents 
Effect on the Lens 
Currentlong-tenn data from cliniCal tnals do not 1nd1cate an adiverse effect of atorvastat1n on the human lens. 
Effect on Ubiquinone ICoCbol levels 
Significant decreases '" clfculabng ubiQUinone levels 1n panents treated with atorvastahn and other stabns have been observed 
The cliniCal Significance of a petenhallong-term stabn·lnduced deficiency of UbiQUinone has not been establislled. ~ has been 
repcrted that a decrease 1n myc~eardiaf ub1qu1nene levels could lead to Impaired card1ac function in patents with oorden~ne 
congestive heart fa1ture (see SELECTED BIBLIOGRAPHY '" product monograph). 
Effect on Liooorotejn Ia) 
In some pabents. the beneliclal effect of lowered total cholesterol and LDL -C levels may be partly biunted by a concomitant increase 
1n Lpta) l1poproleln ooncentrabons. Present knoY.1edge suggests the Importance of high lpta) levels as an emerging risk factor for 
coronary heart disease. n 1s thus desirable to ml3intam and remforce ldestyle changes 1n high nsk patients placed on atorvastatin 
therapy (see SELECTED BIBLIOGRAPHY 1n product mooograph) 
Hypersensitivity 
An apparent hypersensm"ty syndrome has been reperted With other HMG-CoA reductase Inhibitors which has 1ncluded 1 or more 
of the following features anaphylaJOs. angioedema, lupus erythematous-like syndrome, pctymyalgia rheumatica, vasculitis, 
purpura, thrombocytopen~a , leukopen~a. hemolytic anem1a, pos11Jve ANA. ESR increase, eosinophilia, arthritis, arthrnlgia, urticaria, 
asthenia, photosens1hVIy, lever. ch1lls, flush1ng. malaise. dyspnea, tOXIC epidermal necrolysis, erythema multiforme, including 
Stevens-Johnson syndrome. Mhough to date hypersensiti~ty syndrome has not been descnbed as such, UPrTOR should be 
discontinued d hypersens111~ty is suspected 
U i an 
LIPITOR Is contraindicated during pregnancy (see CONTRAJNDICATIONS). 
Atherosclerosis Is a chronic process and d1sconbnuanon of lipid-lowenng drugs during pregnancy should have tinte impact on 
the outcome of long-tenn therapy ol primary hypercholesterolemia. Cholesterol and other products of cholesterol biosynthesis 
are essen11al compenents for fetal development unctud1ng synthesis of steroids and cell membranes). Since HMG-CoA reductase 
1nh1Mors decrease cholesterol synthesis and pcss1bly the synthesiS of other blolog~eat~ active substances deriived from 
cholesterol. they may cause hann to the fetus when adm1n1stered to pregnant women 
There are no data on the use of LIPrTOR dunng pregnancy. UPITOR should be administered to women of childbearing age only 
when such pahents are highly unlikely to conceive and have been Informed of the pctenhal hazards. If the patient becomes 
pregnant while taking UPITOR, the drug sllould be diSCOntinued and the patient apprised of the petential risk to the fetus. 
Nursing Mothers 
In rats, milk concentrations of atorvastabn are similar to those in plasma n is not known whether this drug Is excreted 1n 
human m1lk Because of the petential for adiverse reactions 1n nu~ng 1nfants, women taking LIPITOR should not breast-feed 
(see CONTRANDICATIONS). 
Pediatric Use 
Treatment experience 1n a pediatric ~ulat10n is limrted to doses of UPrTOR up to 80 mg/day for 1 year in s patients with 
homozygous fam,lial hypercholesterolemia. No cl~nK:al or biOChemical abnormalities were reperted in these patients. 
Geriatric Use 
Treatment experience In adults 70 ye~rs . or older (N=221) with dos.es of LIPITOR up to 80 mg/day has demonstrated that the 
safety ~nd effechveness of atorvastalln 1n this peputauon was ~,m,lar to that of patients < 70 years of age Pharrnacol<inetic 
evaluaiiOn of atorvastann 1n subtects over the age ol 65 years 1ndicates an increased AUC. As a precaution~ary measure the 
lowest dose should be adm1n1stered lnihally (see PHARMACOLOGY, Human Pharmacokinetics: SELECTED BIBLIOGRAPHY in 
product monograph) 
e II s clenc 
Plasma concentrations and LDL -C tov.:ering efficacy of UPITOR was shown to be s1mitar in patients with moderate renal 
1nsuff1C1ency compared w1th .patients w1th normal renal function However, since several cases of rhabolomyolysis have been 
reported 1n patients w1th a h1story of renal Insufficiency of unknown severity, as a precautionary measure and pending further 
experience 1n renal d1sease. the tao:vest dose (10 mg/day) of UPrTOR should be used 1n these patients. Similar precautions app~ 
In patients w1th severe renal ~nsuff1c1ency [creatinine clearance <30 mUmin (<0.5 mUsec)J: the lowest dosage should be sed 
and Implemented caut1ous~ (see WARNINGS, Muscle Effects. PRECAUTONS. Drug Interactions). u 
Refer also to DOSAGE AND ADMINISTRAnON. 
EndOICrine Function 
HMG·CoA reductase inhibitors .intert.ere with cholesterol synthesis and as such miQht theoretiCally blunt adrenal and/or dal 
sterOid production. Clinical Studies with atorvastatin and other HMG-CoA reductase inhibitors have suggested that these a S:: 00 
not reduce plasma cort1sol concentratiOn or ''"pa" adrenal rese~ and do not reduce basal plasma testosterone conce~tralion 
Howeve~. the effects of HMG-CoA reductase lnh1brtors on male fertility have net been studied in adequate numbers f ti ts The. 
effects, If any, on the PitUitary-gonadal aJOS In premencpausal women are unknown. 0 pa en · 
Patients treated With atorvasllltin whc develop dinlcal ~dence of endocrine dysfunction should be evaluated appropriately Caubon 
should be exercised 11 an HMG·CoA reductase 1nh1bnor or olller agent used lo klwer cholesterol levels IS adm1msterec to pat1en1S 
receiving olller drugs (e.g. ketoccnazole, spironolactone or cimetid1ne) lllat may decrease the levels of endogenous sterrnd homnones 
hannacoki tic Interaction Studies and Potential Dru lnteractio s 
Pharmacokinelic Interaction stud1es conducted with drugs in healthy sub;eciS may not detect the possibility of a potennal drug 
Interaction In some patien!s due to differences in underlying diseases and use of concomitant medications (see also Geriatnc 
Use; Renal Insufficiency, Patients willl Severe Hypercholesterolemia). 
Concomitant Therapy with Other lipid Metabolism Regulators: Combined drug lllerapy should be approached wilh 
cautJon as infonnaticn from contrOlled stud1es 1s limned. 
Bile Acid Sequestrants: 
Patients with mid to moderate h\llercOOiestero!emia: LDL -C recuctJon was greater when UPITOR 10 mg and colestipol 20 g were 
coadministered (-45%) lllan when eilher drug was admnistered atone (-35% for UPITOR and -22% for colestipol) 
Patients with severe hypercholesterolemia: LDL-C reduction was similar (·53%) when UPITOR 40 mg and colesbpol 20 g were 
coadministerec when compared to lllat with UPrTOR 80 mg atone. Plasma concentration of atorvastabn was lower (appro~mately 
26%) when UPrTOR 40 mg plus colestipOI 20 g were coadministered compared wilh UPrTOR 40 mg alone. 
However, the combination drug lllerapy was tess effectJve in lowering llle triglycerides lllan UPrTOR monclllerapy in bolll types of 
hypercholesterolemic patients (see PHARMACOLOGY, Climcal Studies). 
When UPITOR Is usee concurrently with colestipol or any other resin, an interval of at least 2 hours should be maintained between 
llle two drugs, since llle absorption of UPrTOR may be imparec by llle resin. 
Fibric Acid Derivatives (Gemfibrozil, Rmofibrate, Bezafibrate) and Niacin (Nicotinic Acid): Although lllere IS limited 
exPBrience with llle use of UPITOR given concurrently with fibnc acid derivatives and niacin, the benefits and nsks of such combmec 
lllerapy Should be carefully considered. The riSk of myopallly during treatment with olller drugs in lllis class. including atorvastabn, 
~increased with concurrent administration (see WARNINGS, Muscle EffeciS and SELECTED BIBLIOGRAPHY in product monograph). 
Coumarin Anticoagulants: UPrTOR had no climcally Significant effect on prolllromb1n nme when admm1sterec to palients 
rece1ving chronic wartarin lllerapy (see SELECTED BIBLIOGRAPHY in product monograph). 
Digoxin: In healtlly subjects. digoxin pharmacokinetics at steady-state were not significantly altered by coadministration 
of digo~n 0.25 mg and UPrTOR 10 mg daily. However. digo~n steady-state concentrations increased approximately 20% 
followmg coadministration of digOXIn 0.25 mg and UPITOR 80 mg daily (see Human Phannacol<inetJcs). Panents takJng d1go~n 
should be monitored appropnately. 
Antihypertensive agerrts (amiodipine): In clinical stud1es, UPrTOR was used concomitantly w1th antihypertensiVB agents 
without evidence to date of clinically significant adverse interactions. In healtlly subjects. atorvastatin phannacol<inetics were not 
anerec by llle coadministration of LIPITOR 80 mg and amlod1pme 1 0 mg at steady state (see Human Phamnacokinencs). 
(quinapril): In a randomized, open-labe study 1n heanhy sub;ects, steady-state QUinapnt dosing (80 mg 00) did not Significantly 
affect llle phannacokinetic profile of atorvastatin tablets (1 0 mg 00) (see Human Phamnacokinetics). 
Oral Corrtraceptives and Honnone Replacement Therapy: Coadministranon of UPrTOR witll an oral contracepnve, 
containing 1 mg norethindrone and 35 ~g elll1n~ estrndiot, increased plasma concentraticns ~UC levels) of norethindrone and 
elll1n~ estradiol by appro~matety 30% and 20%, respectively. These 1ncreases should be considered when setecnng an oral 
contraceptive. In clinical studies, UPrTOR was used concomitantly wilh estrogen replacement lllerapy willlout e~dence to date of 
clinically significant adverse interactions. 
Antacids: Administration of aluminum and magnesium based antacids, such as Maato TC Suspens1on, with UPrTOR 
decreased plasma concentrations of UPrTOR by approXImately 35%. LDL -C reduction was not altered but the triglycende-
lowenng effect of LIPrTOR may be affected. 
Cimetidine: Administration of cimetidine with UPrTOR d1d not alter plasma concentrations or LDL -C lowenng efficacy of 
UPrTOR, however, llle triglyceride-lowering effect of UPrTOR was reduced from 34% to 26%. 
Cytochrome P-45G-mediated Interactions: Atorvastann is metabolaec by the cytochrome P-450 ~nzyme. GYP 3A4 
Erylllromycin. a GYP 3A4 inhiMor, 1ncreased atorvastatin plasma levels by 40%. Coadministration of GYP 3A4 inh1Mors, such as 
grapefrurt juice, some macrolide antibiotics Q.e. erythromycin, clarithromycin), immunosuppressants (cyclosporine), azole antifungal 
agents Q.e. ~e. ketoconazole), protease inhiMors. or llle antidepressant, nefazodone, may have llle potential to increase 
plasma ooncentraticns of HMG·CoA reductase mhibnors, inciud1ng UPITOR (see SELECTED BIBIUOGRAPHY 1n product monograph). 
CautJon should lllus be exerc1sed with concomrtant use of lllese agents (see WARNINGS, Phamnacol<inetic lnteracllons. Muscle 
Effects; PRECAUTONS, Renallnsuffciency and Endocrine Function; DOSAGE AND ADMINISTRATION; SELECTED BIBLIOGRAPHY 1n 
product monograph). 
In heailhy subjects, coadministration of maxmum doses of bolll atorvastann (80 mg) and tertenadine (120 mg), a GYP 3A4 
substrate, was shown to produce a modest increase in tertenad1ne AUG. The OT c interval remained unchanged. However, since an 
interaction between lllese two drugs cannot be excluded in patients wiiJl predisposing factors for arrhylllmia, (e.g. pree~sbng 
prolonged OT interval , severe coronary artery disease, hypokalemia), caution should be exercised when lllese agents are 
coadministered (see WARNINGS, Phamnacol<inetic lnteraclicns; DOSAGE AND AOMINISTRATlON). 
Antipyrine: Antipynne was used as a non-specific model for drugs metabolized by llle microsomal hepatic enzyme system 
(cytochrome P-450 system). UPrTOR had no effect on llle phannacokinetics of antipyrine, tllus interactions with other drugs 
metabolized via llle same cytochrome isozymes are not expected. 
Macrolide Antibiotics (azithromycin, ctaritl1romycin, erythromycin): In heailhy adults, ooaministration of UPITOR (1 0 mg OD) 
and azithromycin (500 mg 00) aid not sigmficantly aner llle plasma concentrations o1 atorvastatJn ~r. coadministration of 
atavastann (1 0 mg 00) willl erylllromycin (500 mg OlD) or clanthromycin (500 mg BID), which are bolll GYP 3A4 inhlxtors, increased 
pmro corx:entratioos of atavastatin apprOOrretely 40% and 80%, respectively (see WARNINGS, ML&Ie Effects; Human l'harrnacoiOnetics). 
Protease Inhibitors (nelfinavir mesylate): In healthy adults, coadministration of nelfinavir mes~te (1250 mg BID), a known 
GYP 3A4 inhiMor, and atorvastatin (1 0 mg 00) resu~ec 1n Increased plasma concentrabons of atorvastatin. AUG amd C... of 
atorvastann were increased by 74% and 122% respectively. 
Patients with Severe Hvpercholesterolemia: Higher drug dosages (80 mg/day) required for some patients willl severe 
hypercholesterolemia Qncluding familial hypercholesterolemia) are associated wiiJl increased plasma levels of atorvastatin. 
Caution should be exercised in such patients Who are also severely renally impaired, elde~y, or are concomitanUy 
being administered digoxin or CYP 3A4 inhibitors (see WARNINGS, Phannacokinetic Interactions, Muscle Effects; 
PRECAUTIONS, Drug Interactions; DOSAGE AND ADMINISTRATION). 
Drua/laboratory Test Interactions 
UPrTOR may elevate serum transaminase and creatinine phosphokinase levels (from skeletal muscle) In llle differential diagOOSis 
of chest pain 1n a panent on lllerapy wilh UPrTOR, card1ac and noncard1ac fractK:ns of tllese enzymes should be detennined. 
AOVERSE REACTIONS 
UPrTOR is generally well-tolerated. Adverse reactions have usually been mild and transient In controlled clinical studies 
(placebo-controlled and active-controlled comparative studies wilh other lipid lowering agents) invol~ng 2502 patients, <2% of 
patients were discontinued due to adverse expenences attnbutable to LIPrTOR. Of lllese 2502 patients, 1721 were treated for 
at least 6 monllls and 1253 for 1 year or more. 
Adverse exPBriences occurring at an incidence ;, 1% in patients participating in placebo-controlled clinical stud1es of UPrTOR and 
reported to be possibly, probably or definnely drug related are shown in Table 1 below. 
TABLE 1, Associated Adverse Events Reported in >1% of Patients in Placebo-Controlled Clinical Trials 
GASTROINTESTlNAL 
Constipation 
Diarrhea 
Dyspepsia 
Flatulence 
Nausea 
NERVOUS SYSTEM 
Headache 
MISCELlANEOUS 
Pain 
Myalgia 
Astlhenia 
Placebo % (n 270) LIPrTOR % (n 11 22 ) 
<1 
1 
<1 
The following additional adverse events were reported in clinical. trials; not all events listed below have been associated with a 
causal relationship to LIPrTOR lllerapy: Muscle cramps •. myositiS, myopathy, parestlles1a, penpheral neuropathy, pancreati!Js, 
hepatnis, cholestatic 1aundice, anorexia, vomiting, alopecia, pruritus, rash, Impotence, hyperglycemia, and hypoglycemia. 
Post·mart<eting e!!Derience: Very rare reports: severe myopathy with or without rtlabdomyolysis (see WARNINGS, Muscle EffeciS; 
PRECAUTONS, Renal Insufficiency and Drug Interactions). Isolated reports: lllrombocytopema, arthralgia and allergic reactions 
includmg urticana, angioneurotic edema, anaph~aJOS and bullous raShes v.nciudlng erythema multiforme, Stevens-Johnson 
syndrome and tooc epidemnal necrolysis). These may have no causal relabonsh1p to atorvastabn. 
Ophlllalmolog1c observations: see PRECAUTONS 
Laboratory Tests: Increases 1n serum transam1nase levels have been noted 1n clinical tnals (see WARNINGS) 
SYMPTOMS AND TREATMENT OF OVERDOSAGE 
There IS no specific treatment for atorvastann overdosage. Should an overdose occur, the panent should be treated symptornabcally 
and supportive measures 1nstnuted as required Due to extensiVB drug b1nd1ng to plasma prote1ns, hemodialysis IS not expected to 
Significantly enhance atorvastann dearance. 
DOSAGE AND ADMINISTRATION 
Pat1ents should be placed on a standard cholesteroHowenng d1et ]at least eqUivalent to llle Adult Treatment Panel Ill ~TP IIQ TLC 
diet] before receiVIng UPITOR, and should continue on ltlls d1et dunng treatment w1th UPrTOR. II appropnate, a program of we1ght 
control and physical exerc1se should be implemented 
Pnmary Hvpercholesterolemia and Combmed !MIXed! Hyperhmdem1a lncludmq Fam1hal Comb1ned HyoeriiPidemta The rec-
ommended dose of LIPITOR is 1 0 mg once a day. The ma1onty of pabents ach1eve and mamta1n target cholesterol levels ~Ill 
UPrTOR 1 0 mg/day. A significant therapeutic response is eVIdent Wllh1n 2 weeks, and the maJOmum response IS usually achieved 
within 2-4 weeks. The response is maintained dunng chron1c lllerapy Doses can be giVen at any time of tile day, wilh or ~thou! 
food, and Should preferably be giVBn 1n tile evening Doses should be 1ndMdual1zed aocord1ng to baseline LDL -C and/or TG levels, 
the desired LDL-C and/or TG target (see llle Detecnon and Management of Hypercholesterolemia, Working Group on 
Hypercholesterolemia amd other Oyslipidemias ]Canada] and/or the US National Cholesterol Education Program ]NCEP Adult 
Treatment Panel Ill]), the goal of therapy and the patient's response. Adjustments of dosage, if necessary, should be made at mter-
vals of 4 weeks or more. The recommended dose range for moot patients IS 10 to 40 mg/day The maJOmum dose Is 80 mg/day, 
whiCh may be required 1n a mmonty of pat1ents (see sectKm below) 
lipid levels should be monitored periodically and, if necessary, the dose of LIPfTOR adjusted based on target lipid 
levels recommended by guidelines. 
The follow1ng reductions in total cholesterol and LDL·C levels have baen observed 1n 2 dose-response studies, and may serve 
as a gu1de to treatment of patients w111l m1ld to moderate hypercholesterolemia 
TABLE 2. Dose-Response in Patients With Mild to Moderate Hypercholesterolemia 
(Mean Percent Change from Baseline)' 
Lipid Parameter 
10 
(N-22) 
-29 
·39 
a. Results are pooled from 2 dose-response stud1es. 
b. Mean baseline values. 
Severe Dyslipidemias 
LIPrTOR Dose (mg!day) 
20 
(N-20) 
-33 
-43 
40 
(N-21) 
-37 
-50 
80 
(N-23) 
-45 
-60 
In patients with severe dyslipidem1as, 1nclud1ng homozygous and heterozygous familial hypercholesterolemia and 
dlySbetalipoprotelnemla (Type IIQ, higher dosages (up to 80 mg/day) may be reqUired (see WARNINGS, Phamnacokmetic 
Interactions. Muscle Effects; PRECAUTONS, Drug Interactions) 
Concomitant Therapy 
See PRECAUTIONS, Drug Interactions. 
Dosage in Patients Wrth Renal Insufficiency 
See PRECAUTONS. 
PHARMACEUTICAL INFORMATION 
Drug Substance 
Proper Name: Atorvastatin calc1um 
Chem1cal Name: IR·(R' .R1]·2-(4-fluorophenyf) -B, o·dihydroxy-5-(1-meth~etllyf)-3-phen~-4-i(phen~mmo) carbonyf]-
1ti·pyrrole-1-heptanoic acid, calcium salt (2:1) tnhydrate 
Empirical Fonnula: (C33H34FN20,J2Ca•3H20 
Molecular Weight 1209.42 
Structural Fonnula· 
0 
o-le,·· •3H,O 
2 
DescnptJon: Atorvastatin calcium IS a white to off-white crystalline powder that is pracbcally insoluble 1n aqueous solutions of 
pH 4 and below. Atorvastatin calc1um 1s very slightly soluble 1n diStilled water, pH 7.4 phosphate buffer and acetonrtrile, slightly 
soluble in elllanol, and freely soluble 1n melllanol 
Tablet Composition: 
Each tablet contams eitller 10 mg. 20 mg, 40 mg or 80 mg atorvastann as the aclive 1ngred1ent Each tablet also contains the 
fOllowing non-medicinal1ngredients calc1um carbonate, candelilla wax, croscannellose soc1um, hydroxyprop~ cellulose, lactose 
monohydrate, magnesium stearate, microcrystalline cellulose, hydroxypropyl melll~cellulose , polyelll~ene glycol, talc, trtan1um 
dio~de, polysorbate 80 and simeth1cone emulsion 
Stability and Storage Recommendations: 
Store at controlled room temperature 15 to 30 C. 
AVAILABILITY OF DOSAGE FORMS 
UPrTOR (atorvastatin calcium) is available in dosage strengths of 10 mg, 20 mg, 40 mg and 80 mg atorvastaM per tablet 
10 mg: Whne, elliptical, film-coated tablet. coded "10" on one Side and "PO 155" on llle olller Avrulable 1n bottles of 
90tablets 
20 mg: Wh1te, ellipncal, film-coated tablet, coded "20" on one s1de and "PO 156" on the other. Available 1n bottles of 
90 tablets. 
40 mg:Whrte, elliptical, film-coated tablet, coded "40" on one s1de and "PO 157" on tile other. Available 1n bottles of 
90 tablets. 
80 mg: White, ellipbcal, film-coated tablet. coded "80" on one s1de and "PO 158" on llle olller. Blisters of 30 tablets 
(3 strips x 10). 
References: 
1. UPrTOR (atorvastatin calcium) Product Monograph, Pfizer Canada Inc., February 2002. 2. IMS Global SerVIces, March 1997 
- September 2002. 3. Pitt B, et al. AggressiVe hpid-lowenng therapy compared w1th ang1oplasty 1n stable coronary artery 
disease. N Eng/ J Med 1999,341 :70-76. 4. Data on F1le, Pfizer Canada Inc. 5. S1mon Day Dictionary for Chmcal Tnals, 1999, 
John Wiley & Scns Ltd. 137-38 
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Thunder Bay, Ontario 
Life is Better Here. 
Thunder Bay offers the perfect balance of a dynamic work environment and a vibrant community 
with many outstanding cultural, recreational, and performing arts venues. In fact, we have been 
designated as a "Cultural Capital of Canada." And, we are just minutes away from all of it. 
Thunder Bay Regional Hospital is in a period of dynamic change as we move to a new 375 bed state 
of the art Health Sciences facility. This wiU result in further expansion of our Hospitalist Program. 
Family practitioners have the opportunity to work in a variety of clinic and independent practice 
environments. These include the Family Health Network and Family H ealth Groups. 
We are currently seeking interested candidates, who are eligible for licensing with the CoUege of 
Physicians and Surgeons of Ontario, and/ or possess current ACLS certification in the foUowing 
areas: 
+ Family Practitioners + Lead Hospitalist + Hospitalists (FT, PT or Locum) 
Qualified candidates may be eligible for various incentive and/ or tuition reimbursement grants. 
Please forward your curriculum vitae with the specified position of interest, in confidence to: 
D r. Blair R . Schoales, Chief of Staff 
Thunder Bay Regional Hospital 
Fax (807) 622-6228 
schoaleb@tbh.net 
John G uthrie, Family Physician Recruitment Specialist 
City of Thunder Bay 
Fax (807) 625-3292 
jguthrie@city.thunder-bay.on.ca 
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The rewards 
make all the 
difference 
Les avantages 
font toute Ia 
difference 
Up to $180,000 signing bonus* 
is just one reason to pursue 
Une indemnite de recrutement pouvant 
atteindre 180 000 $* n'est qu'une des 
raisons pour entreprendre une carriere 
differente en medecine familiale au sein 
des Forces canadiennes! 
a family medicine career 
with a difference in the 
Canadian Forces! 
In addition to helpinQ you pay for your education, 
we also offer a great professional work environment, 
competitive salaries and the chance to practise with 
some of Canada's best! 
To learn more about a rewarding career as a 
Canadian Forces Medical Officer, contact us today. 
*Signing bonus based on years of study completed 
(minimum of $40,000) . We can also offer you a 
paid education plus a salary while in school. 
En plus de VOUS aider a payer VOS etudes, nous VOUS offrons un excellent 
milieu de travail , un salaire competitif et !'occasion de travailler avec des 
professionnels hors pair! 
Pour en apprendre d'avantage sur une 
carriere valorisante de medecin militaire, 
communiquez avec nous des aujourd'hui. 
*L 'indemnite de recrutement est basee 
sur le nombre d 'annees d'etudes 
completees (40 000 $au minimum). 
Nous pouvons egalement vous offrir 
de payer vos frais de scolarite ainsi 
qu 'un salaire d 'etudiant. 
Strong. Proud. Today's Canadian Forces. 
Decouvrez vos forces dans les Forces canadiennes. 
CANADIAN FORCES 
Regular ard Reserve • Reguliere et de tese!ve 
1 800 856-8488 
www.forces.gc.ca Canada 
